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ABSTRACT
The aim of this thesis was to investigate GnRH binding activity in human trophoblast
tissue from pregnancies terminated between 6 and 18 weeks and in placentae from full-term,
uncomplicated deliveries. Binding sites for GnRH in the human placenta differ from the well-
characterised pituitary GnRH receptor. The pituitary superagonists Buserelin and Tryptorelin
were bound by placental membranes, as were the salmon and chicken-II isoforms of GnRH,
however placental binding of the GnRH agonist analogues was not enhanced compared to the
two isoforms, which were not bound by the pituitary receptor. Previous studies of GnRH in
the human placenta have been confined to a limited range of gestational ages and the pre-term
placental tissue studied was often obtained by suction curettage, which is often contaminated
by foetal tissue. Therefore, the availability of medically, as opposed to surgically, terminated
early placental tissue was utilised in this study to provide a good source of very early
trophoblast tissue.
Specific activity of the binding of GnRH, GnRH isoforms and GnRH agonist
analogues to the human placental GnRH binding site was found to vary with stage of gestation.
The high levels observed in early trophoblast (6-8 weeks) fell to around the detection limit of
the assay at 12-18 weeks, before increasing to maximal levels by term. Rebinding data
suggested that differential tracer degradation could not account for gestational age-related
variations in binding, and levels of binding were not related to contamination of the membrane
fractions by non-villous tissue. Although the specific activity of binding to placental binding
sites varied with gestation, specificity was unchanged: Tryptorelin, Buserelin, chicken GnRH-
II, salmon GnRH > mammalian GnRH » lamprey GnRH, chicken GnRH-I.
Buserelin, Tryptorelin and chicken GnRH-II were displaced from the membrane
binding site by cytosolic extracts of placenta of all stages of gestation. Cytosol fractions from
12-18 weeks displaced iodinated GnRH tracers from the binding sites of membrane
preparations from the same stage of gestation to a greater extent than an excess of non-
lodinated Buserelin, but did not displace tracer from term membrane binding sites to the same
degree. Placental membrane binding of tracer and the displacement effect of cytosol were
reduced in the presence of protease inhibitors, however this was due to the presence of ethanol
(as a solvent) in the assay. The nature of this ethanol effect remains unidentified.
Placental cytosol of all stages of gestation displaced binding of chicken GnRH-II from
specific chicken GnRH-II antibodies. Protease inhibitors and ethanol had no effect on this
competitive binding. Placental cytosol was also able to bind chicken GnRH-II, but not
Tryptorelin, at physiological pH. At low pH, chicken GnRH-II binding was enhanced at all
stages of gestation and cytosol demonstrated the ability to bind GnRH agonist tracer - gel
exclusion fractionation suggested that the endogenous ligand dissociated from the cytosolic
binding site at acid pH. In addition, human placental cytosol of all stages of gestation
contained a high molecular weight (~60kDa) mitogenic activity, demonstrated in culture with
dispersed ovine pituitary cells using direct (cytometer, Coulter counter) and indirect (tritiated
thymidine, BDU) counting methods.
In conclusion, the effect of gestational age on GnRH binding to placental membranes
may be related to changes in receptor number or down-regulation of receptor binding.
However, the distinct pattern of GnRH binding observed for placental membrane binding sites
suggested that placental GnRH, the placental GnRH binding site or both differed from the well-





1.1 ENDOCRINOLOGY OF THE HUMAN PLACENTA
The placenta secretes large quantities of steroid, peptide and glycoprotein
hormones, with hormone production varying with stage of gestation (Simpson and
MacDonald, 1981). Placenta! hormone secretion may be affected by factors of
maternal, foetal and placental origin, and thus functions in a paracrine fashion, as well
as its well-recognised function as an endocrine organ. Release and release-inhibiting
factors, neuropeptides, neurotransmitters, cytokines, growth factors and prostanoids
have been described to play a role in control of placental hormonogenesis, with
complex and delicately balanced interactions between these factors which are not fully
understood.
1.1.1 HypothaSamic-like Peptides in the Human Placenta
The placenta contains hormonal activities with similarities to the hypothalamic-
pituitary axis with releasing and release-inhibiting hormones, which were localised in
cytotrophoblast cells of the placenta (Petragiia, 1991), acting to control local
production of placental hormones by syncytiotrophoblasts. Placental equivalents of
GnRH, corticotrophin-releasing hormone (CRH), growth hormone release-inhibiting
hormone (somatostatin) and thyrotrophin-releasing hormone (TRH) have been
identified in the human placenta (Siler-Khodr, 1983).
The presence of GnRH-like activity in the human placenta, which stimulated
pituitary LH release in vivo was described by Gibbons ei al. (1975). Placental GnRH
is thought to be distinct from the hypothalamic decapeptide and is discussed in detail in
Section 1.2. GnRH in the placenta has been shown to have an effect on secretion of
hCG, progesterone, oestrogen and prostaglandins, but to have no effect on hPL
secretion (Siler-Khodr et al., 1986a,b,c). Release of placental GnRH is activated by
Ca2+-dependent cell membrane depolarisation and adenylate cyclase/cAMP (Petragiia
et al., 1987a), similar to GnRH release in the hypothalamus. GnRH release in
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placental cultures was modulated by steroid hormones and opiates (Petraglia et al.,
1990a), suggesting similar interactions are possible in the in vivo placenta.
Placental TRH activity was also described by Gibbons et al. (1975) but no
physiological role has been confirmed in the placenta for this peptide. hCT has been
isolated from placental extracts, but does not appear to be identical to pituitary TSH.
A chorionic somatostatin-like activity has been localised in first trimester
cytotrophoblast cells (Kumasaka et al., 1979; Zhang et al., 1991) with gestational
changes in placental somatostatin levels inversely correlated to hPL. This led to the
hypothesis that hPL release was inhibited by placental somatostatin-like activity via the
action of dopamine (Macaron et al., 1978a), although subsequent studies failed to
demonstrate a direct action on hPL secretion (Macaron et al., 1978b). When injected
into the uterus of early pregnant rats, somatostatin antiserum increased the
implantation rate of blastocysts (Zhang et al., 1991), which suggests an inhibitory role
for somatostatin in blastocyst implantation.
Chorionic CRH with placental ACTH, p-endorphin and MSH release-
stimulating activity has also described (Margioris et al., 1987). Pregnant women have
measurable CRH levels in their systemic circulation, whereas CRH was not detected in
non-pregnant females (Thomson et al., 1988), and maternal serum CRH correlates
with CRH mRNA levels in the placenta, suggesting the placenta is a major source of
circulating CRH (Petraglia, 1991). CRH mRNA was expressed from early gestation,
increasing more than 20-fold during the last 5 weeks of pregnancy (Frim et al., 1988).
CRH was localised to the cytotrophoblast of term placental villi (Petraglia et al.,
1987c) and was identical to hypothalamic CRH (Petraglia et al., 1990a). Stimulation
of placental CRH release was analogous to the hypothalamus: noradrenaline and
acetylcholine increased CRH release from both.
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1.1.2 Peptide Hormones of the Human Placenta
1.1.2a Human Chorionic Gonadotropin (hCG)
hCG has a similar structure to the pituitary gonadotrophins FSH and LH and to
TSH. These glycoprotein hormones are comprised of two dissimilar subunits,
designated a and p. The a-subunits of these hormones are interchangeable, with
biological activity determined by the p-subunit, although sequence homologies exist
between p-subunits. The amino acid sequence of hCG has been described (Bahl et al.,
1972) and the molecular weights reported as 10,200Da for the a-subunit and
15,500Da for the p-subunit. 30% of hCG is carbohydrate which probably helps to
prolong its half-life.
The a and p subunits are synthesised independently, with production of the p-
subunit the rate-limiting step for formation of hCG. hCG is secreted almost
exclusively into the maternal circulation and can be detected in the maternal serum as
early as 6 days after ovulation (Braunstein et al., 1976). Peak maternal serum
concentrations were observed at 8 weeks, dropping rapidly after 11 weeks to a nadir
by 18 weeks and staying low for the rest of gestation. At term, hCG levels declined
and free a-subunits appeared in the plasma, suggesting uncoordinated synthesis of the
subunits (Vaitukaitis, 1974). Hence, hCG levels can not be correlated with increasing
trophoblastic mass, but correspond closely with the rate of differentiation of
cytotrophoblasts into syncytiotrophoblasts (Hay, 1988).
hCG was localised, using immunofluorescence, to the syncytiotrophoblast
(Khodr and Siler-Khodr, 1978a), whereas GnRH, which has a similar release profile to
hCG, was localised to cytotrophoblasts (Khodr and Siler-Khodr, 1978a). If the
placenta was analogous to the hypothalamic-pituitary axis, then GnRH released from
cytotrophoblasts would stimulate hCG release from syncytiotrophoblast via plasma
membrane receptors. In vitro, GnRH was shown to increase hCG secretion from
placental explants (Khodr and Siler-Khodr, 1978b), although injections of GnRH had
no detectable effect on circulating levels of hCG in early pregnant women (Seppala et
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al., 1980). Patterns of hCG secretion were reviewed by Bramley (1987) who found
basal hCG release from placental explants peaked at 9-10 weeks, coinciding with peak
levels of hCG in maternal circulation, but showed minimal response to exogenous
GnRH. From 10-17 weeks, maternal hCG levels and hCG release from placental
explants fell, but responsiveness of placental cultures to GnRH rose. In term placental
explants, hCG content fell to low levels but GnRH was still able to stimulate hCG
release. GnRH-stimulated hCG release from mid gestation placental explants (Siler-
Khodr et al., 1987) and perifused first trimester placental explants (Barnea et al.,
1991) was inhibited by GnRH antagonists.
In addition to GnRH, dibutyryl cyclic AMP (Haning et al., 1982; 1988) and
EGF (Barnea et al., 1990) both increased hCG release from placental explants, but no
effect was observed with dibutyryl cGMP, AMP, insulin, progesterone, adrenaline or
PG. Dynorphin (1-13) stimulation of hCG release from trophoblast cultures was
described by Zhang et al. (1991). Dopamine inhibited hCG secretion in vitro whereas
the dopamine antagonist pimozide stimulated hCG secretion (Macaron et al., 1978a).
This is analogous to control of LH secretion by the pituitary, where dopamine
modulates the secretion of hypothalamic GnRH. Licht et al. (1992) described
stimulation of hCG release from perifused first trimester placenta by GABA, which
was independent of GnRH. The action of GABA was inhibited by bicuculline, an
antagonist of GABAa suggesting the involvement ofGABAa receptors, analogous to
GABA stimulation ofLH release in the pituitary (Virmani et al., 1990).
1.1.2b Human Placental Lactogen (hPL; hCS, human chorionic
somatomammofrophin)
hPL is a single chain polypeptide of 191 amino acids with molecular weight
22,300kDa (Simpson and MacDonald, 1981). Unlike hCG it contains no carbohydrate
residues. hPL is similar to the anterior pituitary hormones, prolactin and growth
hormone, and shares lactogenic and somatotrophic properties. hPL has one-hundredth
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of the potency of growth hormone in promoting growth but it is produced in large
quantities (lg per day in term placenta). Therefore considerable physiological effects
could be possible in pregnancy. Little hPL crosses to the foetal circulation and its
precise role has yet to be elucidated (Simpson and MacDonald, 1981).
Hoshina et al. (1982) localised hPL to the syncytiotrophoblast. hPL can be
detected in the maternal circulation 5-10 days after implantation and increasing serum
levels correlate with increasing trophoblast mass. No effect of somatostatin on hPL
release was detected (Macaron et al., 1978b).
1.1.2c Inhibin
Inhibin is a glycoprotein which preferentially suppresses FSH secretion by the
anterior pituitary (de Kretser and Robertson, 1989). It is produced by the granulosa
cells of the ovarian follicle and the corpus luteum in the human female. In the male,
inhibin is produced by the Sertoli cells of the testes.
Inhibin has been isolated as a heterodimer of two dissimilar subunits,
designated a and p (Burger, 1988), which are linked by disulphide bonds. Variations
in the p-subunit give rise to two forms of inhibin, designated Inhibin A and Inhibin B
(Robertson et al., 1985), comprising cx-Pa and a-Pe respectively. Dimers of the p-
subunits, which stimulate FSH secretion (Vale et al., 1986), have been designated
Activin A, the homodimer of the Pa subunit, and Activin A-B, consisting of one p-A
and one P-b subunit (Burger, 1988).
Suppression of FSH secretion by inhibin is thought to be due, at least in part,
to tonic suppression ofFSH synthesis (Farnworth et al., 1988), possibly at the level of
inhibition of transcription of the FSHp gene (Mercer et al., 1987). GnRH-stimulated
release of FSH is also decreased by inhibin, possibly by reduced responsiveness of the
gonadotroph to GnRH (Wang et al., 1990). Inhibin is thought to act beyond the
GnRH receptor, possibly at the level of protein kinase-C and calmodulin, transducers
for calcium, the second messenger for GnRH (Huckle and Conn, 1988).
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In the human female, inhibin levels are cyclical, peaking in the late follicular
phase and again in the mid luteal phase before declining prior to menstruation (de
Kretser and Robertson, 1989). In conception cycles, the late luteal decline does not
occur and levels increase during pregnancy. Inhibin immunoactivity and bioactivity
was identified in extracts from human placentae by McLachlan et al. in 1986. This
placental inhibin-like activity was neutralised by anti-inhibin antisera and had a parallel
immunoactivity to inhibin isolated from human follicular fluid. However differences in
bioactivity : immunoactivity ratios suggest differences may exist between placental and
ovarian inhibins.
Placental inhibin was localised to the cytotrophoblast of term placenta, using
immunohistochemistry, by Petraglia et al. (1987b) and, from studies of placental
monolayer cultures, a putative role for inhibin in the control of hCG secretion in the
placenta was proposed (Petraglia et al., 1989). Inhibin alone had no effect on basal
hCG secretion, but reduced GnRH-stimulated hCG release. Conversely, activin
strongly potentiated the stimulation of hCG release by GnRH: activin action was dose-
related and reversed by inhibin. Activin increased GnRH and progesterone release
from placental cultures, whereas inhibin alone had no effect but reversed the effects of
activin. The functional antagonism of inhibin and activin mirrors their effects on FSH
secretion in the pituitary (de Kretser and Robertson, 1989).
1.1.2d Placental ACTH
Pregnancy is associated with increased maternal plasma Cortisol levels and the
presence of bioactive and/or immunoactive ACTH has been reported in placental
extracts. The human placenta produces the proopiomelanocortin precursor molecule
for ACTH and contains the ACTH release-related hormones p-lipotrophin and
p-endorphin (Simpson and MacDonald, 1981; Petraglia et al., 1990a). Release of
ACTH, p-endorphin and MSH from placental cell cultures was stimulated by CRH,
apparently acting via a specific CRH receptor (Petraglia et al., 1987c).
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1.1.3 Neuropeptides and Neurotransmitters in the Human Placenta
p-endorphin is generated in the pituitary by cleavage of p-lipocortin, which is
formed when proopiomelanocortin is cleaved to release ACTH. Using immunogold-
silver histochemistry, p-endorphin was identified in the syncytiotrophoblast (Zhang et
al., 1991). p-endorphin immunoactivity in the placenta was high at 6 weeks but had
decreased by 10 weeks, with low levels at term (Zhang et al., 1991). Other opioids
were isolated in the placenta by HPLC of methanol extracts of acidified first trimester
cytosol, with methionine-enkephalin > dynorphin (1-13) > p-endorphin > leucine-
enkephalin (Zhang et al., 1991). Interestingly, plasma levels ofmethionine-enkephalin
are not significantly different in pregnant and non-pregnant women (Petraglia et al.,
1990a). When injected into the uterine horn of early pregnant rats, dynorphin
antiserum decreased blastocyst implantation rate, whereas p-endorphin antiserum had
no effect on implantation (Zhang et al., 1991). Opioids were shown to inhibit
placental GnRH release in vitro (Petraglia et al., 1990b) and stimulate hPL from
perifused placental villi (Belisle et al., 1988) via placental opiate receptors. In
addition, dynorphin stimulated hCG release (Barnea et al., 1991a), whereas p-
endorphin inhibited hCG release (Barnea et al., 1991b) from first trimester placenta.
Neuropeptide Y is extensively distributed in the brain and plays a role in
regulation of the hypothalamic-piuitary-gonadal axis. Neuropeptide Y and its specific
binding sites have been found in the cytotrophoblast cells of the term placenta and
stimulates CRH from placental preparations in a dose- and time-dependent manner
(Petraglia et al., 1990a).
Despite the absence of nerve endings in the trophoblast, neurotransmitter
metabolising enzymes and receptors have been described in the placental tissue,
suggesting a role for circulating neurotransmitters in placental function (Petraglia et
al., 1990a). Zhang et al. (1991) also detected four neurotransmitters in first trimester
placental villi: noradrenaline, adrenaline, 5-HT (localised to syncytiotrophoblast by
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immunogold-silver method) and DOPAC, a dopamine metabolite. Quantitatively,
noradrenaline appeared to be the main neurotransmitter in the placenta.
1.1.4 Steroid Hormones in the Human Placenta
In the human, the corpus luteum, under the influence of hCG produced by the
trophoblast, is the dominant source of progesterone and oestradiol until approximately
weeks 6-8 of pregnancy, when the placenta becomes the primary source of these
steroid hormones (Simpson and MacDonald, 1981): late in pregnancy, 250-600mg
progesterone, 15-20mg oestradiol and 50-100mg oestriol are secreted by the placenta
per day. These steroid hormones are required in the establishment of pregnancy, with
a role in ovum transport, proliferation and differentiation of the endometrium,
decidualisation and implantation (reviewed by Albrecht and Pepe, 1990).
Progesterone is essential in the maintenance of pregnancy, with lack of progesterone
associated with termination of pregnancy (Simpson and MacDonald, 1981).
Synthesis of oestrogens by the human placenta is dependent on availability of
C-19 steroid precursors, as the human placenta is unable to convert acetate de novo
into oestrogen: 17p-oestradiol and oestrone are formed from DHA and its sulphate
DHAS, while oestriol is formed from 16a-hydroxy-DHA and its sulphate (Simpson
and MacDonald, 1981). Progesterone is formed mainly from maternal LDL
cholesterol (Simpson and MacDonald, 1981), but Haning et al. (1982) found no effect
of exogenous LDL cholesterol on progesterone release by term placental explants.
However, they did observe that DHAS increased oestradiol output, which was
suppressed by dbcAMP, and that aromatase inhibitor decreased oestradiol release in a
dose-dependent fashion. In mid-gestation placental explants, Siler-Khodr et al. (1983;
1987) effected suppression of progesterone release with the GnRH antagonist [N-Ac-
Pro1,D-p-Cl-Phe2,D-Nal(2)3.6]-GnRH.
In placental monolayers (Branchaud et al., 1983), DHA was required for
oestradiol and oestriol production and GnRH had an inhibitory effect on progesterone
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and oestrogen output. However, stimulation of progesterone, oestrone and oestradiol
from mid-gestation placental explants by GaRH has also been reported (Siler-Khcdr et
al., 1986b).
1.2 GONADOTROPHIN-RELEASING HORMONE IN THE HUMAN
PLACENTA
1.2.1 Characterisation of GnRH in the Human Placenta
GnRH is a decapeptide which is synthesised and stored in the hypothalamus,
and acts on the pituitary gland via a specific plasma membrane receptor to stimulate
the synthesis and release ofLH and FSH (Hazum and Conn, 1988). In 1975, Gibbons
et al. described the in vitro synthesis by homogenates of human placenta, of GnRH-
like activity which was chromatographically identical to GnRH standards on CM-
cellulose and TLC. Using placental fragments, the synthesis of immunoactive GnRH
was also demonstrated (Siler-Khodr and Khodr, 1979), with release ofGnRH from the
placental tissue exceeding the initial tissue GnRH content. De novo synthesis ofGnRH
by human placenta was confirmed by tritiated amino acid incorporation (Khodr and
Siler-Khodr, 1980; Tan and Rousseau, 1982).
GnRH immunoactivity was detected in the human placenta throughout
gestation (Siler-Khodr and Khodr, 1978; Zhang et al., 1991); total GnRH content was
low during 6-7 weeks gestation, increased from 8 to 23 weeks, appeared to plateau
until 36 weeks, then increased significantly by term. No difference was detected
between male and female pregnancies. When expressed per mg of tissue, peak levels
of immunoactive GnRH were detected in early pregnancy, with levels actually
decreasing in mid-gestation and term placentae. This correlated with levels of
immunoactive GnRH measured in maternal circulation (Siler-Khodr et al., 1984)
which were highest in first half of pregnancy and were significantly higher in pregnant
compared with nonpregnant females.
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Using immunofluorescence and immunohistochemical techniques (Khodr and
Siler-Khodr, 1978a; Miyake et al., 1982; Zhang et al., 1991), GnRH was strongly
localised in the cytotrophoblast of first trimester tissue, decreasing through gestation
to low levels at term, possibly reflecting changing cytotrophoblast cell number with
advancing gestation. No staining of the syncytiotrophoblast was found at any stage.
Release of GnRH from cultured placental cells was stimulated by K+ or
veratridine, a sodium ionophore (Petraglia et al., 1987a). This effect was reversible by
calcium antagonists such as cobalt, EGTA and verapamil, suggesting cell membrane
depolarisation is involved in mediating GnRH release, analogous to hypothalamic
GnRH release. dbcAMP, forskolin, theophylline and theobromine also increased
GnRH release, as did prostaglandins E2 and F201 and adrenaline. The latter was
inhibited by propranolol, suggesting the involvement of |3-adrenergic receptors.
Petraglia et al. (1989) described the effects of inhibin and activin on GnRH release
from placental cell cultures: activin increased GnRH release, whereas inhibin alone had
no effect but antagonised the stimulatory effect of activin. Further investigations
(Petraglia et al., 1990b) found no effect of the steroids oestradiol, oestriol or
progesterone on GnRH release from cultured placenta, but observed stimulation of
cAMP-induced GnRH release by oestradiol and oestriol, and inhibition of the same by
progesterone. Stimulation of GnRH release from placental cell cultures by activin
was augmented by oestriol and decreased by progesterone or tamoxifen. Agonists for
the three classes of opiate receptor had no effect on GnRH release from placental cell
cultures (Petraglia et al., 1990b), but morphine, a p-receptor agonist, and U-50,488H,
a k-receptor agonist, decreased cAMP-induced GnRH release. These effects were
reversed in the presence of specific p and k receptors antagonists, and paralleled
inhibition ofGnRH release in the hypothalamus by dynorphin and p-endorphin.
Early evidence (Lee et al., 1981) suggested that term placental GnRH was
indistinguishable from synthetic GnRH after fractionation of methanol extracts by
HPLC, although high molecular weight forms of GnRH were detected in rat placental
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extracts (Gautron et al., 1981). Tan and Rousseau (1982) identified biosynthetic
GnRlI in the placenta as chemically identical to hypothalamic GnRH on HPLC of
partially purified peptide, but postulated the existence of high molecular weight GnRH-
like proteins in placenta. Zhang et al. (1991), using methanol extracts of acidified
placental cytosol, found high molecular weight GnRH and hypothalamic GnRH
immunoactivity.
Studies using antibodies raised against the C-terminal of GnRH (Siler-Khodr
and Khodr, 1978, 1979; Khodr and Siler-Khodr, 1978a, 1980; Seppala et al., 1980;
Lee et al., 1981; Miyake et al., 1982) may have failed to detect any modifications of
the N-terminal of the molecule which may give rise to a distinct placental form of
GnRH. Gautron et al. (1989) used two antibodies, to the C and N termini of GnRH
respectively, to assay human placental extracts after chromatographic fractionation and
concluded that placental immunoactive GnRH levels were over-estimated and that
placental GnRH was not identical to hypothalamic GnRH.
Siler-Khodr (1987) noted that apparent GnRH immunoactivity exceeded the
GnRH decapeptide content of the placenta and concluded that acid extraction
procedures resulted in higher recoveries of placental GnRH-like immunoactivity,
compared with extraction at neutral pH, due to denaturing of larger peptides. GnRH-
like immunoactivity was attributable, in part, to a high molecular weight glycoprotein
which had reduced potency in pituitary bioassays but which enhanced the release of
hCG and prostaglandins from placental explants to a greater extent than the
hypothalamic decapeptide (Siler-Khodr, 1987). This placental activity inactivated
GnRH (and TRH, angiotensin II and, in the presence of DTT, oxytocin and
somatostatin) (Siler-Khodr et al., 1989) and was identified as a 58kDa post-proline
protease unique to the placenta (Kang and Siler-Khodr, 1992).
Seeburg and Adelman (1984) cloned and sequenced cDNA for the precursor of
GnRH (preproGnRH) from human placenta. The precursor gene had an unusually
long 5' untranslated region (>1,000 nucleotides). The cDNA coded for a protein of 92
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amino acids, in which the decapeptide was preceded by a 23 amino acid signal peptide
and was followed by a Gly-Lys-Arg sequence, typical of an enzymatic cleavage site,
then a 56 amino acid extension. This C-terminal GnRH-associated peptide (GAP) had
both gonadotrophin-releasing (Millar et al., 1986) and prolactin-inhibiting (Nikolics et
al., 1985) activity in cultured human pituitary cells. Seeburg et al. (1987) suggested
tissue-specific forms ofGnRH may arise by differential processing of preproGnRH: in
placental preproGnRH mRNA, the first intron is not spliced out. In addition, promoter
regions may differ in the placenta and hypothalamus (Adelman et al., 1986).
1.2.2 GnRH Binding Sites in the Human Placenta
Superagonist analogues of GnRH, such as Buserelin, had equilibrium
association constants (Ka) between 4 and 8 fold greater (Ka = 4.8xl09M"1) than the
natural decapeptide (Ka = 6.6xl08M"1) in the pituitary radio-receptor assay (Clayton
and Catt, 1980)
In the placenta, receptor affinity for analogues like Buserelin were comparable
with the affinity of the native hormone (Ka = 5.5xl07M"1 and 6.2xl07M"1,
respectively) (Currie et al., 1981), using crude membrane preparations. Purification of
placental membranes by sedimentation on a sucrose gradient (Belisle et al., 1984) gave
an 8-fold enrichment of membrane markers but no improvement in receptor affinity
(S.SxlO^*1 to 1.1x107M_1) for GnRH or its agonist analogues. Iwashita et al.
(1986) performed binding studies on particulate and solubilised receptor preparations,
using the GnRH agonists [D-Lys6]- and [D-Ala6]des-Gly10-GnRH-jV-ethylamide, and
obtained affinity constants of 1.6x106M_1 and 5.4xl05M"1 respectively, compared with
Ka = l.lxlt^M"1 for the decapeptide. Placental binding sites were saturable, of a
single class and specific for GnRH (Currie et al., 1981; Belisle et al., 1984; Iwashita et
al., 1986). However Belisle et al. (1987), using suspensions of intact placental cells,
described two classes of binding sites with association constants of 4.7 (± 2.2)xl05M"1
and 1.78 (± 0.8) xIQSM*1 respectively for GnRH agonists, although the high affinity
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sites still fell short of pituitary GnRH receptor affinity constants and the estimated
number of high affinity sites was 1,000 times less than low affinity sites.
Binding sites in the placenta with a high specificity but low affinity for GnRH
agonist analogues suggest the existence of an endogenous GnRH-like ligand in the
placenta which may have a higher affinity for these sites. Alternatively, high local
concentrations of GnRH may allow the placental receptor to operate with a much
lower affinity than that required in the pituitary. High affinity binding sites may be
difficult to demonstrate due to degradation of the synthetic analogue at unprotected
cleavage sites, by placental proteases such as the unique placental post-prolinase
described by Siler-Khodr et al. (1989) and Kang and Siler-Khodr (1992).
The molecular weight of the placental GnRH receptor was estimated to be
53,700 (± 2,700) Da by Iwashita et al. (1986). The receptor migrated as a single band
on SDS-gel electrophoresis, with similar results under reducing and non-reducing
conditions unlike the pituitary receptor. Escher et al. (1988) used photolabelled
analogues of GnRH to identify a 58kDa GnRH-binding subunit on SDS-gel
electrophoresis. This appeared to be associated with other proteins, possibly signal
transduction G-proteins.
The human pituitary GnRH receptor has been cloned (Reinhart et al., 1992;
Kaiser et al., 1992; Kakar et al., 1992) and its function characterised (Anderson et al.,
1993). In immortalised aT3-l pituitary gonadotroph cells, it was shown that these
GnRH receptors are coupled to the phosphatidyl inositol second messenger pathway
via a specific G-protein. To date, however, the placental GnRH receptor has not been
analysed.
1.2.3 Role for GnRH in the placenta
A bolus injection of GnRH at 8-18 weeks pregnancy had no effect on
circulating concentrations of hCG, hPL, pregnancy specific p-1 -glycoprotein or
pregnancy protein 5 (Seppala et al., 1980; Skarin et al., 1982). This may be due to
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low GnRH concentrations reaching the placenta which were unable to activate the low
affinity placental receptors in order to elicit a response. However, injection of anti-
GnRH was followed by termination of pregnancy in early pregnant baboons (Das et
al., 1985). Zhang et al. (1991) injected anti-GnRH into the uterus of early pregnant
rats and found decreased blastocyst implantation, suggesting that GnRH may have a
role in implantation.
In vitro, GnRH stimulated hCG release from placental explants (Khodr and
Siler-Khodr, 1978b; Haning et al., 1982; Siler-Khodr et al., 1986a) in a dose-related
fashion (Siler-Khodr and Khodr, 1981). GnRH stimulated release of hCG most
dramatically at mid term (Siler-Khodr et al., 1986a), when secretion of hCG was
decreasing. GnRH also increased hCG secretion in short-term placental cultures
(Belisle et al., 1984), with the increase in release 4-fold higher in mid-term cultures
compared with term. Similar results were obtained with perifused dispersed
trophoblast cells (Butzow, 1982): GnRH increased hCG secretion by up to 4-times
basal levels. This effect was specific for GnRH; neither TRH nor oxytocin stimulated
hCG release from cultured placentae (Belisle et al., 1984), and the involvement of
GnRH receptors has been implicated, as inhibition of hCG release from first trimester
(Barnea et al., 1991) and mid-gestation (Siler-Khodr et al., 1983) placental explants by
GnRH antagonists has been described. Mathialagan and Rao (1989) observed a role
for extracellular calcium in GnRH-stimulated hCG release from placental explants, and
a corresponding involvement of calmodulin. GnRH stimulation of LH secretion in the
pituitary was also demonstrated to involve calcium (Clapper and Conn, 1985) and
calmodulin (Hart et al., 1983). In the pituitary, activation of the GnRH receptor has
been associated with phosphoinositide hydrolysis (Marian and Conn, 1979). However,
Belisle et al. (1989) failed to show any effect of GnRH on phosphoinositol turnover,
suggesting Ca2+-mediated GnRH-stimulation of hCG release involves activation of
protein kinase-C.
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GnRH had no effect on hPL secretion from placental explants (Khodr and
Siler-Khodr, 1978b; Siler-Khodr etal., 1986a).
Reports of GnRH effects on placental steroid secretion were inconsistent:
Wilson and Jawad (1980) reported suppression of progesterone production in a dose-
related manner by GnRH in 12 and 22 week and term placental explants, and inhibitory
effects of GnRH on both progesterone and oestrogen have been reported in term
monolayer cultures (Branchaud et al., 1983), although Haning et al. (1982) found
GnRH had no effect on progesterone or oestradiol secretion by term placental
explants. However, inhibition of progesterone release from mid-gestation placental
explants by a GnRH antagonist has been documented (Siler-Khodr et al., 1983) and
GnRH was found to stimulate the release of progesterone, oestradiol and oestrone
from mid-gestation and term placental explants (Siler-Khodr et al., 1986b).
Using placental explants, Siler-Khodr et al. (1986c) found a dose-related
inhibition of release of prostaglandins E and F and 15-keto-prostaglandin F by GnRH
at 13 weeks gestation, followed by stimulation of release at 15-17 weeks gestation and
at term.
1.3 GROWTH FACTORS
The human placenta produces and is a target for many growth factors. Insulin¬
like growth factors (IGFs), epidermal growth factor (EGF), fibroblast growth factors
(FGF), transforming growth factors a and p (TGF-a and -p) and platelet-derived
growth factor (PDGF) have all been described in the human placenta.
IGFs have structural and biological similarities to insulin and act on specific cell
membrane receptors to stimulate proliferation of various cell types. The human
placenta expresses mRNA for both IGF-I and II and placental cells carry IGF receptors
(Fant et al., 1986). Binding sites for IGF-I and -II are different and, in the placenta,
two distinct IGF-I receptors are present suggesting the possibility of tissue-specific
isotypes of the IGF-I receptor (Petraglia et al., 1990a). IGFs and insulin increased
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hPL release from placental cell cultures and are thought to have a role in growth and
development. IGF receptor levels are higher in early placenta, suggesting IGFs
regulate the early phase of foetal growth, with insulin influencing later growth
(Petraglia et al, 1990a).
High levels of EGF receptors have been detected in the human placenta (Lai
and Guyda, 1984), although there is no evidence of placental EGF synthesis. Placental
EGF receptor levels are significantly higher in early pregnancy than in term pregnancy
(Maruo et al., 1987), correlating with differentiation of cytotrophoblast into
syncytiotrophoblast. In early placental cell cultures, EGF was noted to induce
differentiation, resulting in increased hCG and hPL release (Morrish et al., 1987).
Frolik et al. (1983) purified TGF-13 from human placenta, which inhibited
trophoblast differentiation in monolayer cultures (Morrish et al., 1991) in a dose-
dependent manner (Graham et al., 1992).
Basic FGF is present in human placenta (Gospodarowicz et al., 1985) and
stimulates synthesis of hCG p-subunit (Petraglia et al., 1990a). FGF stimulates
angiogenesis in other tissues and may be associated with the high degree of
neovascularisation during the initial stages of placental development.
The first trimester placenta actively expresses s/'s-proto-oncogene, which is the
structural gene for a component ofPDGF (Goustin et al., 1985) and PDGF expression
was demonstrated throughout pregnancy, with especially high levels at mid-trimester
(Taylor and Williams, 1988).
1.4 PLACENTAL DEVELOPMENT AND DIFFERENTIATION
In the human, the blastocyst attaches to the endometrium after 7 days of
gestation (Moll and Lane, 1990). Implantation mimics neoplastic behaviour but is
highly regulated, with invasive activity peaking at about 12 weeks gestation and
declining rapidly thereafter. The placenta derives from trophectoderm of the
blastocyst and differentiates into either villous or extravillous trophoblast (Ringler and
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Strauss, 1990). The latter forms the main invasive element and anchors the placenta.
Cytotrophoblast and syncytiotrophoblast cells are different lineages of the same
trophoblast cell type. During pregnancy a permanent differentiation process from
cytotrophoblast to syncytium occurs (Fant et al., 1986; Kliman et al., 1986).
Cytotrophoblast cells of the chorionic villi fuse to form syncytiotrophoblast, the main
source of placental hormones such as hCG and hPL. Growth of the placenta is most
rapid during the first trimester, with replication of cytotrophoblast cells under
stimulation of growth factors such as IGF-II and PDGF (Ohlsson, 1989; Taylor and
Williams, 1988). Maturing cytotrophoblasts lose mitotic activity and then fuse to form
multinucleated syncytiotrophoblast, terminally differentiated trophoblast cells. During
the second and third trimesters, placental growth slows and the relative ratio of
syncytiotrophoblast to cytotrophoblast increases dramatically (Ringler and Strauss,
1990).
1.5 AIMS OF THIS STUDY
Previous investigations of GnRH in the human placenta have focussed on a
limited range of gestational ages. Moreover, early trophoblast from suction
terminations tended to be contaminated with foetal tissue. Medical termination of
pregnancy leads to the expulsion of the intact gestational sac and we therefore
investigated placental GnRH activity in normal placentae from terminations of
pregnancy from 6-18 weeks and from full-term uncomplicated deliveries.
Preliminary investigations of the nature of high molecular weight mitogenic and





Chemicals and reagents were obtained from Sigma Chemical Co. Ltd., Poole,
Dorset, England, or from BDH Chemicals Ltd., Poole, Dorset, England, unless
indicated.
2.2 PREPARATION OF HUMAN PLACENTAL MEMBRANES
2.2.1 Collection of Tissue
Placentae were collected from the Simpson Memorial Maternity Pavilion,
Edinburgh, Scotland, and were transferred to the laboratory on ice. Preparation of the
placental tissue was carried out at 4°C.
Term placental tissue was obtained from uncomplicated pregnancies after
vaginal delivery at 37-42 weeks gestation. Pre-term placental tissue was obtained after
therapeutic abortion carried out between 6 and 18 weeks gestation. Early pregnancies
(6-9 weeks) were terminated by vacuum aspiration of the conceptus or by pre-
treatment with the anti-gestagen mifepristone (Mifegyne®, 600mg orally; Roussel
Laboratories Ltd., Uxbridge, Middlesex, England) followed by medical induction of
labour with gemeprost, a prostaglandin Ei analogue (Cervagem®, lmg vaginal
pessary; May & Baker, Dagenham, Essex, England) (Cameron and Baird, 1988).
Early pregnancy is dependent on progesterone, which is essential for successful
implantation of the embryo and for the maintenance of the endometrium and
quiescence of the myometrium. Mifepristone has a high binding affinity for the
progesterone receptor but is devoid of progestational agonist activity and has been
used for the medical induction of early pregnancy, although mifepristone alone is
associated with a high incidence of incomplete abortion (Avrech et al., 1991).
Analogues of prostaglandins elicit powerful uterine contractions and induce complete
abortion in over 90% of women. However, their widespread use is limited by
unpleasant side effects. As mifepristone sensitises the uterus to prostaglandins,
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mifepristone and prostaglandins in combination allow the dose of prostaglandin to be
reduced, minimising side effects (World Health Organization, 1991).
From 9 to 18 weeks gestation, pregnancies were terminated by prostaglandin
induction with gemeprost vaginal pessaries. Vaginal pessaries (lmg) were inserted
every 3 hours until the conceptus was expelled or until 5 pessaries had been given. If
abortion had not occurred within 24 hours of the first pessary, a maximum of 5 further
pessaries was given (Rodger and Baird, 1990). All second trimester placental tissue
was obtained within 48 hours of the first pessary.
2.2.2 Preparation of Placental Membranes
2.2.2a Variation of the Method ofCurrie et al. (1981)
Trophoblast was dissected from maternal membranes, washed in ice-cold PBS
(Flow Laboratories, Irvine, Scotland) to remove blood, blotted on filter paper and
weighed. Term placental cotyledons were teased apart with forceps to remove large
blood vessels, and placental villi were minced finely with scissors. Minced tissue was
homogenised (lg tissue per 2ml) in either PBS or isotonic SET (0.3M Sucrose - ImM
EDTA - 15mM Tris, pH 7.4 ) using a Polytron homogeniser (2x10 seconds at setting
8 interspersed with 1 minute on ice). Cellular debris was pelleted by centrifugation at
l,000x,g for 15 minutes at 4°C, and placental membranes were obtained by
centrifugation of the supernatant at either 30,000xg or 100,000xg for 1 hour at 4°C in
a Sorvall OTD50 ultracentrifiige. Membrane pellets were gently re-suspended in SET
by gentle homogenisation with a loose fitting glass Dounce hand homogeniser and
stored at -70°C. Supernatants from the ultracentrifiigation step were stored at -70°C
as placental extract.
Trophoblast prepared in the presence of protease inhibitors was processed as
above in SET containing 2mM EDTA, 2mM N-ethyl maleimide, 2mM PMSF and
1.46pM Pepstatin A. Membrane pellets were resuspended in SET containing the same
concentrations of protease inhibitors.
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2.2.2b Variation of the Method of Smith and Brush (1978)
Cotyledons from different regions of term placenta were dissected free from
maternal membranes, rinsed in PBS, blotted and weighed. Tissue was spread out and
agitated gently in ice-cold 0.9% (w/v) NaCl for 30 minutes with a magnetic stirrer,
ensuring the chorionic villi were well irrigated. The saline wash was centrifuged at
l,000xg for 15 minutes at 4°C and the supernatant re-centrifuged at 30,000xg for 1
hour at 4°C. The placental membrane fraction was resuspended in SET and stored at
-70°C.
2.3 PREPARATION OF RAT PITUITARY HOMOGENATES
Pituitaries were excised from immature (28-35 day old) Sprague-Dawley rats,
following CO2 asphyxiation, and homogenised (2 glands per ml) in isotonic SET using
a glass Dounce homogeniser. Aliquots were stored at -20°C until required.
2.4 GnRH ISOFORMS AND AGONIST ANALOGUES
The GnRH agonist analogue Buserelin was the gift of Dr J Sandow, Hoechst
AG, Frankfurt, Germany. Chicken GnRH-I and -II were obtained from Peninsula
Laboratories, Belmont, California, USA, and mammalian GnRH from Ayerst
Laboratories Ltd, Andover, Hants, England. Salmon and lamprey isoforms of GnRH
were the gifts of Dr J King, MRC Regulatory Peptides Research Unit, University of
Cape Town, RSA.
2.4.1 Iodination ofGnRH Isoforms and Agonist Analogues
GnRH isoforms and synthetic agonist analogues were labelled with radio-iodine
using a modification of the glucose oxidase/lactoperoxidase method ofMiyachi et al.
(1973). 5pg of hormone or analogue was incubated in a 75 x 12mm borosilicate glass
tube for 4 minutes at room temperature with 0.2M phosphate buffer, pH 7.4; 0.5pg
lacto-peroxidase in 0.1M sodium acetate, pH 5.6; 5U glucose oxidase (Miles
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Laboratories Inc., Elkhart, Indiana, USA); 0.1% (w/v) glucose; and lmCi radio-
labelled sodium iodide (Amersham International pic, Amersham, Bucks., England).
By this iodination method, peroxide is generated by the glucose/glucose oxidase
system, to avoid potential damage to the hormone or analogue by addition of relatively
high concentrations of hydrogen peroxide to the reaction. In the presence of peroxide,
lactoperoxidase oxidises radio-iodide to radio-iodine and tyrosine residues are radio-
iodinated.
The reaction was stopped with 500pl lOmM acetic acid and the reaction
products were isolated, as described below.
2.4.2 Purification of Iodinated GnRH Isoforms and Agonist Analogues
The iodination products were transferred to a 1 x 45cm Sephadex G25 (Fine)
column (Pharmacia Ltd., Milton Keynes, Bucks., England) equilibrated with 0.1%
(w/v) BSA in lOmM acetic acid. The column was pre-adsorbed with 5% (w/v) BSA
in lOmM acetic acid, to minimise non-specific binding of the reaction products to the
column. Fractions were eluted with lOmM acetic acid-0.1% (w/v) BSA and 2ml
aliquots were collected in glass tubes containing lOmM acetic acid-5% (w/v) BSA.
Elution of radioactivity was determined with a Mini-assay Type 6-20 counter.
All GnRH isoforms and agonist analogues studied gave a characteristic elution
profile of 4 peaks of radioactivity (Figure 2.1). Peak I corresponded to a high
molecular weight component which eluted in the void volume of the column, V0, and
peak II was un-incorporated radio-iodide which eluted in the total column volume, Vt-
Elution of peaks III and IV was retarded. Relative elution volumes (REV) were
calculated, using the formula (Ve-V0)/(Vt-V0), where Ve is the elution volume of the
peak. Peak III eluted at a similar position (REV = 2.6 ± 0.2) for Buserelin, Tryptorelin
and chicken GnRH-II (mean ± s.d.; n=l 1), and for other GnRH isoforms (Bramley et
al., 1992). However, peak IV was retarded to different degrees for the various tracers
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Figure 2.1 Representative elution profiles for products of GnRH
iodination
GnRH isoforms and agonists were radiolabeled by the
lactoperoxidase method and purified on 1 x 45cm Sephadex G25
(Fine) column, eluted with lOmM acetic acid-0.1% (w/v) BSA.
Fractions were collected and counted. Four peaks of radioactivity
were detected, with active iodinated hormone eluting in peak IV.
Data shown were representative elution profiles of the iodination
products for chicken GnRH-II (A) and Buserelin (B).
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Tryptorelin and chicken GnRH-II iodinations was retarded more strongly on the
column with REVrv of 8.9 ± 0.2 (mean ± s.d.; n=3) and 8.0 ± 1.0 (mean ± s.d.; n=4),
respectively.
The binding activity of the peaks of radioactivity from agonist iodinations was
determined in the rat pituitary and human placental receptor binding assays (Bramley et
al., 1992). Peak III bound poorly to GnRH receptors, while Peak IV bound well. A
similar profile of binding activity was observed for GnRH isoforms using an anti-
GnRH antibody (EL-14) to determine activity. When subjected to ion-exchange
chromatography on Sephadex QAE-A25, peak IV was not retarded, whereas peak III
bound strongly, suggesting this iodinated species carried a strong negative charge.
Sharpe and Fraser (1980) suggested that peak III represented di-iodinated, inactive
GnRH and peak IV, mono-iodinated active hormone. However, thin layer
chromatography of peaks III and IV suggested that both peaks contained mono-
iodinated GnRH (Bramley et al., 1992). Therefore, peak III appeared to represent a
charged, mono-iodinated form of GnRH, with poor binding activity. Fractions
containing active, mono-iodinated GnRH (Peak IV) were pooled and stored at -20°C.
The elution of unlabelled hormone, as determined by inhibition of binding of
1251-GnRH agonist binding to rat pituitary receptors in the presence of aliquots of
Sephadex G25 fractions, was always well separated from the active tracer peak
(Bramley et al., 1992).
2.5 MEASUREMENT OF 125I-GnRH BINDING ACTIVITY
2.5.1 125I-GnRH Binding to Placental Membrane Preparations
Placental membrane preparations (~lmg protein per tube, unless stated) were
incubated in 12 x 75mm polystyrene tubes with 100,000cpm iodinated GnRH agonist
or isoform tracer, in the presence and absence of 10"5M unlabelled Buserelin.
Incubations were carried out in triplicate, in a total volume of 1.0ml with 40mM Tris-
HC1, pH 7.4, containing 0.5% (w/v) BSA, for 1 hour at 20°C.
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After incubation, bound and free hormone were separated by precipitation with
ice-cold 0.5ml 0.5% (w/v) IgG and 1ml 25% (w/v) PEG at 4°C, followed by
centrifugation at 2,500x(g for 10 minutes at 4°C (Bramley et al., 1985). Supernatants
were aspirated and radioactivity bound to the pelleted membranes was determined
using a Packard Crystal 5400 Series Multidetector Gamma Counting System with a
counting efficiency of 75%.
Specific binding of 125I-GnRH agonist was determined by subtracting
radioactivity bound in the presence of 10"5M unlabelled hormone (non-specific
binding) from binding in the absence of unlabelled hormone (total binding). Specific
binding, corrected for membrane protein content, was expressed as % binding of the
total radioactivity added to the incubation to allow comparison between assays and
GnRH tracers.
Controls without tissue ± unlabelled hormone were always included to correct
for binding of tracer to the assay tubes and its displacement by high concentrations of
cold agonist. This was always found to be negligible (< 1% of total counts added).
2.5.2 125I-GnRH Binding to Rat Pituitary Homogenates
Binding activity of iodinated GnRH analogues to rat pituitary homogenates
was determined as described in Section 2.5.1, except incubation was for 4 hours at 4°C
and non-specific binding was determined in the presence of 10*6M unlabelled
Buserelin.
2.5.3 Determination of the Specific Activity of 125I-GnRH
The specific activity of GnRH agonist tracers was determined by self-
displacement from rat pituitary homogenates. Self-displacement curves were obtained
by incubating immature rat pituitary homogenates, as described in Section 2.5.2, with




Figure 2.2 Binding inhibition curve for Busereiin
Aliquots of rat pituitary homogenate were incubated at 4°C for 4
hours with 100,000cpm iodinated Busereiin in the presence of
increasing concentrations of unlabelled Busereiin.
Bound and free hormone were separated by PEG precipitation and
binding determined. Binding was expressed as % of total counts
added, corrected for non-specific binding to assay tubes.
Inset: Scatchard plot of the binding data.
Data shown were means ± s.d. of triplicate estimates from a single
representative experiment.
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unlabelled hormones required to reduce specific binding by 50%, i.e. IC50 cold (Figure
2.2).
In addition, specific binding of 125I-labelled GnRH agonist to rat pituitary
homogenate was measured at a range of tracer concentrations in the absence of
unlabelled GnRH analogue. Bound hormone was recovered by PEG precipitation and
(hormone bound)/(total hormone added), [B/T], was plotted against logio(hormone
added). The concentration of tracer required to decrease [B/T] to 50% was calculated
([IC50 hot]) and the specific activity of the tracer was calculated by [IC50 hot]/[ICso cold],
and expressed as pCi/pg. Specific activity for GnRH agonist binding to rat pituitary
assays ranged from 160-880 pCi/pg (Bramley et al., 1992).
Specific activity of GnRH isoforms was determined using self-displacement
from the anti-GnRH antibody EL-14 and ranged from 60-1104pCi/pg (Bramley et al.,
1992).
Scatchard plots for GnRH agonist binding to rat pituitary homogenate
indicated the presence of a single class of binding sites with affinity constants (Ka)
similar to previously published data (Figure 2.2, inset).
2.6 MEASUREMENT OF 125I-GnRH INACTIVATION
GnRH isoform and agonist analogue re-binding to placental membrane
preparations was determined by incubating excess tracer (300,000cpm) with placental
membranes in the presence and absence of 10"5M unlabelled Buserelin, as in Section
2.5.1. Bound and free tracer were separated by high speed centrifugation (30,000xg)
for 10 min at 4°C and the supernatant was carefully aspirated. Specific binding to the
placental membranes was determined and expressed as % of total counts added.
Supernatant was adjusted with Tris-BSA buffer to give 100,000cpm per tube and was
re-incubated with fresh placental membranes for 1 hour at 20°C and bound and free
hormone were separated by IgG/PEG precipitation, as described in Section 2.5.1.
10"5M unlabelled Buserelin was added to the supernatant from membranes incubated in
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the presence of unlabelled Buserelin in the first incubation, to measure non-specific
binding in the second incubation. Specific binding was expressed as % of totai counts
and tracer inactivation (decrease in binding following first incubation) was determined.
2.7 MEASUREMENT OF 125I-EGF BINDING ACTIVITY TO
PLACENTAL MEMBRANE PREPARATIONS
Unlabelled mouse EGF and 125I-EGF were the generous gift of Dr K. Brown,
AFRC Institute ofAnimal Physiology, Babraham, Cambridge, England.
Membrane protein (~0.1mg) was incubated 12 x 75mm polystyrene tubes with
50,000cpm 125I-EGF in 1.0ml total volume with 40mM Tris-HCl, pH 7.0, containing
1% (w/v) BSA and 2mM manganese chloride. Non-specific binding was determined in
the presence of lOOng EGF. After incubation at 37°C for 3 hours, bound tracer was
precipitated with IgG/PEG, separated from free by centrifugation and counted, as
described in Section 2.5.1.
2.8 ANTI-CHICKEN GnRH-II ANTIBODY BINDING ASSAY
Anti-chicken GnRH-II antisera (chll-Ab) was kindly gifted by Dr P. Sharp, The
Roslin Institute, Roslin, Midlothian, Scotland (Sharp et al., 1987; 1989). This
antibody was specific for chicken GnRH-II: the synthetic GnRH analogues, Buserelin
and Tryptorelin, were not recognised by the antibody (Figure 2.3a), and 125I-chicken
GnRH-II was not displaced from chll-Ab by the mammalian and chicken GnRH-I
isoforms ofGnRH (Figure 2.3b). Although displacement was observed in the presence
of salmon and lamprey GnRH, half maximal activity was of the order of 2,500 and
25,000 times the 50% self-displacement of chicken GnRH-II, respectively.
The effects of placental cytosol on binding of 125I-chicken GnRH-II to
antibody were determined by incubating ~30,000cpm 125I-chicken GnRH-II with
antibody in a total volume of 1ml with 40mM Tris-HCl containing 0.1% (w/v) BSA,
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Figure 2.3a Binding of iodinated Buserelin, Tryptorelin and chicken
GnRH-II to anti-chicken GnRH-II antibody
Antibody dilutions from 1:1000 to 1:1,000,000,000 were incubated
with ~30,000cpm iodinated Tryptorelin (O ), Buserelin (# ) and
chicken GnRH-II (# ) in 0.1% (w/v) BSA-40mM Tris-HCl, pH 7.4,
at 4°C for 16h.
Bound and free tracer were separated by PEG precipitation and
tracer-antibody complexes in the pellet determined. Binding was
expressed as % of total counts.
Data shown were means ± s.d. of triplicate determinations from a
single representative experiment.
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Figure 2.3b Displacement of chicken GnRH-II from anti-chicken
GnRH-II antibody by GnRH isoforms
Antibody (1:20,000 dilution) was incubated with ~30,000cpm
iodinated chicken GnRH-II in 0.1% (w/v) BSA-40mM Tris-HCl,
pH 7.4, in the presence of increasing concentrations of
unlabelled chicken GnRH-I (O) and -II (@), salmon GnRH (O),
lamprey GnRH (#) and mammalian GnRH (n) for 16h at 4°C.
Bound and free hormone were separated by PEG precipitation
and binding to antibody determined and expressed as % of total
counts added.
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placental cytosol. The bound and free tracer were separated by PEG precipitation and
tracer recovered in the pellet determined using a Packard Crystal 5400 Series
Multidetector Gamma Counting System.
2.9 DETERMINATION OF CYTOSOL BINDING BY DEXTRAN-
COATED CHARCOAL (DCC) SEPARATION
Placental cytosol was incubated with ~30,000cpm 125I-chicken GnRH-II in 1ml
(total volume) 0.1% (w/v) BSA - 40mM Tris-HCl, pH 7.4 for 2 hours at 4°C. Bound
and free tracer were separated by addition of 500pl DCC (0.25% (w/v) charcoal and
0.025% (w/v) dextran in 0.1% (w/v) BSA - 40mM Tris-HCl, pH 7.4) and
centrifugation at 2,500xg for 15 minutes at 4°C. Supernatant, containing radioactivity
not adsorbed to DCC, was decanted and counted in a Packard Crystal 5400 Series
Multidetector Gamma Counting System.
2.10 DETERMINATION OF PROTEIN
The concentration of protein in placental membrane and cytosol preparations
was determined by the method of Lowry et al. (1951). 5-lOpl of membrane or cytosol
was assayed in alkaline copper solution with Folin-Ciocalteau phenol reagent, using
crystalline bovine albumin as standard. A coloured complex was formed between the
alkaline copper-phenol reagent and tyrosine and tryptophan residues of the protein
molecules.
Absorbance at 750nm was measured using a Pye Unicam SP6-500 UV
spectrophotometer and protein values were expressed as mg protein/lOOpl. Assay
limit of detection was lOpg protein per tube.
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2.11 DETERMINATION OF ALKALINE PHOSPHATASE ACTIVITY
The method of Bessey et al. (1946) measured hydrolysis of colourless p-
nitrophenol phosphate by alkaline phosphatase in serum samples, resulting in the
liberation ofyellow /?-nitrophenol.
Using a modification of this method, ~0.05mg placental membrane protein was
incubated with 3mM p-nitrophenol phosphate (substrate) at 37°C for 15 minutes, in
1.0ml total volume with 0.2M piperazine-HCl at pH 10.3, containing ImM magnesium
acetate and O.OlmM zinc sulphate. The reaction was stopped by addition of 3ml 0. IN
NaOH-lmM EDTA solution, and /?-nitrophenol liberated was measured by absorbance
at 420nm using a Pye Unicam SP6-500 UV spectrophotometer.
2.12 STATISTICAL ANALYSIS





IN THE HUMAN PLACENTA
3.1 INTRODUCTION
Placental binding sites for GnRH differ from pituitary GnRH receptors in their
affinity and specificity for the hormone and its agonist analogues. In the pituitary, the
GnRH analogue Buserelin ([D-Ser(tBu)6]-des-Gly10-GnRH N-ethylamide) is a
superagonist with an affinity constant of 4.8 x 109 M"1, approximately ten times the
receptor affinity for mammalian GnRH, the native hormone (Clayton and Catt, 1980).
However superagonist analogues do not possess higher binding affinity for the
placental binding site, which has been found to have affinities in the range 5.5 x 105 -
6.2 x 107 M"1, similar to values quoted for the native hormone (Currie et al., 1981;
Belisle et al., 1984; Iwashita et al., 1986). In addition, certain isoforms ofGnRH will
bind specifically to placental but not to pituitary membranes (Bramley, 1989).
While the human placenta expresses mRNA for GnRH (Seeburg and Adelman,
1984) and a physiologically active decapeptide identical to the hypothalamic hormone
has been isolated from placental extracts (Lee et al., 1981; Tan and Rousseau, 1982),
the major GnRH-like activity in the placenta may differ from the native hormone
(Siler-Khodr, 1987). Differential transcription of the GnRH gene in the hypothalamus
and placenta gives rise to an unusually long 5'- untranslated region of placental GnRH
mRNA. In the placenta, the first intron is not removed from the primary gene
transcript, suggesting that different promoters are involved in GnRH expression in the
two tissues (Adelman et al., 1986; Radovick et al., 1990). If endogenous placental
GnRH is structurally different from the hypothalamic decapeptide, then this may
explain the comparatively low affinity of the placental receptor for the native hormone
(and agonist analogues derived from it).
Previous studies have used variations of the pituitary radio-receptor assay to
measure GnRH agonist binding to placental membrane preparations (Currie et al.,
1981; Belisle et al., 1984; Iwashita et al., 1986), with incubations of 60 - 90 minutes at
20 - 22°C in the presence of 10"5M unlabelled agonist used for placental binding
assays. Placental membranes tended to be prepared by differential centrifugation of
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homogenised tissue with various refinements introduced to attempt to maximise
binding affinity. Iwashita et al. (1986) homogenised the tissue in buffer containing the
kallikrein inhibitor aprotinin, and Belisle et al. (1984) obtained a 30-fold biochemical
enrichment of the membrane preparation by sedimentation on a continuous sucrose
density gradient without improving the low affinity binding observed by Currie et al.
(1981). It was therefore necessary to validate the binding assay and placental
preparation methods used in this study, prior to further investigation of the hormone
binding site.
Unless otherwise stated, the GnRH binding assay used was the method
described in 2.5.1 and the placental preparation method used was the variation on the
method ofCurrie et al. (1981), as described in 2.2.2a.
3.2 BINDING ACTIVITY OF 125I-BUSERELIN TO TERM PLACENTAL
MEMBRANES
3.2.1 Effect of Time and Temperature of Incubation on 125I-Buserelin Binding
to Term Placental Membranes
Term placental membranes were incubated with 125I-Buserelin at 4°C, 20°C
and 37°C for up to 6 hours, to determine the stability of the receptor and/or ligand.
From Figure 3.1, specific binding was dependent on both the time and
temperature of the incubation. At 4°C, binding reached maximal levels slowly, and
considerable inter-assay variation was observed in the maximal binding levels achieved
and the duration of incubation required to achieve equilibrium. Ligand-receptor
association was rapid at 37°C, peaking in under 30 minutes, but quickly fell to
indeterminable levels. At 20°C, however, equilibrium was reached after 30 minutes
and binding remained stable for up to 90 minutes incubation, before slowly declining.
Therefore, incubation of 20°C for 60 minutes was selected as standard to assay for
placental binding, to give optimal binding ofGnRH analogue to placental membranes.
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INCUBATION (h)
Figure 3.1 Effect of time and temperature of incubation on the binding
characteristics of radio-labelled Buserelin
Term placental membranes (~lmg protein/tube) were incubated
with 100,000cpm radio-labelled Buserelin in the presence and
absence of lOjiM uniodinated Buserelin at 4°C ( a), 20°C ( ®)
and 37°C ( ) for up to 6h.
Bound and free hormone were separated by PEG precipitation,
specific binding was determined and expressed as % of total
counts, corrected for protein concentration.
Data shown were from a representative term placenta; points
are mean ± s.d. for one experiment in triplicate.
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3.2.2 Effect of Pre-incubation of Placental Membranes on 125I-Buserelin
Binding
Term placental membranes were incubated at 4°C, 20°C and 37°C for up to 6
hours prior to assay, as described in 2.5.1, for 125I-Buserelin binding (Figure 3.2).
Binding of ligand to membranes was not affected by up to 6 hours pre¬
incubation at 4°C, when compared to controls thawed and assayed immediately. At
20°C and 37°C, binding was stable for up to 2 hours pre-incubation, decreasing after 6
hours to 79% and 37% of control binding, respectively.
All placental membranes were frozen after preparation until required for assay,
when aliquots were thawed at room temperature and stored on ice, typically for less
than 10 minutes, before adding to the incubate. From Figure 3.2, membrane binding
was unaffected by this procedure. As all buffers were equilibrated to 20°C before
assay, the addition of small volumes of ice-cold membranes had a negligible effect on
the temperature of the binding assay.
3.2.3 Effect of Method of Tissue Preparation on 125I-Buserelin Binding
3.2.3a Preparation by variation of the method of Currie et al. (1981)
Placental membranes were prepared from individual term placentae by the
method of Currie et al. (1981), by homogenisation in PBS and centrifugation for 1
hour at 100,000xg, or by homogenisation in SET and centrifugation for 1 hour at
30,000xg or 100,000xg (for details see 2.2.2a). Specific binding of 125I-Buserelin
tracer to the three types of membrane preparations was compared by assay as
described in 2.5.1.
No significant difference between the binding activity of membranes prepared
in SET or PBS was found (Table 3.1), allowing comparison of membranes prepared
under any of these conditions, although SET appeared to facilitate membrane pellet
formation at a lower centrifuge speed, as binding per mg protein did not increase in






























Figure 3.2 Effect of pre-incubation of membranes on binding of
radio-labelled Buserelin
Term placental membranes (~lmg protein) were incubated at 4°C
(A), 20°C (• ) and 37°C (« ) for up to 6h, then incubated for lh at
20°C with 100,000cpm radiolabelled Buserelin, in the presence and
absence of 10(iM uniodinated Buserelin.
Bound and free hormone were separated by PEG precipitation and
specific binding was determined. Specific binding was corrected for
protein, and expressed as % of control binding (no pre-incubation).
Data shown were mean ± s.d. of triplicate determinations from a
representative term placenta.
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METHOD I II III
(n) (9) (3) (6)
SPECIFIC BINDING 15.9± 1.6 15.2 ± 1.3 17.1 ±2.1
(% total counts/mg)
protein (mg) 0.941 ±0.075 1.002 ±0.080 0.897 ±0.249
Table 3.1 Comparison of method of membrane preparation: variation of the
method ofCurrie et al. (1981)
Membranes were prepared from a term placenta, by the method of Currie et al.
(1981), homogenised in SET and centrifuged at 30,000xg- (method I) or 100,000xg
(method II) or homogenised in PBS and centrifuged at 100,000xg (method III).
Placental membranes (~lmg protein)were incubated with 100,000cpm 125I-Buserelin
for lh at 20°C, in the presence and absence of 10pM uniodinated Buserelin. Bound
and free hormone were separated by PEG precipitation and specific binding
determined. Specific binding was expressed as % of total counts added, corrected for
protein concentration. By student's t-test, binding was not significantly different. Data
represents mean ± s.d.; n = number ofbinding assays.
METHOD I II III
(n) (5) (5) (5)
SPECIFIC BINDING
(% total counts/mg)
3.8 ±0.5 3.8 ±0.3 4.0 ±0.4
protein (mg) 1.042 ±0.282 1.065 ±0.220 1.017 ± 0.190
Table 3.2 Comparison of method of membrane preparation:variation of the
method of Smith and Brush (1978)
Membranes were prepared from a term placenta by the method of Currie et al. (1981),
homogenised in SET and centrifuged at 30,000xg- (method I) or homogenised in PBS
and centrifuged at 100,000xg (method II) or by the method of Smith and Brush (1978)
in SET and centrifuged at 30,000xg (method III).
Placental membranes (~lmg protein) were incubated with 100,000cpm 125I-Buserelin
for lh at 20°C, in the presence and absence of lOpM uniodinated Buserelin. Bound
and free hormone were separated by PEG precipitation and specific binding
determined. Specific binding was expressed as % of total counts added, corrected for
protein concentration. By student's t-test, binding was not significantly different. Data
represents mean ± s.d.; n = number ofbinding assays.
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3.2.3b Comparison of membrane preparation by the methods of Currie et ah
(1981) and Smith and Brush (1978)
Cotyledons from individual term placentae were processed by the method of
Currie et al. (1981) by homogenisation in PBS and centrifiigation for 1 hour at
100,000xg , or by homogenisation in SET and centrifugation for 1 hour at 30,000x,g
(2.2.2a), or by the method of Smith and Brush (1978) as described in 2.2.2b.
Membranes prepared by all three methods demonstrated similar levels of
specific GnRH agonist binding per mg of protein (Table 3.2). No enrichment of the
membrane binding site was observed in NaCl-washed preparations, and placental
membranes were routinely prepared by the former method.
3.2.4 Effect of Placental Membrane Protein Concentration on 125X-Buserelin
Binding
Increasing concentrations of term placental membranes were incubated with
125I-Buserelin under standard assay conditions (see 2.5.1).
Total binding, non-specific binding and specific binding of Buserelin increased
with protein concentration in a linear manner at low concentrations (Figure 3.3).
However, at protein concentrations greater than ~1.5mg, binding began to plateau.
When binding was expressed as specific binding/mg protein, the non-linear behaviour
of high levels of protein had an appreciable effect on interpretation of specific binding
activity and so assays were routinely standardised to 1.0 (± 0.2) mg protein.
3.2.5 Effect of Uniodinated Buserelin on 125I-Buserelin Binding to Placental
Membranes
The affinity of 125I-Buserelin for the term placental membrane binding site was
determined by self-displacement assay, where term placental membranes were
incubated with 125I-Buserelin in the presence of increasing concentrations of









Figure 3.3 Effect of protein concentration on
characteristics of radiolabeled Buserelin
the binding
Increasing volumes of term placental membranes were
incubated at 20°C for lh with l()(),()()0cpm iodinated Buserelin,
in the presence and absence of l()p.M unlabelled Buserelin.
Bound and free hormone were separated by PEG precipitation
and specific binding was determined. Total binding (O ), non¬
specific binding, ie binding in the presence of unlabelled
hormone (#•) and specific binding ( ; )were expressed as % of
total counts added.
Data shown were from a representative term placenta; points are
mean ± s.d. for one experiment performed in triplicate.
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Iodinated Buserelin was displaced from term placental membranes by
increasing concentrations of cold hormone (Figure 3.4). Absolute levels of binding of
the labelled agonist to placental membranes varied between individual placental
membrane preparations, but displacement by cold hormone was consistently observed
in the presence of concentrations of uniodinated Buserelin in excess of 30ng, with 50%
displacement observed with approximately 300ng uniodinated Buserelin. Binding
remaining at lOOpg uniodinated Buserelin represented non-specific binding of the
radio-labelled hormone to membranes and test tube.
3.2.6 Effect of Protease Inhibitors on 125I-Buserelin Binding to Term Placental
Membranes
Bramley (1987) described the rapid inactivation ofBuserelin immunoactivity by
placental membranes at 20°C, and Kang and Siler-Khodr (1992) have described a
cytosolic chorionic protease which specifically degrades the proline-containing
molecules GnRH, thyrotrophin releasing hormone and angiotensin II in the placenta.
The specificity of placental binding sites for analogues of GnRH has been
demonstrated (Bramley et al., 1992) but, as GnRH binding was shown to plateau at
high levels of membrane protein (Figure 3.3), the possibility that the low affinity
binding of GnRH in placental membrane preparations may represent, at least in part,
binding to a degradative protein was investigated by determination of specific binding
in the presence of protease inhibitors.
3.2.6a Effect of a 'cocktail' of inhibitors on 125I-Buserelin binding
Term placental membranes were incubated with 125I-Buserelin under standard
assay conditions, as described in 2.5.1, in the presence of the protease inhibitors
EDTA (2mM), N-ethyl maleimide (2mM), PMSF (2mM) and Pepstatin A (1.46pM).
This 'cocktail' of inhibitors had activity against the four major classes of tissue
proteases (Barrett, 1977).
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Figure 3.4 Effect of unlabelled Buserelin on the binding characteristics of
radio-labelled Buserelin
Term placental membranes (~lmg protein) were incubated with
100,000cpm radio-labelled Buserelin at 20°C for lh in the presence of
increasing concentrations of unlabelled hormone.
Bound and free hormone were separated by PEG precipitation.
Binding was determined, corrected for non-specific binding to the
tube, and was expressed as % of control binding, ie binding in the
absence of unlabelled Buserelin.
Data shown were the mean ± s.d. of three displacement assays
performed in triplicate.
*P<0.05; **P<0.01; ***P<0.005 when compared to binding in in the
absence of unlabelled Buserelin.
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The presence of the 'cocktail' of protease inhibitors, with combined activity
against a broad spectrum of proteases, reduced binding to negligible levels in
membrane preparations from term placentae (Table 3.3), irrespective of levels of
binding activity in the absence of inhibitors. This suggested that GnRH binding
represented binding to degradative enzymes, not binding to membrane receptor sites.
3.2.6b Effect of individual inhibitors on 125I-Buserelin binding
To identify which protease inhibitor was responsible for the reduction of
binding shown in Table 3.3, term placental membranes were incubated with 125I-
Buserelin under standard conditions (see 2.5.1), in the presence of each individual
protease inhibitor. In addition, membranes were incubated as a control with ethanol
(10% v/v), the vehicle for PMSF.
Binding ofBuserelin to placental membranes in the presence of Pepstatin A and
EDTA was comparable to binding in the absence of inhibitors (Figure 3.5). Binding
was decreased by -25% in the presence of N-ethyl maleimide. This was significant
(P<0.05) and suggested that a component of binding may be due to binding of GnRH
to thiol protease(s). Binding was reduced to negligible levels in the presence of the
inhibitor 'cocktail' and PMSF. However, ethanol, the vehicle for PMSF which has low










A 2.6 ±0.9 0.1 ±0.3
B 15.0 ±1.5 0.0 ±0.5
C 8.1 ±0.6 0.4 ± 0.1
D 3.5 ±0.9 0.2 ±0.2
E 3.9 ±0.6 0.2 ±0.1
Table 3.3 Effect of protease inhibitors on 125I-Busere!in binding
to placental membranes
Term placental membranes (~lmg protein) were incubated with
100,000cpm 125I-Buserelin, in the presence and absence of lOpM
uniodinated Buserelin, for lh at 20°C, in the presence and absence of a
'cocktail' of protease inhibitors. Bound and free hormone were separated
by PEG precipitation and specific binding determined.
Specific binding was expressed as % of total counts added, corrected for
protein concentration.
Data shown represent mean ± s.d. of triplicate determinations for five
individual term placental membrane preparations.
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inhibitors 'cocktail' Pcpstatin EDTA N-EM PMSF ethanol
A
INHIBITOR
Figure 3.5 Effect of individual protease inhibitors on the binding
characteristics of radio-labelled Buserelin
Term placental membranes (~lmg protein) were incubated, in the
presence and absence of lOjiM uniodinated Buserelin, with
l()(),0()()cpm iodinated Buserelin at 20°C for lh in the presence of
protease inhibitors.
Bound and free hormone were separated by PEG precipitation.
Specific binding was determined and expressed as % of total counts
added per mg protein.
Data shown were from a representative term placental membrane
preparation, assayed in triplicate - error bars represent s.d.; asterisks
denote significant differences from control i.e. binding in the
absence of inhibitors (*P<0.05; **P<().()01).
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3.2.6c Effect of ethanoS on 125I-Buserelin binding
To investigate the effect of ethano! on Buserelin binding, term placental
membranes were incubated under standard conditions (see 2.5.1) in the presence of
increasing concentrations of ethanol.
Binding ofBuserelin was reduced to halfmaximal levels by the presence of 1%
(v/v) ethanol in the assay medium and reduced to negligible levels in the presence of
20% (v/v) ethanol (Figure 3.6).
3.2.7 Effect of Preparing Placental Membranes in the Presence of the 'Cocktail'
of Protease Inhibitors
Term placental membranes from individual placentae were prepared in the
presence and absence of the protease inhibitor 'cocktail', as described in 2.2.2a. To
allow direct comparison, individual placentae were dissected, placental tissue was
randomly divided into two lots of approximately equal weight and homogenised in the
presence or absence of protease inhibitors. Membranes prepared in the presence of
inhibitors were resuspended and stored in inhibitor-containing medium, while
membranes prepared in the absence of inhibitors were resuspended and stored in
medium alone. Inhibitor-containing medium contained 1% (v/v) ethanol.
Membranes were incubated with 125I-Buserelin under standard assay conditions
(see 2.5.1). The effect of preparing membranes with or without inhibitors is shown in
Table 3.4.
Binding of iodinated Buserelin to membranes prepared in the presence of
protease inhibitors was reduced by 20-45%, compared to membranes from the same
placenta prepared without inhibitors. This difference in binding was statistically
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Figure 3.6 Effect of ethanol on the binding characteristics of
radio-labelled Buserelin
Term placental membranes (~lmg protein) were incubated with
100,000cpm radio-labelled Buserelin, in the presence and
absence of 10|iM uniodinated Buserelin, at 20°C for lh with
increasing concentrations (0-20% (v/v)) of ethanol.
Bound and free hormone were separated by PEG precipitation,
specific binding was determined and expressed as % of total
counts added, corrected for protein concentration.
Data shown were from a representative term placental











A 14.2 ±1.3 10.9 ±0.7
B 15.0 ±0.6 8.1 ± 1.2
C 21.8 ± 1.0 12.5 ±0.5
D 16.9 ±0.8 10.2 ±0.5
E 12.5 ± 0.6 10.3 ±0.9
Table 3.4 Effect of preparing placental membranes in the
presence of protease inhibitors on the binding
characteristics of 125I-Busere!in
Term placental membranes were prepared in the presence and absence of
a 'cocktail' of protease inhibitors (2mM EDTA, 2mM N-ethyl maleimide,
2mM PMSF and 1.46pM Pepstatin A).
Placental membranes (~lmg protein) were incubated with 100,000cpm
125I-Buserelin for lh at 20°C in the presence and absence of lOpM
uniodinated Buserelin. Bound and free hormone were separated by PEG
precipitation and specific binding determined.
Specific binding was expressed as % of total counts added, corrected for
protein concentration.
Data shown represent mean ± s.d. of triplicate determinations for five
individual term placental membrane preparations.
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3.2.8 Summary
The optimal assay conditions for determining binding of iodinated GnRII
analogues to placental membranes were confirmed to be incubation with tracer at 20°C
for 1 hour, with non-specific binding measured in the presence of 10"5M uniodinated
hormone. Membranes were stable for up to 6 hours at 4°C and for 2 hours at 20°C,
and hormone binding was not affected by storing thawed membranes on ice prior to
assay. Membrane protein was standardised at ~lmg due to the non-linear effect of
high protein concentrations on ligand binding.
Placental membranes were routinely prepared as described in 2.2.2a, by
homogenisation in SET and centrifiigation at 30,000xg or homogenisation in PBS and
centrifiigation at 100,000xg. Preparing membranes by the method of Smith and Brush
(2.2.2b) did not improve the specific activity ofGnRH binding.
Binding was significantly decreased in the presence of N-ethyl maleimide and
ethanol in the incubate. 2mM N-ethylmaleimide was thought to inhibit tracer binding
to thiol protease activity in the membrane preparation. The nature of the ethanol effect
on binding was uncertain but was observed to be dose-dependent.
3.3 BINDING ACTIVITY OF 125I-BUSERELIN TO PRE-TERM
PLACENTAL MEMBRANES
3.3.1 Comparison of 125I-Busere!in Binding to Pre-term and Term Placental
Membranes
The binding of Buserelin to early, mid- and full term placental membranes,
under the standard assay conditions described above, was compared. Mean binding ±
standard deviation of the mean was calculated for Buserelin binding of membranes
prepared from placentae from early, mid- and full term gestation and a summary plot
ofbinding with stage of gestation is shown in Figure 3.7.
For membranes prepared from placentae of 6-10 weeks gestation, mean
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Figure 3.7 Comparison of binding of radio-labelled Buserelin to pre-term
and term human placental membranes
Pre-term (ranging from 6-18 weeks gestation) and full term
placental membranes (~lmg protein) were incubated with
100,000cpm iodinated Buserelin at 20°C for lh, in the presence
and absence of IOjiM uniodinated Buserelin.
Bound and free hormone were separated by PEG precipitation.
Specific binding was determined and expressed as % of total
counts added, corrected for protein concentration.
Each point represents mean of triplicate determinations. n=27 for
6-10 weeks; n=23 for 11-18 weeks; n=43 for term. Error bars have
been omitted for clarity.
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weeks gestation), binding fell to 1.0±0.8% of total counts added per mg protein. In
comparison, binding for term placental membranes was 9.2±4.7% of total counts
corrected for protein concentration. Average protein concentration was 0.97±0.22
mg.
The difference between the binding levels observed at 6-10 weeks gestation,
11-18 weeks gestation and full term were significant (P<0.001 for all three pairs of
t-tests).
3.3.2 Protein Concentration and 125I-Buserelin Binding to Pre-term Placental
Membranes
Specific binding of increasing concentrations of pre-term placental membranes
was determined after incubation with 125l-Buserelin for 1 hour at 20°C.
For placental membranes of 6-10 weeks gestation, specific binding of Buserelin
increased with protein concentration in a linear manner at low concentrations (Figure
3.8). However above ~2mg protein, binding began to plateau. For early pre-term
placentae, however, the small size of the tissue meant that only low levels ofmembrane
protein were usually recovered.
For mid-term gestation membranes, low levels of binding (<2% of total counts)
were observed at all protein concentrations and Buserelin binding did not increase with
increasing protein concentration.
3.3.3 Self-displacement of Buserelin from Pre-term Placental Membranes
The effect of incubating pre-term placental membranes with 125I-Buserelin in
the presence of increasing concentrations of uniodinated hormone, under standard
assay conditions (as 2.5.1), is shown in Figure 3.9.
As for term placental membranes, radio-labelled Buserelin was displaced from
pre-term placental membranes by concentrations greater than 30ng of uniodinated
hormone. However, maximal displacement of labelled agonist from pre-term placental
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Figure 3.8 Effect of protein concentration on the binding of radio-labelled
Buserelin to pre-term placental membranes
Increasing volumes of early and mid-term placental membranes
were incubated with 10(),000cpm iodinated Buserelin at 20°C for
lh, in the presence and absence of lOjiM Buserelin.
Bound and free hormone were separated by PEG precipitation.
Specific binding was determined and expressed as % of total
counts added.
Data shown were mean ± s.d. for membranes prepared from four
representative placentae of 6-10 weeks gestation (°) and from two




Figure 3.9 Displacement of iodinated Buserelin from pre-term
placental membranes by uniodinated analogue
Early and mid-term placental membranes (~lmg protein) were
incubated with 100,00()cpm radio-labelled Buserelin at 20°C
for lh in the presence of increasing concentrations of
unlabelled Buserelin.
Bound and free hormone were separated by PEG precipitation.
Binding was determined, corrected for non-specific binding to
the tube and expressed as % of control binding in the absence
of 'cold' hormone.
Data shown were representative curves for Buserelin binding to
membranes prepared from early placentae p ) and from
mid-term placenta (<> ). Each point was mean ± s.d. for
triplicate determinations from a single experiment.
membranes varied with gestational age. 10"5M uniodinated Buserelin displaced 90%
of labelled agonist from early gestation placental binding sites and displaced 80% of
binding at mid-term. Half-maximal self-displacement of Buserelin from early placental
membranes was consistent with displacement from term placental membranes, i.e.
~300ng. At mid-term, 50% displacement was approximately ten-fold higher.
3.3.4 Protease Inhibitors and Buserelin Binding to Pre-term Placental
Membranes
Buserelin was incubated with early and mid-term placental membranes in the
•< *'
presence and absence of the protease inhibitors listed in 3.2.6a.
GnRH agonist binding to early placental membranes was inhibited by the
presence of the mixture of protease inhibitors (Table 3.5). However, insufficient
membrane protein was available to investigate the particular inhibitory factor(s)
involved. Binding of Buserelin to mid-term placental membranes was very low in the
absence of protease inhibitors and the inclusion of inhibitors in the incubation failed to
increase binding.
3.3.5 Summary
Binding of the GnRH agonist Buserelin to human placental membranes varied
throughout gestation. The high levels of GnRH binding observed in early trophoblast
(6-10 weeks gestation) fell to almost non-specific levels by 11-18 weeks, returning to
high levels again at term.
At both early and mid gestation, Buserelin binding increased in a linear fashion
at low protein concentrations, but began to plateau at higher protein levels. However,
maximal binding at mid-term was markedly lower and levelled off at lower protein
concentrations. However, incubation in the presence of the cocktail of protease










7 8.2 ±0.3 1.8 ±0.4
13 0.8 ±0.6 0.4 ±0.2
15 0.1 ±0.4 0.2 ±0.3
16 1.2 ±0.8 0.8 ±0.5
Table 3.5 Effect of protease inhibitors on 125I-BusereIin binding
to pre-term placental membranes.
Pre-term placental membranes (~lmg protein) were incubated with
100,000cpm 125I-Buserelin, in the presence and absence of 10pM
uniodinated Buserelin, for lh at 20°C in the presence of a 'cocktail' of
protease inhibitors. Bound and free hormone were separated by PEG
precipitation and specific binding determined.
Specific binding was expressed as % of total counts added, corrected for
protein concentration.
Data shown represent mean ± s.d. of triplicate determinations.
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3.4 CHARACTERISATION OF BINDING ACTIVITY OF GnRH
ISOFORMS TO PLACENTAL MEMBRANES
The five isoforms of GnRH investigated were designated mammalian GnRH
(the hypothalamic decapeptide), chicken GnRH-I and II, salmon GnRH and lamprey
GnRH. Their primary structure is shown in Figure 3.10. Mammalian GnRH has been
found in the hypothalamic tissue of various mammalian species, e.g. mice, rats, pigs,
sheep and humans, and in human placental tissue. Of the two forms of GnRH which
have been sequenced from chicken brain, chicken GnRH-II appears to have evolved
earlier than chicken GnRH-I and has been found in species from all major vertebrate
groups, including primitive mammals such as marsupials (King et ai, 1989). It has
been postulated that chicken GnRH-II has a role as a neurotransmitter or
neuromodulator (Katz et al., 1990).
3.4.1 Comparison of Isoform Binding to Rat Pituitary Homogenate and Human
Placental Membrane Preparations
Human placental membranes and rat pituitary homogenates were incubated
under the standard assay conditions described in 2.5.1 with iodinated isoforms of
GnRH and the GnRH agonist analogue Buserelin.
Binding of the iodinated GnRH isoforms and Buserelin to human placental
membrane preparations of 7, 11, 14 and 40 weeks gestation and to homogenate of rat
pituitaries is compared in Figure 3.11. Rat pituitary specifically bound Buserelin, but
binding of the five GnRH isoforms studied was negligible (<1% of total counts added).
Specific binding of Buserelin to placental membrane preparations was less than that
observed with rat pituitary homogenate. However, specific binding of salmon GnRH
and chicken GnRH-II to placental membrane preparations was comparable to binding
of Buserelin. Placental membrane binding of mammalian GnRH was low but
detectable, while binding of chicken GnRH-I and lamprey GnRH was negligible (<1%
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1 2 3 4 5 6 7 8 9 10
LAMPREY pGlu His Tyr Ser Leu Glu Trp Lys Pro Gly-NH2
CHICKEN II pGlu His Trp Ser His Gly Trp Tyr Pro Gly-NH2
SALMON pGlu His Trp Ser Tyr Gly Trp Leu Pro Gly-NH2
CHICKEN I pGlu His Trp Ser Tyr Gly Leu Gin Pro Gly-NH2
MAMMALIAN pGlu His Trp Ser Tyr Gly Leu Arg Pro Gly-NH2
BUSERELIN pGlu His Trp Ser Tyr D-Ser(tBu) Leu Arg Pro NHEt
Figure 3.10 Primary structure of five isoforms of GnRH and a synthetic
agonist analogue ofGnRH
GnRH isolated from species from classes of Aves (chicken),
Osteichthyes (salmon), Agnatha (lamprey) and Mammalia
(human, porcine, murine, ovine, rat) is highly conserved
(Sherwood, 1987).
All characterized forms of GnRH are 10 amino acids in length.
The terminal residues and positions 2, 4 and 9 are invariant. The
pyro-glutamate and N-terminal glycine may protect the molecule
against degradation; substitution of Gly10 by ethylamide further
decreasing the susceptibility of buserelin to degradation.
Positions 2 and 9 are thought to stabilize the conformation of the
molecule (a (3 turn is hypothesized at positions 5 and 6).
Changes at positions 3 and 7 are conservative, between strongly
hydrophobic amino acids; both tyrosine and tryptophan are
aromatic amino acids.
Positions 5-8 are thought to be involved in receptor binding, and
most evolutionary amino acid substitutions have occurred in this
region. The most striking changes are at positions 5 and 8 where
both strongly hydrophilic (histidine, lysine and arginine) and
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GESTATION
Figure 3.11 Comparison of binding of GnRH isoforms and Busereiin to human
term placental membrane preparations and rat pituitary homogenate
Human placental membrane fractions and rat pituitary homogenate were
incubated under standard assay conditions in the presence and absence of
excess unlabelled Busereiin with 100,000cpm of iodinated Busereiin (H ),
salmon GnRH ( H ), chicken GnRH-II ( IB ), mammalian GnRH ((3 ),
lamprey GnRH (m) and chicken GnRH-I (H).
Bound and free hormone were separated by PEG precipitation and specific
binding determined, corrected for protein and expressed as % of total
counts added ± s.d.
57
of total counts added). Lower levels of binding were observed for all isoforms
and Busereiin at mid-gestation.
At all stages of gestation, the pattern of binding activity to placental
membranes was: Busereiin, salmon GnRH, chicken GnRH-II
> mammalian GnRH» lamprey GnRH, chicken GnRH-I
3.5 CHARACTERISATION OF BINDING ACTIVITY OF GnRH
AGONIST ANALOGUES TO PLACENTAL MEMBRANES
The binding activity of the GnRH agonist analogues Busereiin ([D-Ser(tBu)6]-
des-Gly10-GnRH N-ethylamide) and Tryptorelin ([D-Trp6]-des-Gly10-GnRH N-
ethylamide) was compared. The structures of the two analogues and their relation to
mammalian GnRH is shown in Figure 3.12.
1 6 10
MAMMALIAN pGlu His Trp Ser Tyr Gly Leu Arg Pro Gly-NH2
GnRH
BUSERELIN pGlu His Trp Ser Tyr D-Ser Leu Arg Pro NHEt
(tBu)
TRYPTORELIN pGlu His Trp Ser Tyr D-Trp Leu Arg Pro NHEt
Figure 3.12 Primary structure of mammalian GnRH and two synthetic
analogues of mammalian GnRH
3.5.1 Comparison of GnRH Agonist Binding to Rat Pituitary Homogenate and
Human Placental Membranes
Human placental membranes and rat pituitary homogenates were incubated
under standard conditions (as described in 2.5.1) with the iodinated GnRH agonist
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analogues Buserelin or Tryptorelin. Binding of the two agonist analogues of
mammalian GnRH are compared in Figure 3.13.
Rat pituitary bound both analogues of mammalian GnRH, but specific binding
of Tryptorelin was significantly greater than Buserelin by 42 - 49% (P < 0.002; n=4).
The rat pituitary homogenates were standardised for protein concentration (0.22-
0.32mg protein).
Term placental membranes specifically bound both agonists, with specific
binding of Tryptorelin ranging from 20 - 35% greater than specific binding of
Buserelin. This was statistically significant (P<0.05; n=10).
Both analogues also bound specifically to pre-term placental membranes, with
a general trend of greater binding of Tryptorelin compared to Buserelin. However,
binding of GnRH analogues to pre-term preparations was more variable than binding
to term placental membranes and, with those preparations which exhibited lower levels
of GnRH binding, Tryptorelin did not consistently exceed Buserelin binding.
Preparations of mid-term membranes exhibited significantly lower levels of binding of
both analogues when compared to membranes from early gestation placentae (P<0.05;
n=8).
3.5.2 Effect of Protein Concentration on Agonist Binding to Placental
Membranes
Increasing concentrations of term placental membranes were incubated under
standard binding assay conditions (see 2.5.1) with 125I-Buserelin or 125I-Tryptorelin.
At low concentrations of membrane protein, specific binding of Tryptorelin
increased with membrane protein in a linear manner. Binding began to plateau above
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Figure 3.13 Comparison of Buserelin and Tryptorelin binding to human
placental membranes and rat pituitary homogenates
Rat pituitary homogenate (A ; -0.27 mg protein) and human placental
membranes (®: early, <> mid, c term;-lmg protein) were incubated
under standard conditions with 100,000cpm iodinated Buserelin or
100,000cpm iodinated Tryptorelin, in the presence and absence of
excess unlabelled Buserelin.
Bound and free hormone were separated by PEG precipitation. Specific
binding was determined and expressed as % of total counts added.
Each point represents mean for triplicate determinations; error bars have





Figure 3.14 Effect of protein concentration on binding of the GnRH
agonists Buserelin and Trytorelin to term placental membranes
Increasing volumes of term placental membranes were incubated at
2G°C for lh with I00,000cpm iodinated Buserelin p) and with
l()(),()()0cpm iodinated Tryptorelin (• ), in the presence and absence
of l()p.M unlabelled Buserelin.
Bound and free hormone were separated by PEG precipitation,
specific binding was determined and expressed as % of total counts
added.
Membranes were prepared from a single term placenta, as described
in Section 2.2.2, homogenised in SET and centrifuged at 30,000x,g
(dashed line) and homogenised in PBS and centrifuged at
100,()00xg (solid line).
Each point is mean ± s.d. for triplicate determinations from a single
experiment.
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3.5.3 Comparison of the Effect ofMembrane Preparation on Agonist Binding
The preparations shown in Figure 3.14 were prepared from the same term
placenta by the method described in 2.2.2a, homogenised in SET and centrifuged at
30,000xg or homogenised in PBS and centrifuged at 100,000xg. The difference in
binding of 125I-Buserelin and 125I-Tryptorelin to the two membrane preparations was
not statistically significant.
3.5.4 Summary
Binding of Tryptorelin to rat pituitary homogenate and human term placental
membranes was significantly greater than Buserelin binding to the same preparations
(P<0.002 and P<0.05, respectively). Binding to pre-term membranes was more
variable and, especially with those preparations which bound lower levels of hormone,
binding of Tryptorelin did not always exceed the levels ofbound Buserelin.
Binding of Tryptorelin to term placental membranes increased with protein
concentration in a similar manner to that of Buserelin, although levels of binding were
consistently higher. As for Buserelin, placental membrane binding was not affected by
preparation in SET or PBS.
3.6. TRACER DEGRADATION BY PLACENTAL MEMBRANES
In order to determine if gestational age-related differences in the degradation of
Buserelin by placental membrane preparations were responsible for the marked
reduction in binding observed between 11 and 18 weeks, the ability of iodinated
Buserelin to rebind to placental membranes, following an incubation with placental
membranes, was investigated.
125I-Buserelin was incubated with placental membranes under standard
conditions and bound and free tracer were separated by high-speed centrifugation, as
described in Section 2.6. Unbound tracer was then re-incubated with either fresh
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membranes of the same preparation or with a term placental membrane preparation
used as a standard.
From Figure 3.15, re-binding to the same preparation was usually slightly less
than binding to the first incubation, but the difference was always <1.2 % of total
counts. Re-binding of tracer to a standard term membrane fraction was within ±5% of
control binding for the term preparation. Tracer previously incubated with mid-term
placental membranes, which bound low levels of iodinated hormone, bound to term
standard membrane preparations with no loss activity. Re-binding to mid-term
membranes, however, was still low.
3.7 RECOVERY AND PURITY OF PLACENTAL MEMBRANES
The purity of the membrane fraction recovered at each stage of gestation was
compared in order to determine if contamination of mid-term membranes with non-
villous tissue could account for the decreased binding observed at mid-gestation. The
placental surface membrane markers EGF receptors and alkaline phosphatase activity
(Smith and Brush, 1978) were determined to assess any correlation existed between
GnRH and EGF binding, alkaline phosphatase activity and stage of gestation.
3.7.1 Binding of EGF to Pre-term and Term Placental Membranes
Increasing concentrations of term and pre-term placental membranes were
incubated with 125I-EGF under standard binding conditions for the growth factor,
described in Section 2.7.
From Figure 3.16, specific binding of EGF to placental membranes increased
with protein concentration in a similar manner at all stages of gestation. At low levels
































Figure 3.15 Degradation of iodinated Buserelin by placental membranes
Pre-term and term placental membranes (~lmg protein) were
incubated in duplicate at 20°C for lh with 300,000cpm radio-labelled
Buserelin, in the presence and absence of uniodinated Buserelin.
Bound and free tracer were separated by centrifugation at 30,000xg,
specific binding was determined and expressed as % of total counts
added, corrected for protein concentration (H).
100,000cpm of the unbound tracer recovered from the first incubation
was then incubated with either fresh placental membranes from the
same preparation (11) or a term placental membrane standard (jH) for
lh at 20°C, in the presence and absence of unlabelled Buserelin.
Bound and free hormone were separated by PEG precipitation and
specific binding determined and corrected for protein concentration.
Re-binding to membranes of the same preparation was expressed as %
of total counts added and binding to the term standard was expressed




Figure 3.16 EGF binding to placental membranes
Increasing concentrations of pre-term and term placental membrane
protein were incubated with 5(),0()()cpm iodinated EGF for 3h at 37°C
in the presence and absence of unlabelled EGF.
Bound and free EGF were separated by PEG precipitation, and
specific binding was determined and expressed as % of total counts
added.
Data shown were for binding to membranes of 8 weeks (<& ), 12 weeks
(<>), 14 weeks (A), 16 weeks ( A) and 40 weeks ( ) gestation.
Points are mean for triplicate determinations; error bars have been
omitted for clarity.
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3.7.2 Alkaline Phosphatase Activity in Pre-term and Term Placental
Membranes
Activity of alkaline phosphatase in placental membrane preparations was
determined by a variation of the method ofBessey et al. (1946).
At all stages of gestation, alkaline phosphatase activity increased linearly with
membrane protein (Figure 3.17). Levels of enzyme activity were much greater in
membranes prepared from term placentae, compared to membranes prepared from
pre-term placentae. However, there was no statistically significant difference between
alkaline phosphatase activity in early and mid-term placentae.
3.7.3 Comparison ofRecovery of Placental Membranes and GnRH Binding
Placental membranes were assayed for GnRH binding, EGF binding and
alkaline phosphatase activity to determine if differences in membrane recovery could
account for gestational age-related differences in GnRH binding (Table 3.6).
No relation was observed between levels of specific binding of GnRH, alkaline
phosphatase activity and specific binding of EGF to placental membrane preparations
of different gestational age. This suggests that differences between GnRH binding
with gestational age are not caused by differences in recovery of the placental villous
membranes.
3.8 DISCUSSION
Binding sites for GnRH in the human placenta differ from the well-
characterised pituitary GnRH receptor. The pituitary GnRH superagonists Buserelin
and Tryptorelin were bound by the placenta, as were the salmon, chicken-II and
mammalian isoforms ofGnRH. However, placental binding of the GnRH agonists was
not enhanced compared to the two isoforms, which were not bound by the pituitary
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Figure 3.17 Alkaline phosphatase activity in term and pre-term placental
membrane preparations
Increasing concentrations of placental membrane protein wereincubated with /?-nitrophenol phosphate for 15 minutes at 37°C.
The hydrolysis reaction was stopped by dilution with alkali and
optical density at 420nm was determined.
Optical density reflected liberation of /?-nitrophenol by alkaline
phosphatase activity in the membrane preparation.
Membranes were prepared from early (O ), mid-term (<#■ ) and term
(it) placentae.
















8 3.9 ±0.6 16.0 ± 1.0 0.091 ±0.008
12 0.8 ±0.2 20.5 ±0.6 0.067 ±0.014
14 1.9 ±0.4 16.8 ± 1.3 0.318 ±0.042
16 3.6 ±0.6 15.5 ±0.9 0.343 ±0.060
40 3.9 ±0.2 19.1 ±0.8 1.091 ± 0.092
Table 3.6 GnRH binding activity, EGF binding activity and
alkaline phosphatase activity of placental membrane
preparations of early, mid and term gestation
Placental membranes were incubated with 125I-Buserelin and 125I-EGF
under standard assay conditions. Bound and free hormone were
separated by PEG precipitation and specific binding determined. Specific
binding was expressed as % of total counts added, corrected for protein
concentration.
The alkaline phosphatase activity of the placental membranes was
measured by standard assay, and the three parameters compared.
Data were mean ± s.d. for triplicate determinations.
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(Bramley et al., 1992). Differences in binding could not be accounted for by
differences in tracer degradation between the two tissues: isoforms of GnRH were
capable of appreciable levels of binding to EL-14 anti-GnRH antibody after incubation
with rat pituitary or human placental membranes, irrespective of whether or not they
bound to the tissue of the first incubation (Bramley et al., 1992). This antibody is
specific for GnRH isoforms and does not bind GnRH analogues as it recognises both
N- and C- terminal regions of the GnRH molecule, which suggests that appreciable
levels of intact isoform molecules remained after the first incubation.
GnRH binding in the placenta appeared to be specific for molecules with the
structure of GnRH, as Buserelin binding was not inhibited by a range of proteins,
steroids, peptides and hormones (Bramley, 1987). However, unlabelled GnRH
antagonist analogues did not inhibit Buserelin binding in the human placenta except at
concentrations 200- to 50,000-fold higher than observed for pituitary GnRH receptors
(Bramley et al., 1992).
Low affinity binding sites for GnRH have been reported to be due to binding of
degradation resistant analogues of GnRH to proteases (Clayton et al., 1979).
However, Menzies and Bramley (1992) demonstrated that the placental GnRH binding
site was distinct from GnRH degrading activity when human placental membranes
were centrifuged on a continuous sucrose density gradient. In addition, analogue and
isoform binding were localised to the same region of the gradient as the plasma
membrane markers, EGF receptors and alkaline phosphatase activity.
As previous studies have looked at placental GnRH binding at a limited range
of gestational ages, placentae were obtained at 6-18 weeks from therapeutic abortions
and from normal term pregnancies and the binding characteristics of placental GnRH
receptors at early, mid and term gestation were determined.
Levels of binding of GnRH, GnRH isoforms and synthetic agonist analogues in
the human placenta varied throughout gestation. The high levels of binding observed
in early trophoblast (6-10 weeks gestation) fell to non-determinable levels by 18
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weeks, increasing to maximal levels at term (Figure 3.7). The profile of GnRH binding
activity in pre-term placentae parallels levels of hCG in the maternal serum (Braunstein
et al., 1976). However, Siler-Khodr and Khodr (1978) found that levels of apparent
GnRH immunoactivity in the placenta increased with gestational age but that, relative
to weight, highest concentrations were found from 12-28 weeks. This correlated with
the presence of immunoactive GnRH in the maternal serum (Siler-Khodr et al., 1984)
but, unfortunately, the GnRH levels at earlier pregnancy were not determined.
Although relative binding changed with gestation, the profile of tracer
specificity was the same at each stage, i.e. Tryptorelin, Buserelin, chicken GnRH-II,
salmon GnRH > mammalian GnRH » lamprey GnRH, chicken GnRH-I (Figure 3.11).
Rebinding data (Figure 3.15) suggested that increased levels of degrading enzymes at
mid-gestation could not account for variations in agonist binding at different stages of
pregnancy, as tracer incubated with mid-term placental membranes was capable of
binding to a term placental membrane fraction with no appreciable loss in specific
activity. Decreased binding at 11-18 weeks could not be accounted for by
contamination of villous membrane preparations by membranes of other tissues at mid-
gestation, as no corresponding decrease in EGF receptors or alkaline phosphatase
activity, both markers for villous plasma membrane, was found. As moderate levels of
binding were measured in early placental membranes of 10 weeks gestation, which
were obtained by termination of pregnancy by prostaglandins alone, the method used
for terminating pregnancy did not appear to be related to gestational age-related
differences in binding.
From the above, differences in GnRH binding with gestation can only be
explained by: a) increased degradation of the GnRH receptor at mid gestation, which
would be very difficult to measure as levels are already very low; b) decreased
expression or synthesis of the GnRH receptor at mid gestation, which requires an
antibody to the GnRH receptor or a cDNA probe for the gene, neither of which are
presently available; or c) differential occupancy of the GnRH receptor at mid gestation.
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From Figure 3.8, at mid gestation, binding activity did not increase with
increasing concentrations of membrane protein, which suggested that, if receptor
number is not decreased at mid-gestation, the receptor site could occupied by an
endogenous ligand with a greater affinity for the placental binding site than the
pituitary superagonist. Investigation of GnRH binding was therefore extended to
include placental cytosol and the putative GnRH-like ligand for the placental GnRH




IN THE HUMAN PLACENTA
4.1 INTRODUCTION
Many studies have demonstrated a role for GnRH in the stimulation of hCG
secretion (Khodr and Siler-Khodr, 1978b; Butzow, 1982; Siler-Khodr et al., 1986a;
Elkind-Hirsch et al., 1989; Currie et al., 1992) and the pattern of GnRH binding to
pre-term placental binding sites correlates with hCG levels in the maternal serum (Hay,
1988), peaking at 8-10 weeks and falling by mid-gestation. However, Siler-Khodr et
al. (1984) measured circulating GnRH levels in maternal serum and found highest
levels occurred at 7 to 17 weeks, declining significantly in the second half of gestation.
In addition, the immunoactive GnRH content of the human placenta was highest at 12-
22 weeks (Siler-Khodr and Khodr, 1978).
We have shown that the decrease in GnRH binding at mid gestation cannot be
accounted for by changes in affinity of the binding site, increased degradation ofGnRH
or changes in recovery of the membrane binding sites at this stage of pregnancy. From
Figure 3.8, increasing membrane protein concentration did not result in increased
binding of GnRH at mid-gestation, suggesting that GnRH receptors may be down-
regulated at this stage, possibly by high levels of an endogenous GnRH-like factor.
Menzies and Bramley (1992) demonstrated that placental cytosol contained
activity which rapidly inactivates GnRH-like molecules, whereas the GnRH binding
site was associated with placental cell-surface membrane fractions. Therefore, the
existence of GnRH-like activity in placental cytosol which could interfere with GnRH
binding to placental membrane receptors but was distinct from degradative activity was
investigated.
4.2 BINDING ACTIVITY OF 125I-GnRH AGONIST ANALOGUES TO
HUMAN PLACENTAL MEMBRANES IN THE PRESENCE OF
PLACENTAL CYTOSOL
Placental membranes were obtained by differential centrifugation of
homogenates of placental tissue and were recovered by a high-speed centrifugation
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step (Smith and Brush, 1978). The supernatant obtained from this step represented the
placental cytosolic fraction.
4.2.1 Effect of Increasing Concentrations of Placenta! Cytosol on Membrane
Binding
Binding of 125I-Buserelin to mid-gestation and term placental membrane
preparations was measured in the presence of placental cytosol of the same gestation.
In addition, the effect of mid-term placental cytosol on Buserelin binding to term
placental membranes was determined.
Binding of Buserelin to mid-term placental membranes was decreased to levels
of non-specific binding to the tube (assay blanks) in the presence of placental cytosol
from the same preparation (Figure 4. la). However, the maximal decrease ofBuserelin
binding to term placental membranes by term placental cytosol was only by -15% of
binding in the absence of placental cytosol. In contrast, cytosol extract from mid-
gestation placentae decreased binding of Buserelin to term placental membranes to
levels of non-specific binding to the tube. The difference in Buserelin binding to term
placental membranes in the presence of term and mid-term placental cytosol was
statistically significant (P<0.02).
When 125I-Buserelin binding in the presence of ~1.5mg placental cytosol was
compared with binding in the presence of 10"5M unlabelled Buserelin (Figure 4.1b),
mid-term cytosol consistently decreased binding of mid-term placental membranes to
levels below that observed with excess Buserelin (P<0.05). This was not observed for
term binding sites.
4.2.2 Effect of Time and Temperature of Incubation
Placental membranes and cytosol were incubated with 125I-Buserelin at 4°C,
20°C or 37°C for up to 6 hours (Figure 4.2) to determine the effect of cytosol on





Figure 4.1a Displacement of Buserelin from placental membranes by placental
cytosol
Placental membrane fractions (~lmg membrane protein) were incubated
for 1 h at 20 °C with 100,000cpm iodinated Buserelin in the presence of
increasing concentrations of placental cytosolic extract.
Bound and free hormone were separated by PEG precipitation and
binding expressed as % of total counts added.
Buserelin binding is shown in the presence of 13 week cytosol (® , « ), 15
week cytosol O , a ), 16 week cytosol (|| , ) and term cytosol ( ).
Closed symbols represent binding to membranes of same gestation and
open symbols represent binding to term placental membranes. Values





Figure 4.1b Displacement of Buserelin from placental membranes by placental
cytosol
Placental membrane fractions (~lmg membrane protein) were incubated
for 1 h at 20 °C with 100,000cpm radio-labelled Buserelin in the
presence and absence of unlabelled Buserelin or in the presence of
placental cytosolic extract (~lmg cytosol protein).
Bound and free hormone were separated by PEG precipitation and
binding determined. Non-specific binding (@ ), specific binding (M )
and binding in the presence of cytosol (S) were expressed as % of total
counts.
Data were means ± s.d. of triplicate determinations from a representative
experiment. *P<0.05 when compared to non-specific binding in the






















Figure 4.2 Effect of time and temparature of incubation on the displacement
of Buserelin from placental membranes by placental cytosol
Placental membrane fractions (~lmg protein) were incubated with
100,000cpm radio-labelled Buserelin at 4°C (°), 20°C (#•) and 37°C
( ) in the presence of placental cytosolic extract (~lmg protein).
Bound and free hormone were separated by PEG precipitation and
binding expressed as % of total counts added.
Data shown were mean ± s.d. for a single representative experiment
performed in triplicate.
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At 37°C, binding was reduced to levels of non-specific binding to the
tube within 30 minutes. At 20°C, the temperature of the standard binding assay,
binding was reduced by 50% after 1 hour and to non-specific levels by 4 hours.
Binding was stable for up to 1 hour at 4°C, then decreased slowly; maximal decrease in
binding was reached in excess of 6 hours incubation.
4.2.3 Effect of Pre-incubating Placental Membranes with Placental CytosoS
Term placental membranes were incubated with placental cytosol for up to 6
hours at 4°C, 20°C and 37°C, then assayed for Buserelin binding to membranes under
standard conditions (1 hour at 20°C). Binding was calculated as % of binding in the
presence of cytosol with no pre-incubation.
After 6 hours pre-incubation at 4°C and 20°C, no effect of pre-incubation was
observed suggesting that cytosol had no degradative effect on the placental membrane-
bound binding site at low temperatures (Figure 4.3). At 37°C, however, binding
increased by 85% after 4 hours incubation.
4.2.4 Effect of Protease Inhibitors
The displacement effects observed in 4.2.1-3 could be accounted for either by
the presence in the placental cytosol of a ligand with a greater affinity for the GnRH
binding site than pituitary GnRH analogues, or by GnRH degradative activity
associated with the cytosolic fraction (Menzies and Bramley, 1992) which reduced the
level of tracer capable of binding to the membrane binding site. In order to determine
if the effect of the cytosol was due to enzymatic activity, the binding of Buserelin to
placental membranes was assayed in the presence of placental cytosol and protease
inhibitors with activity against the four major classes to proteases (see 3.2.6 for
description of activities).
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Figure 4.3 Effect of pre-incubation of placental membranes with
placental cytosol on Buserelin binding
Term placental membrane fractions (~lmg protein) were
incubated with placental cytosol (~lmg protein) at 4°C (° ),
20°C ( 4* ) and 37°C ( ) for up to 6h, then incubated with
100,000cpm iodinated Buserelin at 20°C for lh.
Bound and free hormone were separated by PEG precipitation
and binding expressed as % of total counts added.
Data shown were means ± s.d. from triplicate estimations for a
single representative experiment.
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1.46pM Pepstatin A, early, mid- and term cytosol did not decrease binding of GnRH
analogues to placental membranes of the same age (Figure 4.4).
When the effect of individual inhibitors was investigated (Figure 4.5), EDTA
and Pepstatin A had no effect on either Buserelin binding or on the reduction of
binding in the presence of placental cytosol. Specific binding was significantly
decreased in the presence of N-ethyl maleimide (P<0.05) but no effect of N-ethyl
maleimide was observed on Buserelin binding with cytosol. However, PMSF and
ethanol, the vehicle for PMSF, reduced both specific binding and binding in the
presence of placental cytosol to levels of non-specific binding (P<0.01). Thus no
specific effect of the protease inhibitors on Buserelin binding in the presence of cytosol
was identified, although the presence of ethanol was observed to interfere with
Buserelin binding, as previously described (3.2.6).
4.2.5 Effect of Placental Cytosol on the Binding Activity of Tryptorelin and
Chicken GnRH-II
As chicken GnRH-II has an affinity for the placental GnRH receptor which is
comparable to synthetic agonist analogues of GnRH (as discussed in Section 3.4), the
effect of placental cytosol on the binding of iodinated Tryptorelin, Buserelin and
chicken GnRH-II to placental membrane preparations of the same gestation was
compared (Figure 4.6).
At all stages of pregnancy, binding of each GnRH analogue was decreased in
the presence of placental cytosol. Lower concentrations of cytosol were required to
inhibit chicken GnRH-II binding, compared with Buserelin and Tryptorelin which both
incorporate modifications to protect the molecule from proteolytic degradation.
The effect of placental cytosol on the binding of Buserelin and chicken GnRH-
II to placental membranes was compared in the presence and absence of inhibitors of
the four major classes of protease activity, in order to determine if increased




























































































Figure 4.4 Effect of protease inhibitors on Buserelin displacement from
placental membranes by placental cytosol
Placental membranes were incubated at 20°C for lh with 100,000cpm
iodinated Buserelin and increasing concentrations of cytosol fraction in
the presence (open symbols) and absence (closed symbols) of a
'cocktail' of protease inhibitors.
Data shown were for a) 8 week cytosol and 7 week membranes, b) 15
week cytosol and membranes, c) 18 week cytosol and membranes and
d) term cytosol and membranes. Data represents the mean ± s.d. of
triplicate determinations for individual experiments.
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Figure 4.5 Effect of individual protease inhibitors on the displacement of
Busereiin from placental membranes by placental cytosol
Placental membranes (~lmg protein) were incubated for lh at 20°C
with radioiodine-labelled Busereiin, in the presence and absence of
lOfiM uniodinated Busereiin or placental cytosolic extract (~lmg
protein).
Bound and free hormone were separated by PEG precipitation and
non-specific binding (H), specific binding (M) and binding in the
presence of placental extract (H) were expressed as % of total counts.
Data shown were means ± s.d. of triplicate determinations from an
individual, representative term placental membrane and term placental
cytosol determination. *P<0.05; **P<0.01 when compared to binding
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Figure 4.6 Comparison of binding of Buserelin, Tryptorelin and
chicken GnRH-II to placental membranes in the
presence of placental cytosol
7 week (a), 16 week (b) and term (c) membranes (~lmg
protein) were incubated under standard conditions with
100,000 cpm iodinatedBuserelin (o ), Tryptorelin (• ) and
Chicken GnRH-II ( ) in the presence of increasing
concentrations of cytosol of matched age.
Bound and free hormone were separated by PEG
precipitation. Binding was determined and expressed as %
of total counts.
Data shown were for an individual representative
experiment for each gestation; each point is mean ± s.d. of
triplicate determinations.
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for this effect of placental cytosol. From Figure 4.7, no conclusive pattern was
observed: with protease inhibitors increasing binding in the presence of cytosol for
chicken GnRH-II binding with mid-gestation placental membranes and cytosol alone.
4.3 GnRH BINDING ACTIVITY OF HUMAN PLACENTAL CYTOSOL
The GnRH binding activity of cytosolic extract in the standard GnRH binding
assay was negligible: for a representative term placental preparation, binding of the
cytosol was 0.3% of total counts/mg protein compared with 3.6% of total counts per
mg for the placental membrane fraction. Measurement of the effects of cytosol on
binding to placental microsomes required large amounts of placental membranes, and
assays were complicated by differentiation between effects of cytosol on membranes
and general effects of assay conditions on membrane binding. However, the
availability of specific anti-chicken GnRH-II antibodies allowed the development of a
radio-immunoassay, as described in Section 2.8, which did not require the use of
placental microsomes.
4.3.1 Effects of Human Placental Cytosol on Binding of Chicken GnRH-II to
Anti-chicken GnRH-II Antibody
The displacement of iodinated chicken GnRH-II from chll-Ab by unlabelled
chicken GnRH-II and human placental cytosol of all stages of gestation was compared
in the presence and absence of protease inhibitors, as described in 2.8.
Placental cytosol and unlabelled hormone both displaced 125I-chicken GnRH-II
from chll-Ab (Figure 4.8). The effects of cytosol on chll-Ab binding were dose-
dependent and correlated well with the inhibition of 125I-chicken GnRH-II binding to
placental membranes, shown in Figure 4.6. Protease inhibitors in the assay medium did
not interfere with the binding of chll-Ab to tracer, hormone or placental cytosoi,
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Figure 4.7 Effect of protease inhibitors on Buserelin and chicken
GnRH-II binding to placental membranes in the presence
of placental cytosol
13 week (a) and 40 week (b, c) membranes (~lmg protein)
were incubated under standard conditions with 100,000cpm
iodinated Buserelin (circles) and chicken GnRH-II (squares)
in the presence of increasing concentrations of 13 week (a),
18 week (b) and 40 week (c) cytosol. Bound and free
hormone were separated by PEG precipitation and binding
expressed as % of total counts added. Binding in the
presence and absence of protease inhibitors is represented by
closed and open symbols respectively.
Data shown were means ± s.d. from a single experiment
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Figure 4.8 Displacement of iodinated chicken GnRH-II from chll-Ab by
placental cytosol
Anti-chicken GnRH-II antibody (1:50,000 dilution) was
incubated with 30,000cpm iodinated chicken GnRH-II and
increasing concentrations of unlabelled chicken GnRH-II ( ),
pre-term human placental cytosol (8 weeks* ;15 weeks ^ ;16
weeks * ) or term human placental cytosol (®: , ) for 16h at
4°C, in the presence and absence of protease inhibitors.
Bound and free iodinated hormone were separated by PEG
precipitation, binding determined and expressed as % of control
binding (in the absence of cytosol, unlabelled hormone or
inhibitors).
Data shown were means ± s.d. for triplicate estimations in the
absence of protease inhibitors. Protease inhibitors had no effect
on binding and data was not shown for clarity. Term placental
cytosol represented extract obtained from one placenta prepared
in the presence (* ) and absence ( ) of protease inhibitors.
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fold less, compared with cytosol prepared in the absence of inhibitors (Figure 4.8).
4.3.2 Binding Activity of Fractionated Human Placental Cytosol to Anti-
chicken GnRH-H Antibody
Term placental cytosol was fractionated by gel exclusion chromatography on a
Sephadex G-100 column eluted with PBS and the activity of individual fractions was
determined using the chll-Ab assay in the presence and absence of protease inhibitors.
Placental cytosol fractions from gel permeation chromatography had little
activity in the chll-Ab assay (Figure 4.9). However, in the presence of inhibitors of
protease activity, displacement of chicken GnRH-II from chll-Ab was observed by
placental cytosol fractions, corresponding to an apparent Mr of 60-80,000. As
inhibition of chicken GnRH-II binding was observed only in the presence of protease
inhibitors, a component of the inhibitor mixture was thought to either activate the
endogenous ligand or interfere with chicken GnRH-II binding to the antibody in the
presence of placental cytosol.
4.3.3 Effect of Individual Protease Inhibitors on Cytoso! Binding to Anti-
chicken GnRH-II Antibody
Inhibition of binding of 125I-chicken GnRH-II to chll-Ab by high molecular
weight fractions of placental cytosol in the presence of protease inhibitors was
investigated to determine the effect of individual protease inhibitors.
Pooled active fractions of cytosol consistently failed to inhibit binding of
chicken GnRH-II to anti-chicken GnRH-II antibody in the absence of protease
inhibitors (Figure 4.10), and inhibitors had no effect in the absence of cytosol (Figure
4.8). However, in the presence of the high molecular weight fractions and PMSF,
Pepstatin A, or ethanol, the vehicle for the protease inhibitors, chicken GnRH-II
binding to anti-chicken GnRH-II antibody was demonstrated. Thus, ethanol appeared
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Figure 4.9 Effect of fractionated human placental cytosol on binding of
iodinated chicken GnRH-II to chll-Ab
4ml human term placental cytosol was chromatographed on a 1.6cm x
50ml column of Sephadex G-100 (Fine) equilibrated and eluted with
PBS. 2ml fractions were collected and 30ql aliquots assayed for
inhibition of anti-chicken GnRH-II antibody (1:50,000 dilution) binding
to 30,000cpm iodinated chicken GnRH-II in the presence (@ ) and
absence (o) of a 'cocktail' of protease inhibitors (2mM EDTA, 2mM
PMSF, 2mM N-EM and 2(iM Pepstatin A).
After incubation at 4°C for 16h, bound and free iodinated hormone were
separated by PEG precipitation. Binding was determined and expressed
as % of control binding (in the absence of cytosol or inhibitors).
Data shown were means ± s.d. for triplicate estimations from an
individual representative experiment.
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Figure 4.10 Effect of individual protease inhibitors on binding of chicken
GnRH-n to ChH-Ab
Anti-chicken GnRH-II antibody (1:50,000 dilution) was incubated with
30,000cpm iodinated chicken GnRH-II and pooled, active high
molecular weight fractions of human placental cytosol for 16h at 4°C.
The effect of individual protease inhibitors (2mM EDTA, 2mM PMSF,
2mM N-EM and 2pM Pepstatin A) was determined.
Bound and free iodinated hormone were separated by PEG
precipitation, binding determined and expressed as % of control
binding (in the absence of cytosol or inhibitors).
Data shown were means ± s.d from an individual representative
experiment. *P<0.01 when compared to binding in the absence of
protease inhibitors.
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4.3.4 Effect of Ethanol on Cytosol Binding to Anti-chicken GnRH-II Antibody
Ethanol had no effect on chicken GnRH-II binding to chll-Ab. However, a
dose-dependent inhibition of chicken GnRH-II binding to chll-Ab was observed in the
presence of pooled active fractions of placental cytosol in the presence of ethanol was
dose-dependent (Figure 4.11). Tracer binding was reduced by 50% in the presence of
30pi of fraction with 1% (v/v) ethanol in the assay.
Increasing concentrations of the high molecular weight fraction of placental
cytosol were assayed for displacement activity in the presence and absence of 1%
ethanol in the chll-Ab assay (Figure 4.12). No displacement was seen with cytosol
fraction in the absence of ethanol, or with pooled fractions of low molecular weight
cytosol in the presence or absence of ethanol. However, in the presence of ethanol the
high molecular weight fraction of placental cytosol decreased 125I-chicken GnRH-II
binding to antibody in a dose-dependent manner. Ethanol had no effect on the self-
displacement of 125I-chicken GnRH by unlabelled hormone, nor on the displacement
activity of pre-term and term cytosol (Figure 4.8).
4.3.5 Binding of 125I-chicken GnRH-II to an Endogenous Placental Cytosol
Ligand
In order to determine if an endogenous GnRH binding protein was present in
cytosolic extracts, increasing volumes of placental cytosol were incubated with
iodinated chicken GnRH-II and separated by PEG precipitation, as described in
Section 2.5.1, or by DCC separation, as described in Section 2.9.
PEG precipitation of tracer-ligand complexes indicated very low levels of
tracer binding to the cytosol (Figure 4.13). However, as the cytosolic ligand was not
pelleted with microsomes by differential centrifugation, it would presumably be a very





Figure 4.11 Effect of increasing concentrations of ethanol on chicken
GnRH-II binding to Chll-Ab
Anti-chicken GnRH-II antibody (1:20000 dilution) was
incubated with 30,000cpm radio-labelled chicken GnRH-II
in the presence of the high molecular weight fraction of
placental cytosol and increasing concentrations of ethanol,
for 16 h at 4°C.
Bound and free hormone were separated by PEG
precipitation and binding determined. Binding was
expressed as % of control, with no ethanol.
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Figure 4.12 Effect of ethanol on displacement of iodinated chicken GnRH-II
from Chll-Ab
Anti-chicken GnRH-II antibody (1:50,000 dilution) was incubated
with 30,000cpm iodinated chicken GnRH-II and increasing
concentrations of unlabelled chicken GnRH-II (♦, ♦), pooled fractions
of 'active' cytosol («, •) or pooled fractions of 'inactive' cytosol ( , )
for 16h at 4°C, in the presence (*,• , ) and absence (♦,« ) of
ethanol (1% v/v).
Bound and free iodinated hormone were separated by PEG
precipitation, binding determined and expressed as % of control











Figure 4.13 Binding of chicken GnRH-II tracer to binding sites in
placental cytosol
Increasing volumes of placental cytosol were incubated with
30,000cpm iodinated chicken GnRH-II for 2h at 4°C.
Bound and free labelled hormone were separated using :
a) PEG which precipitates large tracer-ligand complexes or
b) DCC which adsorbs small molecules such as free tracer.
The radioactivity of the PEG precipitate (■), DCC precipitate (« )
and DCC supernatant ( ), which contained the tracer-ligand
complexes, was determined.
Data shown were mean ± s.d. of triplicate determinations for a
representative experiment.
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Separation of unbound and bound 125I-chicken GnRH-II by adsorbing free
tracer with BCC showed that binding of chicken GnRH-II increased in a dose-
dependent fashion in the presence of increasing concentrations of placental cytosol
(Figure 4.13).
4.4 ISOLATION OF CYTOSOLIC CHICKEN GnRH BINDING ACTIVITY
Gel exclusion chromatography separates molecules on the basis of their size,
whereas ion-exchange chromatography utilises the attraction between oppositely
charged particles to separate biological compounds which carry a net positive or
negative charge. Cation exchangers, eg. CM-Sepharose (Pharmacia Ltd., Milton
Keynes, Bucks, England), possess negatively charged groups and will attract positively
charged molecules. Conversely, anion exchangers, such as DEAE-Sepharose
(Pharmacia Ltd, Milton Keynes, Bucks, England), have positively charged groups
which will attract negatively charged groups.
A variety of functional groups can be attached covalently to sepharose gels and
can be used to isolate specific molecules according to their affinity. For example, the
carbohydrate-binding lectin gel Concanavalin A-Sepharose can be used to isolate
glucose/mannose-containing glycoproteins.
4.4.1 Properties of Binding of Placental Cytosolic Binding Proteins to Ion-
exchange and Lectin-binding Gels
Placental cytosol was incubated with CM-Sepharose CL-6B, DEAE-Sepharose
CL-6B and Concanavalin A-Sepharose 4B were incubated for 3 hours at room
temperature, on a rotating board. Changes in salt concentration or pH alter the
association of compounds with the gels and so the effect of increasing concentrations
of salt on cytosol GnRH binding activity to each type of gel was determined. In
addition, the effect of the sugar a-methyl-D-mannoside on the association of the
placental GnRH binding protein with Concanavalin A was investigated.
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Association of cytosol GnRH binding activity with the gel was determined by
assay of eluted fractions using the DCC chicken GnRH-II binding assay (Figure 4.14).
Cytosol GnRH binding activity was adsorbed to DEAE-Sepharose, and eluted by 0.3-
0.5M NaCl. Association of the binding protein with Concanavalin A was observed
only at high salt concentrations but cytosol GnRH binding activity was eluted by
increasing concentrations ofa-methyl-D-mannoside. No adsorption was observed with
CM-Sepharose incubation and controls (cytosol incubated with increasing salt or
sugar) discounted any effect of NaCl or a-methyl-D-mannoside on cytosol binding in
the DCC assay.
As the cytosol GnRH binding activity was retained with DEAE-Sepharose at
physiological pH, this activity appeared to be negatively charged under these assay
conditions. Association with Concanavalin A appeared to occur only in the presence
of high salt but the cytosol GnRH binding activity was eluted from the gel in the
presence of a-methyl-D-mannoside.
4.4.2 Isolation of Cytosol GnRH Binding Activity: NaCl
Adsorption of the binding protein to DEAE was utilised to attempt to isolate
the cytosolic GnRH binding activity. Cytosol was incubated with the gel, then the gel
was washed with sequentially higher concentrations of salt. The supernatants isolated
at each step were assayed for cytosol binding activity in the DCC assay (Figure 4.15).
GnRH binding activity was negligible in the supernatant from the incubation
with gel alone, from the distilled water (dH20) wash and from the Tris-HCl wash.
Binding increased ten-fold in the supernatant from the 0.5M NaCl wash, then fell to
negligible levels by the 3M NaCl wash. However, maximal binding activity of the





Figure 4.14 Association of cytosol with ion-exchange and lectin-Iinked gels
Term placental cytosol was incubated, with rotation, for 4h at 20°C
with DEAE-Sepharose CL-6B ( ® ), CM-Sepharose CL-6B (* ) or
Concanavalin A-Sepharose 4B ( ■ ) in the presence of increasing
NaCl concentration or a-Me-D-Mannoside ( , Con A only). The
effect of salt ( ♦) and sugar ( ) on cytosol was also determined.
Gels (and adsorbed molecules) were packed and supernatant
assayed for chicken GnRH-11 binding (incubated with 30,000cpm
iodinated chicken GnRH-II for 2h at 4°C and binding activity
determined by DCC separation). Binding was corrected for
non-specific binding to tube and expressed as % of total counts.
9 5
2 3 4 5 6








Figure 4.15 Isolation of the endogenous cytosolic GnRH binding
protein by increasing salt concentration
The effect of increasing concentrations of salt on the binding of
cytosol to DEAE gel was determined.
Cytosol was incubated alone (H) and with DEAE-Sepharose
CL-6B (H) for 4h at 20°C with rotation (Incubation 1). The gel
was then packed and the supernatant assayed for binding of
125I-chicken GnRH-II by DCC separation.
The gel was then washed sequentially with distilled water (2),
40mM Tris-HCl, pH7.4 (3), 0.5M NaCl (4), 1M NaCl (5) and
3M NaCl (6) under the same incubation conditions and the
supernatant from each stage assayed for GnRH binding activity.
Cytosol alone acted as the control for incubations 2 and 3, but
incubations 4, 5 and 6 were incubated at the same salt
concentration as the gel.
Binding was corrected for non-specific binding to the tube and
expressed as % of total counts added.
Data shown were mean ± s.d. for triplicate determinations for
an individual experiment. *P<0.05; **P<0.01 when compared
to binding activity after Incubation 1.
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binding activity of placental cytosol was decreased significantly following prolonged
incubation in the presence on NaCl.
4.4.3 Isolation of Cytosol GnRH Binding Activity: pH
The reduction in activity observed using NaCl to displace the binding activity
from the positively charged groups of DEAE-Sepharose suggested that salt effects
were complicating the purification of the GnRH ligand. As the net charge exhibited by
biological materials is dependent on the pH of the solution, the selective desorption of
the bound molecule can be achieved by changes in pH, as well as changes in ion
concentration.
Cytosol was incubated to equilibrium with DEAE-Sepharose and the gel was
washed with dH20 and 40mM Tris-HCl. Gel was then incubated with citrate buffer of
pH ranging from 3-8.5 (Figure 4.16). Binding activity was low in the supernatant from
the acidified washes, but was increased in the pH 6.5 and alkaline (pH 8.0 - 8.5)
washes.
4.4.4 Use of Gel Exclusion Chromatography to Isolate Cytosolic GnRH Binding
Activity
Gel exclusion chromatography separates molecules on the basis of their size
and shape: smaller molecules enter the 3-dimensional network of pores in the gel and
elute slowly, whereas large molecules pass through the interstitial spaces of the gel and
elute quickly from the gel. Sephadex is prepared by cross-linking dextrans to varying
degrees to give differences in porosity, giving Sephadex G25 a fractionation range of
lxlO3 - 5xl03 daltons. Sephadex G25 columns were equilibrated to pH 3.5, 6.5 or 10
with citrate buffer, cytosol was applied to the column and eluted with the equilibration
buffer, to determine the effect of pH on binding activity.
Fractions were assayed for chicken GnRH-II binding in the DCC assay at pH
3.5, 6.5 and 10 (Figure 4.17). Binding activity was eluted in the same position for all
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Isolation of the endogenous cytosolic GnRH binding
protein by increasing pH
In order to determine the effect of pH on the binding of cytosol
to DEAE gel, cytosol was incubated with DEAE-Sepharose
CL-6B for 4h at 20°C with rotation. The gel was then packed
and the supernatant assayed for binding of iodinated chicken
GnRH -II by DCC separation.
The gel was then washed sequentially with distilled water,
40mM Tris-HCl (pH 7.4), and citrate buffer under the same
incubation conditions and the supernatant from each stage
assayed for GnRH binding activity. Citrate buffer ranged from
pH 3 - 8.5.
Binding was corrected for non-specific binding to the tube and
expressed as % of total counts added.








































Figure 4.17 Effect of pH on gel permeatation chromatography of term placental
cytosol
Placental cytosol was eluted from a 20 x 1cm Sephadex G25 (Fine)
column with 0.2M citrate buffer of pH 3.5 (a), 6.5 (b) or 10 (c).
2ml fractions were collected and assayed in duplicate for 125I-chicken
GnRH-Ii binding at pH 3.5 (° ), 6.5 (*) and 10 (®), by incubation
overnight at 4°C. Controls were included to determine the effect of pH
on binding activity of unfractionated cytosol.
Bound and free tracer were separated by DCC and unadsorbed (bound)
activity determined and expressed as % of total counts added.
Data shown were from a representative experiment; each point is mean
± s.d. for triplicate determinations.
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pHs. High levels of binding activity were found in the active fractions of
cytosol eluted at pH 3.5 at all assay pHs, with maximal binding at assay pH 3.5. For
cytosol eluted from Sephadex G25 at pH 6.5, binding activity was maximal in the pH
3.5 assay with significantly lower levels of activity in the assays at pH 6.5 and 10.
Binding activity was reduced in the cytosol fractions eluted at pH 10 at all assay pHs.
Chicken GnRH-II binding activity of unfractionated cytosol was also increased
when assayed at pH 3.5, and acidified cytosol and active fractions also acquired the
ability to bind 125I-Buserelin. This was absent at neutral pH. Increased GnRH binding
of cytosol at acid pH suggested that the endogenous placental GnRH-like molecule
may dissociate from the cytosolic binding site at acid pH, increasing the number of
cytosolic binding sites available for the iodinated tracers.
4.4.5 Cytosolic Binding Activity of Pre-term and Term Placental Cytosol
Typically, hormones and growth factors can be dissociated from their binding
proteins/receptors at low pH. Cytosol from mid-gestation and term placentae was
assayed at pH 3.5 and 6.5 for chicken GnRH-II and Buserelin binding in the DCC
assay (Figure 4.18). Binding of chicken GnRH-II to placental cytosol was significantly
enhanced when incubated at pH 3.5, compared with binding at pH 6.5 (P<0.001).
Levels of binding to term placental cytosol were greater than binding to pre-term
cytosol (P<0.05).
Levels of Buserelin binding to placental cytosol at pH 6.5 were comparable
with assay blanks, which reflect non-adsorbed tracer present in the DCC-stripped
supernatant. However, when incubated at pH 3.5, Buserelin binding was high (note
difference in scale) with term placental cytosol binding greater than pre-term cytosol
(P<0.05).
As binding is increased at low pH, this may represent dissociation of














15 16 18 40 40 40 40 40 40 40 40 40
GESTATION
(weeks)
15 16 18 40 40 40 40 40 40 40 40
GESTATION
(weeks)
Figure 4.18 Binding activity of mid-gestation and term placental
cytosol at pH 3.5 and pll 6.5
Placental cytosol was incubated at 4°C for 16h with125I-
chicken GnRH-II (a) or 125 I-Buserelin (b) in 0.2M citrate
buffer, pH 3.5 (H) or pH 6.5 (0).
Bound and free tracer were separated by DCC and bound
tracer determined and expressed as % of total counts.
Data shown were mean ± s.d. for determinations in triplicate
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binding as more binding sites are available. At neutral pH, binding is low, as most
binding sites are occupied by the endogenous ligand, which may have a greater affinity
than either the GnRH isoform or agonist. However, binding to acidified term placental
cytosol was greater than binding to acidified pre-term cytosol, therefore there was no
evidence to suggest that increased occupancy was the reason for depressed binding at
mid-gestation.
4.5 DISCUSSION
Attempts to extract immunoactive placental GnRH from placental extracts
were reviewed by Siler-Khodr (1983). The following differences were identified
between placenta! and hypothalamic GnRH: hypothalamic GnRH was soluble in
acetone, methanol and ethanol, whereas placental GnRH was not; placental GnRH was
heat-labile but hypothalamic GnRH was heat stable; extracts of placental GnRH lose
all immunoactivity in the presence of acid, base, urea and guanidine, while
hypothalamic GnRH is stable under these conditions. Neutral extraction of placental
extract indicated that immunoactive placental GnRH had a molecular weight of
~60kDa (Siler-Khodr, 1987).
Placental cytosol was observed to reduce binding of iodinated GnRH analogues
to placental membrane binding sites in a concentration-, time- and temperature-
dependent manner (Figures 4.1 and 4.2). However this activity was attenuated in the
presence of protease inhibitors, suggesting that membrane binding activity was reduced
through degradation of the tracer by placental cytosol enzymatic activity. Indeed
membrane binding of chicken GnRH-II tracer was more susceptible to inhibition by
placental cytosol than Buserelin and Tryptorelin, GnRH analogues which were
modified to protect degradation of the molecule. On the contrary, the inhibition of
GnRH binding to placental membranes by cytosolic fractions in the presence of
protease inhibitors was found to be due to a non-specific effect of ethanol on binding,
as previously discussed (Chapter 3).
102
Binding of chicken GnRH-II to a specific anti-chicken GnRH-II antibody was
inhibited by placenta! cytosol in a dose-dependent manner. Protease inhibitors and
ethanol had no effect on this activity, suggesting the possibility that a cytosolic
molecule may compete with chicken GnRH-II for the antibody binding site. When
placental extract was fractionated under neutral conditions on Sephadex G25, the
inhibitory activity of cytosol was eluted as a high molecular weight (-60-80 kDa)
fraction. However, inhibitory activity was only observed in the presence of ethanol.
Activation by ethanol was dose-related and specific for high molecular weight fractions
of placental cytosol.
The GnRH-like ligand was present in placental cytosol at all stages of gestation
and appeared to be bound to a cytosolic binding protein. Binding of chicken GnRH-II
to this cytosolic binding site was dose-dependent. Chromatography on DEAE-
Sepharose suggested that the cytosolic binding activity was negatively charged at
neutral pH. However, attempts to isolate this protein were hampered by loss of
activity on extended incubation with salt.
Fractionation and assay of this binding activity at acid pH resulted in an
approximately three-fold increase in cytosolic binding of chicken GnRH-II. At acid
pH, placental cytosol also bound significant levels of Buserelin. Binding of both
chicken GnRH-II and Buserelin to term placental extract was significantly higher than
binding to placental extract from mid-gestation, although this was determined using a
small number of cytosol samples. Thus, the presence of GnRH-like activity in human
placental cytosol was suggested by the displacement of GnRH analogues from specific
membrane binding sites. This GnRH-like activity appears to be associated with a
specific binding protein.
Several authors have identified GnRH-degrading activity in placental cytosol
(Siler-Khodr et al., 1989; Bramley and Menzies, submitted). However, inhibition of
cytosolic activity appeared to be unaffected by protease inhibitors, although it was
sensitive to ethanol in the incubate.
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CHAPTER 5
DESCRIPTION OF A NOVEL
GROWTH FACTOR ACTIVITY
IN THE HUMAN PLACENTA
5.1 INTRODUCTION
A non-steroidal gonadal activity which specifically suppressed FSH secretion
by the anterior pituitary was first described in 1923 and since then much direct
evidence for the existence of inhibin has been published (de Kretser and Robertson,
1989). A component of suppression of FSH secretion by pituitary gonadotrophs by
inhibin may involve GnRH, possibly via reduced responsiveness of the gonadotroph to
GnRH (Wang et al., 1990).
Inhibin has been localised in the human placenta (Petraglia et al., 1987b) and a
possible role for inhibin in the endocrinology of the placenta proposed (Petraglia et al.,
1989). Activin was found to increase the release of GnRH and progesterone from
placental monolayer cultures and potentiated GnRH-stimulation of hCG release.
Inhibin alone had no effect on these parameters but reversed the effects of activin.
Although the production of activin has not been demonstrated in the human placenta,
excess p-subunit mRNAs, compared with a-subunit mRNAs, have been demonstrated
in the human placenta (Meunier et a/., 1988), which suggests that the formation of pp
dimers is likely.
Tsonis et al. (1986) developed an extremely sensitive bioassay for inhibin based
on inhibition ofFSH secretion by cultured ovine pituitary cells. This assay system was
30-40 times more sensitive than rat inhibin bioassays. However, when applied to
determine the bioactivity of crude human placental extracts, the results of this bioassay
were complicated by the mitogenic effect of the placental extract on the cultured ovine
pituitary cells.
As growth factors and protooncogenes have a pivotal role in the control of the
development of the human placenta throughout gestation (Ohlsson, 1989), initial
characterisation of the factors in placental cytosol with mitogenic activity in the ovine
pituitary was carried out.
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5.2 METHODS
5.2.1 Ovine Pituitary Ceii Culture
Ovine pituitary cells were cultured according to the method of Tsonis et al.
(1986) with slight modification.
The heads of freshly slaughtered, sexually mature, female sheep were obtained
from Edinburgh Meat Plant, Edinburgh, Scotland. The pituitary glands were removed,
weighed and washed in Dulbecco's PBS (DPBS) (Flow Laboratories, Irvine, Scotland)
containing 7.5mM glucose. A maximum of 3g pituitary tissue was chopped into 3-4
mm blocks under sterile conditions in a laminar flow cabinet and, using aseptic
techniques, was washed with DPBS supplemented with 7.5mM glucose and 0.1%
(w/v) BSA. The blocks of tissue were then incubated in a siliconised spinner flask with
0.5% (w/v) trypsin in DPBS supplemented with 7.5mM glucose and 0.1% (w/v) BSA
for 30 minutes at 37°C. The enzyme solution was discarded and the tissue washed and
stirred gently for 30 minutes at 37°C with Dulbecco's Modification of Eagles Medium
(DMEM) (Flow Laboratories, Irvine, Scotland) supplemented with 10% (v/v) lamb
serum, 2.5% (v/v) foetal bovine serum, 2mM glutamine, Penstrep (250 IU penicillin
and 250pg streptomycin) (all from Flow Laboratories, Irvine, Scotland) and lOmM
NaHCC>3. The media was discarded and the tissue washed and incubated with Ca2+
and Mg2+ free DPBS (Flow Laboratories, Irvine, Scotland) supplemented with 2mM
EDTA and 0.1% (w/v) BSA in a spinner flask for 10 minutes at 37°C.
The pituitary cells were mechanically dispersed in Ca2+ and Mg2+ free DPBS
using siliconised Pasteur pipettes of decreasing bore (5-2mm) and the harvested cells
centrifuged twice at 500xg for 10 minutes at room temperature in DMEM
supplemented as above. The pelleted cells were resuspended in 20ml supplemented
DMEM and any undispersed cells and clumps of cell debris removed. An aliquot of
cell suspension was counted using a Neubauer haemocytometer and viability was
assessed by trypan blue exclusion. Average viability for 16 ovine pituitary cell
preparations was 86.8% (±4.0). Cells were diluted as required in DMEM,
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supplemented as above, and added to individual chambers of multiwell plates. Ovine
pituitary cell cultures were incubated at 37°C in a 5% CO2, water-saturated
atmosphere. In the standard bioassay protocol (Tsonis et al., 1986), the cells were
incubated for 48 hours prior to the removal of the medium to allow the cells to adhere
to the culture plate and for basal hormone secretion to stabilise. Medium was replaced
with sterilised sample in supplemented DMEM and incubated for 48 hours under the
same culture conditions.
5.2.2 Comparison of Ceil Counting Methods
5.2.2a Haemocytometer
200,000 ovine pituitary cells per well were pre-incubated for 48 hours, in 600pl
of supplemented DMEM, as described above, then incubated with sample and
supplemented DMEM in a final volume of 600pl for 48 hours under the same
incubation conditions.
Media was removed and the cells were washed with Ca2+ and Mg2+ free
DPBS. The cells were recovered from the culture plates by gentle trypsinisation (0.2%
(w/v) trypsin in Ca2+ and Mg2+ free DPBS containing 0.08% (w/v) EDTA) for 30
minutes at 37°C. The activity of trypsin was neutralised by addition ofDMEM and the
cell suspension was centrifuged at 400xg for 10 minutes at room temperature. The
ovine pituitary cells were then resuspended in 400pl DMEM and aliquots counted
using a Neubauer haemocytometer and the number of cells per well was calculated.
5.2.2b Coulter counter
Cells were cultured and resuspended as described in Section 5.2.2a and
aliquots counted in Isoton II (Coulter Electronics Ltd., Luton, Bedfordshire, England),
using a Coulter Counter Model D Industrial automatic cell counter with a 200|im
nominal diameter orifice, allowing the number of cells per well to be determined.
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Attenuation, threshold and aperture current were set according to a calibrated size
analysis.
5.2.2c Tritiated thymidine incorporation
Incorporation of tritiated thymidine into DNA by ovine pituitary cells was
measured to assess levels of replication according to the method ofDas (1981).
Cells were prepared as described in Section 5.2.1 and incubated with
2mCi/mmol [3H]-thymidine (Amersham International pic, Amersham, Bucks.,
England) for 24 hours at 37°C, during the period of active proliferation. Medium was
aspirated and the cells were washed with Ca2+ and Mg2+ free DPBS. The cells were
then incubated at 4°C for 20 minutes with 5% trichloroacetic acid (TCA) and the acid-
insoluble radioactivity sticking to the culture wells was washed with 5% TCA and
methanol. Insoluble material was dissolved with 0.5M NaCl, neutralised with HC1 and
the solution assayed for radioactivity in 4ml scintillant (Ecoscint®, National
Diagnostics, Atlanta, Georgia, USA) on a RackBeta Liquid Scintillation Counter.
5.2.2d Bromodeoxyuridine incorporation
5-bromo-2'-deoxyuridine (BrdU) is an analogue of thymidine and, like
thymidine, is incorporated into the DNA of proliferating cells. Uptake ofBrdU can be
measured using a monoclonal antibody to BrdU, which incorporates a nuclease to
allow the antibody access to the incorporated BrdU. This assay was a modification of
the procedure kindly supplied by Dr P. Perros, Endocrine Unit, Department of
Medicine, University ofNewcastle upon Tyne.
Cells were plated at a concentration of 10,000 cells per well in 96-well culture
plates and incubated for 48 hours at 37°C in serum supplemented DMEM, as
described in Section 5.2.1. The supplemented medium was then replaced with DMEM
supplemented only with 2mM glutamine, 1% (v/v) Penstrep and lOmM NaHC03.
After 24 hours of serum restriction, cells were incubated with sample diluted in serum
free DMEM for 48 hours. BrdU (Amersham International pic, Amersham, Bucks.,
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England) was then added to the incubation and, after 6 hours, medium was aspirated,
the plates were washed with Ca2+ and Mg2+ free DPBS and the cells were fixed with
absolute methanol. At room temperature, cells were washed with DPBS containing
0.5% (w/v) casein, then incubated for 18 hours with monoclonal anti-BrdU
(Amersham International pic, Amersham, Bucks., England) diluted in DPBS-casein.
Casein was included in the diluting and washing buffer to minimise non-specific
binding to the culture plates. The unbound antibody was removed, the cells washed
four times with DPBS-casein and incubated with anti-mouse IgG conjugated with
horseradish peroxidase (Scottish Antibody Production Unit, Law Hospital, Carluke,
Scotland) diluted in DPBS-casein for 2 hours. The conjugate was aspirated, the plates
washed twice with DPBS-casein, then twice with DPBS alone, as casein forms a
precipitate with the substrate, and the cells were incubated with 2.2mM o-
phenylenediamine in 30% H2O2 and 25mM citric acid-50mM Na2HPC>4, pH 5, for 30
minutes. O-phenylenediamine is a colourless substrate which is converted to a
coloured product by peroxidase. The reaction was stopped by the addition of 20%
sulphuric acid and the optical density at 492nm was determined using a Titertek
Multiskan MCC.
5.2.3 Sterilisation of Samples
Under sterile conditions, all samples were passed through 0.2pm PTFE
Minisart filters. Filtrate was collected in autoclaved glass tubes and stored at -20°C
until assay.
5.3 COMPARISON OF CELL COUNTING METHODS
Ovine pituitary cells were cultured in 24- or 96-well plates, according to the
protocol for each counting method, in the presence of increasing concentrations of
term placental cytosol. Cell number or incorporation was determined and expressed as
% of control cultures in the absence of cytosol (Figure 5.1).
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HAEMO- COULTER 3H-THYMIDINE BrdU
CYTOMETER COUNTER INCORPORATION INCORPORATION
CELL COUNTING
METHOD
Figure 5.1 Comparison of cell counting methods
Ovine pituitary cells were cultured as described in 5.2, with 2% (H),
4% (H), 10% (0), 15% (0) and 20% (S3) solutions of sterilised
term placental cytosol for 48 hours.
Cell number was determined by haemocytomter, Coulter Counter,
tritiated thymidine incorporation and bromodeoxyuridine
incorporation. Cell number was expressed as % of control, i.e. cells
cultured in the absence of placental cytosol (II).
*P<0.05 when compared to cells cultured in the absence of placental
cytosol.
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Cell counting by haemocytometer and Coulter counter gave similar levels of
stimulation, with cell number increasing progressively with cytosol concentration,
although the haemocytometer may have been less accurate at higher cell counts due to
the large correction factor involved. Incorporation of tritiated thymidine was more
variable, with a narrow concentration window for detection of effect, whilst
incorporation of BrdU was the most sensitive assay for the mitogenic effect of
placental cytosol, reaching a plateau at cytosol concentrations in excess of4% (v/v).
5.4 EFFECT OF CULTURE TIME ON CELL PROLIFERATION
The effect of incubation time on the response of ovine pituitary cells to
placental cytosol was determined by pre-incubating cells for 24 or 48 hours, then
adding extract from pre-term or term placental tissue and incubating for 24 or 48 hours
(Figure 5.2).
Cells pre-incubated for 24 hours and incubated with placental cytosol for 24
hours showed no increase in cell number with any cytosol preparation. A similiar lack
of response was observed with cells pre-incubated for 48 hours and incubated with
cytosol for 24 hours. Thus, incubation of 24 hours with placental cytosol appears to
be insufficient for cell replication to occur.
After 48 hours incubation, an increase in cell number, compared with control,
was observed with all cytosol preparations for both pre-incubation times, although 48
hour pre-incubation gave significantly increased cell number compared with 24 hour
pre-incubation.
No effect of stage of pregnancy on mitogenic activity was detected in the ovine
pituitary cell assay due to variation between the activity of samples of similar gestation.
5.5 FRACTIONATION OF PLACENTAL CYTOSOL
Term human placental cytosol was fractionated on a 50 x 1.6cm column of













Figure 5.2 Mitogenic activity of pre-term and term placental cytosol
with incubation time
Ovine pituitary cells were cultured as described in 5.2, and
pre-incubated for 24 hours ($fg, gg) or 48 hours f§§ ,0), then
incubated with 10% sterilised term placental cytosol for 24
hours mm or 48 hours 1^,11).
Data shown were obtained from a single experiment by
determining cell number using a haemocytomter but were
representative of other methods. Cell number was expressed
as % of control, i.e. cells cultured in the absence of placental
cytosol.
*P<0.05; **P<0.01 when compared to cells incubated in the
absence of cytosol.
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dextran, which eluted in the void volume of the column, bovine serum albumin (MW
67,000), cytochrome c (MW 12,500) and 125I. 2ml fractions were collected and
assayed for protein concentration and mitogenic activity in the ovine pituitary cell
assay (Figure 5.3).
The mitogenic activity in human placental cytosol corresponded to a high
molecular weight fraction (Mr A 60,000). Cell number was increased by a factor of
2.8.
5.6 EFFECT OF ACIDIFICATION OF MITOGENIC FRACTIONS
In order to investigate if the high molecular weight growth factor was bound to
a binding protein, term placental cytosol was fractionated on a column of Sephadex
G100 and fractions containing the high molecular weight mitogenic activity were
pooled, lyophilised and reconstituted in 0.1M acetic acid. Acidified extract was then
fractionated on an acidified Sephadex G100 column, using 0.1M acetic acid as the
eluting buffer. The acidified fractions were dried down under nitrogen and
reconstituted in PBS, but no mitogenic activity was observed in the reconstituted
fractions in the ovine pituitary cell assay.
5.7 AMMONIUM SULPHATE PRECIPITATION OF TERM PLACENTAL -
EXTRACT
On ice, granular NH4SO4 was added to term placental extract, slowly with
constant stirring, to 25% saturation. After 1 hour, precipitated protein was pelleted by
centrifugation at 10,000xg and resuspended in PBS. NH4SO4 was then added to the
supernatant to 50% saturation and the pellet recovered as before. This was repeated
to obtain a precipitate for 75% NH4SO4 saturation. Resuspended precipitate from
each stage was dialysed against PBS, before sterilisation and assay.
Mitogenic activity was absent and low levels of protein were precipitated by up




Figure 5.3 Mitogenic activity of fractionated placental cytosol
Sterilised fractions of term placental cytosol, prepared by gel
exclusion chromatography on Sephadex G-1G0, were incubated
with cultured ovine pituitary cells for 48 hours. Cell number was
determined («■) and expressed as % of controls incubated without
cytosol.
Data shown were obtained from a single experiment by Coulter
counter, but were representative of data obtained by other counting
methods. Values are mean ± s.d. for 8 determinations per fraction.
Protein concentration (o ) was determined by the method of Lowry
et al. (1951). Values are mean ± s.d. for triplicate determinations -













Figure 5.4 Ammonium sulphate purification of term placental cytosol
Term placental cytosol was incubated with increasing
concentrations of ammonium sulphate and the precipitated
protein assayed for mitogenic activity in the ovine pituitary cell
bioassay (H).
Data shown were determined by BrdU incorporation, which
was representative of other methods of determination, and
expressed as % of control, in the absence of cytosolic protein.









apparent with the protein precipitates obtained with 25-50% NH4SO4 saturation and
50-75% NH4SO4 saturation, with BrdU incorporation increasing almost 3-fold on
addition of these reconstituted proteins. This suggests that the mitogenic activity is
'salted-out' around 50% NH4SO4 saturation, with the range of effective NH4SO4
concentrations overlapping the two steps, or that more than one protein, with a
spectrum of salting-out points, is responsible for the mitogenicity of the placental
cytosol. This could be determined by chosing different ranges ofNH4SO4 saturation,
e.g. 0-20%, 20-40%, etc.
Protein concentration was maximal in the precipitate obtained from the
addition of 50-75% NH4SO4. Thus, mitogenic activity was greater, per mg of protein,
in the precipitate formed by 25-50% NH4SO4 saturation of placental cytosol.
5.8 DISCUSSION
In the human placenta, various growth factors, receptors and oncogene
products appear in a developmentally regulated fashion during pregnancy. Ohlsson
(1989) described placental development as a 'pseudomalignant process' and reviewed a
variety of possible growth stimulatory pathways in the human placenta. In early
pregnancy, the trophoblast is highly invasive, proliferates rapidly and there is a lack of
cell contact inhibition. This is curbed in a temporal fashion and the 'pseudomalignant'
characteristics of the placenta are lost by mid-gestation.
The purification of a novel peptide growth factor from human placenta was
described by Sen-Majumdar et al. (1986a;b). This growth factor was distinct from the
major classes of peptide growth factors with respect to its molecular weight, binding
specificity and antigenicity. The 34kDa growth factor was expressed at a high level
during the first trimester, but levels were significantly lower by term. It was associated
with cell types of an invasive and proliferative nature and was proposed to influence
cell growth in an autocrine manner.
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The mitogenic activity observed when human placental cytosol was cultured
with ovine pituitary ceils was not evident until after 24 hours incubation and was
eluted from Sephadex G100 as a high molecular weight fraction (~60kDa). This is
much larger than other placental peptide growth factors, such as EGF (~6-7kDa) or
PDGF (~25-30kDa). However, acidification and fractionation of the high molecular
weight activity, to determine if the putative growth factor was bound to a binding
protein, resulted in a loss of bioactivity. Ammonium sulphate precipitation suggested
that either the mitogenic activity precipitated around 50% saturation or that more than
one cytosolic protein, with a wider range of precipitation concentrations, was involved
in this activity. No difference of activity with gestation was determinable from the
preliminary results obtained, due to individual variation of cytosol preparations.
Comparison of cell counting methods suggested that the routinely used
methods (direct count of cell number by haemocytometer or Coulter counter, or
indirect methods such as determination ofBrdU incorporation by ELISA) gave similar
profiles in comparative assays. BrdU incorporation proved to be a very effective
method of screening a large number of samples: less cells were required per well and
more samples per plate with more replicates were possible as 96-well plates were used
as opposed to 24-well plates.
Initial purification of the cytosolic mitogenic activity requires further
investigation of the behaviour of salt precipitates of placental cytosol, to identify if a
narrow range of salting out points were responsible for the increase in ovine pituitary
cell number when cultured with placental cytosol, or if a variety of precipitated
proteins were involved. Mitogenically active precipitates could be further purified by
SDS-free (non-denaturing) gel electrophoresis to isolate active bands to give purified




6.1 SUMMARY, DISCUSSION AND CRITICAL ANALYSIS OF RESULTS
Much evidence is available in support of a paracrine role for GnRH in the
human placenta (Bramley, 1989). The GnRH gene has been identified in the human
placenta (Seeburg and Adelman, 1984) and, using in situ hybridisation, GnRH mRNA
has been found in placenta from first trimester to term (Kelly et al., 1991; Duello et
al., 1993). GnRH has a role in modulation of hCG release in the placenta (Siler-Khodr
et al., 1986a) and, in agreement with paracrine activity, levels of GnRH mRNA were
0.1-1% of that of B-hCG (Kelly et al., 1991).
Differentiation between paracrine and autocrine actions of GnRH would
require demonstration of GnRH receptors on the cytotrophoblasts and a response of
the cytotrophoblast to GnRH. No evidence is presently available to confirm such a
role for GnRH in the cytotrophoblast.
Many similarities have been observed between GnRH activity in the pituitary
and in the placenta. For example, in the hypothalamic-pituitary axis, opioid regulation
of LH release was modulated by GnRH and a similar system was demonstrated for
opioid regulation of hCG secretion in the placenta (Cemerikic et al., 1994). In
pituitary gonadotrophs, GnRH receptor activation produced a biphasic rise in cytosolic
calcium concentration (Anderson et al., 1992), characterised as an initial transient
increase - involving both IP3-mediated release of calcium ions from intracellular stores
and an influx of extracellular calcium via second messenger-operated calcium channels
- followed by a smaller secondary plateau involving extracellular influx via protein
kinase C-activated calcium channels. In the human placenta, Neki et al. (1993) found
that GnRH-mediated hCG release was inhibited by protein kinase inhibitors, which
suggested that the GnRH receptor-second messenger system was similar for both sites.
In accordance with previous studies (Currie et al., 1981; Belisle et al., 1984;
Iwashita et al., 1986), pituitary superagonists, such as Buserelin and Tryptorelin, were
found to have similar affinities for the placental GnRH binding site as the hypothalamic
mammalian GnRH decapeptide. In addition, the salmon and chicken GnRH-II
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isoforms were observed to bind to the human placental receptor with affinities
comparable to the synthetic agonists (Bramley, 1989).
It was demonstrated that specific binding of GnRH, its isoforms and synthetic
analogues to the placental binding site was dependent on stage of gestation. High
levels of specific binding were observed with membrane fractions isolated from early
trophoblast (6-10 weeks), but between 11-18 weeks levels of specific binding fell to
almost non-detectable levels. Maximal levels of GnRH binding were seen with term
placental membranes. Although the specific activity of GnRH binding varied with
gestation, the specificity of the binding site was unchanged: at all stages of gestation,
the placental receptor bound comparable levels of Buserelin, Tryptorelin, salmon
GnRH and chicken GnRH-II. Specific binding of mammalian GnRH, i.e. the
hypothalamic decapeptide, was decreased but still significant, whereas binding of the
lamprey and chicken GnRH-I isoforms was on the detection limits of the binding assay.
Although membrane preparations slowly degraded binding sites (Figure 3.2;
Bramley, 1989) and Clayton et al. (1979) suggested that low affinity extra-pituitary
binding sites represented binding of degradation-resistant GnRH analogues to tissue
proteases, differential tracer binding at different stages of gestation could not be
accounted for by changes in tracer degradation: tracer incubated to equilibrium with
mid-gestation placental membranes was capable of binding to term placental
membranes with little loss of activity (Figure 3.15). Menzies and Bramley (1992)
demonstrated by membrane purification that the GnRH binding site was equilibrated
with the microsomal fraction, whereas GnRH degrading activity was present in the
cytosolic extract. In addition, the binding site co-localised with EGF receptors and
alkaline phosphatase activity (both markers for plasma membranes) on sucrose density
gradient fractionation. No correlation was observed between GnRH and EGF binding,
alkaline phosphatase activity and stage of pregnancy, suggesting that reduced recovery
of placental membranes was not responsible for the observed changes in binding with
stage of gestation.
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Specific binding of GnRH tracers to placental membranes was not altered by
inhibitors of serine, carboxyl or metallo-proteases at any stage of gestation; in
particular, binding activity to mid-term placental membranes was not enhanced.
However, N-ethyl maleimide, a thiol protease inhibitor, significantly reduced binding
(by ~25%), suggesting that a component of detectable GnRH binding may involve
binding of GnRH to thiol proteases. Ethanol was observed to have a dramatic, dose-
dependent effect on GnRH binding to placental membranes, with 1% (v/v) ethanol in
the assay reducing binding to 50% ofmaximal levels. As ethanol was used as a vehicle
for some insoluble protease inhibitors, this could have masked a specific effect and
repeat experiments using a wider range of protease inhibitors, especially soluble serine
inhibitors, may reveal additional forms of non-receptor binding.
Standardisation of the method used to obtain all preterm placental tissue would
have removed one variable between the comparators. However, the treatment regimes
used to induce termination of pregnancy were governed by medical considerations.
The same applied to term placentae: tissue was simply classified as vaginal delivery,
forceps, etc. Details of drugs used during labour were not available to us, owing to
confidentiality of patients' notes, nor was background information like alcohol
consumption. These factors could conceivably affect binding activity of individual
tissues, as demonstrated by the inhibition of binding in the presence of low
concentrations of ethanol in the assay.
Gestational age-related differences in GnRH binding activity in the human
placenta may be due to decreased receptor number at mid-gestation. However, no
GnRH receptor antibody or cDNA probe for the receptor was available to allow
further investigation of receptor numbers.
Pituitary GnRH receptors have now been cloned and their molecular function
was discussed by Davidson et al. (1994). The GnRH receptor had the characteristic
structure of a G-protein-coupled receptor, i.e. comprising a single polypeptide chain
with seven hydrophobic, transmembrane domains connected by hydrophilic extra- and
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intra-cellular loops. The sequence of mouse, human, rat and sheep GnRH receptors
shared >85% amino acid identity, with the transmembrane regions and extracellular
loop being the most highly conserved areas (>90%). As attempts to isolate the
placental GnRH receptor using a probe for the pituitary GnRH receptor gene have
been unsuccessful (Eidne, K., pers. commun.), cloning of the placental receptor may
allow elucidation of the differences between the pituitary and placental systems.
Placental GnRH was initially thought to be very similar to the hypothalamic
hormone (reviewed by Siler-Khodr, 1983), with respect to its immunological, physio-
chemical and biological activities. However, more recent attempts to isolate placental
GnRH suggested that this tissue may contain more than one GnRH-like activity and
that high molecular weight GnRH is elaborated by the human placenta (Siler-Khodr,
1987). In the human placenta and other reproductive tissues, GnRH gene transcripts
are derived from a transcriptional start site which is upstream from the hypothalamic
start site (Dong et ai, 1993), supporting the possibility of placental GnRH existing in a
different form from the hypothalamic decapeptide.
The presence of placental cytosol decreased binding of Buserelin, Tryptorelin
and chicken GnRH-II to placental membranes in a dose-, time- and temperature-
dependent manner. This effect was observed at all stages of gestation, with inhibition
of binding to mid-gestation placental membranes by mid-gestation placental cytosol
exceeding displacement of tracer by an excess of unlabelled hormone. Inhibition of
binding by cytosol did not appear to be due to protease activity as the presence of a
range of protease inhibitors did not reverse the observed decrease in binding,
suggesting a component of the placental cytosol was competing with GnRH analogues
and isoforms for the placental binding site.
Binding of chicken GnRH-II to a specific anti-chicken GnRH-II antibody was
also decreased in the presence of placental cytosol. Again, protease inhibitors had no
effect on this inhibition,.suggesting that the cytosol activity was sufficiently similar to
chicken GnRH-II to be recognised by and compete for the antibody binding site. After
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fractionation under neutral conditions, inhibitory activity was only detectable in the
presence of ethanol, and was associated with a high molecular weight fraction (-60-
80kDa). Ethanol had no effect on binding of tracer to the antibody or on the inhibition
by unfractionated cytosol or by cytosol fractions pooled from inactive regions of the
eluate.
GnRH binding activity was observed in placental cytosol from all stages of
gestation. However, binding activity was potentiated by assay and/or fractionation at
acid pH, compared with neutral or alkaline conditions. It was hypothesised that at low
pH, endogenous placental GnRH-like activity was displaced from its binding protein.
However, insufficient pre-term samples were obtained to determine whether this
GnRH-like activity could account for decreased binding at mid-gestation.
Although it could be demonstrated that a component of placental cytosol was
recognised by the placental membrane GnRH binding sites and the specific anti-
chicken GnRH-II antibody, it was not known if the cytosolic GnRH-like substance
possessed biological activity and was capable of eliciting a response upon binding to
the GnRH binding site in vivo.
Human placental cytosol of all stages of gestation possessed a high molecular
weight factor which displayed mitogenic activity in culture with dispersed ovine
pituitary cells. From gel permeation chromatography, this activity had a molecular
weight of ~60kDa, which was much larger than reported molecular weights for other
growth factors found in placental extracts, such as EGF (-6-7 kDa) and PDGF (-25-
30 kDa). Mitogenic activity was lost on fractionation of acidified fractions. However,
ammonium sulphate precipitation suggested that this activity was precipitated around
50% saturation.
Various methods of evaluating cell proliferation were employed. Initial
determinations of cell number was by cell counting using a haemocytometer or a
Coulter counter. This was time consuming and may have been influenced by
correction factors required to calculate cell number per well from cells per aliquot.
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Estimation of proliferation by determination of BrdU incorporation was a very
effective and sensitive method of screening large numbers of samples and gave similar
profiles to direct cell counting methods.
6.2 FURTHER INVESTIGATIONS
Studies of placental GnRH activity have been conducted with analogues of the
hypothalamic decapeptide. As placental GnRH appeared to be a distinct form of
GnRH, these analogues may be only partial agonists for the placental GnRH receptor.
Thus, placental GnRH data may need to be re-interpreted if it can be demonstrated
that "placental GnRH" is different from hypothalamic GnRH.
In order to fully elucidate the nature of decreased binding observed at mid-
gestation, GnRH receptor expression and degradation throughout pregnancy could be
determined. Differential occupancy of GnRH receptors by the hypothesised higher-
affinity endogenous ligand could not be confirmed in this study. However, screening
larger numbers of cytosol fraction from all gestations would give a clearer result.
Further investigation of the inhibitory effect of ethanol on GnRH binding would
be pertinent as this may have implications on alcohol abuse in pregnancy. As GnRH
has a modulating role on growth factor activity in pregnancy, this may be linked to low
birth weights associated with foetal alcohol syndrome.
GnRH-like activity may be isolated from DEAE-Sepharose if optimal
conditions for displacement of the GnRH-like factor from the gel were determined.
The activity eluted from a column of the gel with 0.5M NaCl. However, prolonged
incubation with high salt concentrations decreased control binding significantly,
suggesting incomplete recovery of activity was obtained. More detailed investigation
of salt conditions may provide high yield of intact GnRH-like activity from the
placenta.
Further characterisation of the mitogenic activity in placental cytosol would
extend ammonium sulphate precipitation to include a wider range of concentrations to
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identify whether one or more activities are present. Non-denaturing gel
electrophoresis of the samples obtained would provide a more accurate determination
ofmolecular weight and better resolution of individual activities.
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SUMMARY
Radioiodinated gonadotrop/tin-releasing hormone tracers were preparedfrom mam¬
malian (m GnRH), salmon (s GnRH), lamprey (I GnRH) and the two forms of
chicken GnRH (ch GnRH I and ch GnRH II), and also from the GnRH agonist
(GnRHfi analogues, Buserelin ([D-Ser(tBu)6] 1-9 GnRH ethylamide) and
Tryptorelin ([.D-Trp6 GnRH] 1-9 ethylamide) and a GnRH antagonist
(GnRHANri [Ac 3,4-dehydro-Pro1, D-p-F-Phe2, D-Trp3,6] LHRH). Specific
binding ofhormone tracers was compared in homogenates and membrane fractions
from human placenta and rat pituitary.
GnRH agonist tracers bound readily to pituitary and placental binding sites.
Bindingofm GnRH to ratpituitary membranes was low compared to agonist binding,
whereas other GnRH iso-forms were not bound. Binding of,2'I-labelled m GnRH to
human placental membranes was also low compared to that ofBuserelin, and I GnRH
and ch GnRHI tracers boundpoorly. However, human placental membranes bound s
GnRHand ch GnRH II to the same extent as GnRH'A. Studies ofthe inactivation of
GnRH tracers following incubation with rat pituitary and human placental mem¬
branes demonstrated that, although GnRH isoforms were degraded at different rates
in these tissues, the differential ability of GnRH isoforms to bind to pituitary or
placental binding sites was not related to differences in degradation of tracers, but
rather to differences in ligand specificity.
Specific binding of '231-labelled GnRH agonists (GnRH,) and mammalian
GnRH (m GnRH), s GnRHand ch GnRH II tracers to human placental membrane
fractions increased linearly with increasing membrane protein at low concentrations.
Binding was dependent on both the duration and temperature ofincubation, andpH
profiles of ,2H-labelled GnRHs GnRh and ch GnRH II binding to placental
membranes were similar. Once bound s GnRH formed a tighter complex with
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placental receptors than GnRHA, though /2jI-labelled s GnRHwas inactivatedmore
rapidly than agonist tracer during incubation with placental membranes.
Binding of GnRH tracers was specific for molecules with the GnRH structure.
Deletions of amino acid residues at positions 1-3 and/or deamidation at Gly'°
reduced binding potencies for both human placental and rat pituitary binding sites,
indicating that both ends of the GnRH molecule were requiredfor optimal binding.
Modifications which conferred increased agonist activity led to markedly increased
receptor binding potency in the rat pituitary, but only slightly increased potency for
placental receptors. In contrast, GnRH antagonist analogues had increased potency
towards pituitary receptors, but much reduced potency towards human placental
binding sites.
These studies highlight further the differences between human placental and rat
pituitary GnRH receptors.
INTRODUCTION
The gene for GnRH was first cloned and sequenced from human placenta (Seeburg and
Adelman, 1984; Seeburg et al, 1987), and both GnRH (Osathanondh and Elkind-Hirsh,
1981; Tan and Rousseau, 1982; Zhuang et al, 1991) and GnRH-like peptides (Siler-Khodr,
1987; Mathialagan and Rao, 1986a; Zhuang et al, 1991) have been isolated from human
placenta. GnRH stimulates the release and synthesis ofchorionic gonadotrophin (hCG) in a
dose-dependent fashion (Butzow, 1982; Mathialagan and Rao, 1986b; Siler-Khodr and
Khodr, 1981; Belisle et al, 1984,1986; Siler-Khodr et al, 1986a; Kim et al, 1987; Iwashita et
al, 1989; Merz et al. 1991), and the stimulatory effects ofGnRH in vitro could be blocked by
high levels of a GnRH antagonist (Siler-Khodr et al, 1983; 1986d; 1987) indicating the
involvement of GnRH receptors. Moreover, GnRH also stimulated the release of prosta¬
glandins (Siler-Khodr et al, 1986c,d) and steroids (Siler-Khodr et al, 1983; 1986b) from
placental tissue explants and placental cells in vitro [though others found no effect (Haning et
al 1988) or inhibition ofsteroid secretion (Wilson andjawad, 1980; Branchaud, Goodyerand
Lipowski, 1983), differences perhaps explained by modulation ofGnRH effects by placental
steroids (Ahmed and Murphy, 1988; Barnea and Kaplan, 1989; Wilson, Jawad and Dickson,
1980; Siler-Khodr et al, 1986b; Iwashita et al, 1989) or gestational age (Siler-Khodr et al,
1986a; 1987)].
The human placenta binds radiolabelled GnRH analogues with high specificity (Currie,
Fraser and Sharpe, 1981; Belisle et al, 1984, 1986; Iwashita et al, 1986; Mackiewicz et al,
1987; Escher et al, 1988), though the affinity of these binding sites for GnRH agonists is low^
(Kd, 10~6 to 10~7 m) relative to that of the pituitary receptor (Kd, 10~10 \1; Hazum, 1985;
Clayton and Catt, 1981). Since circulating levels ofhypothalamic GnRH (ca 10_1, \l) are far
too low to activate placental receptors, it has been suggested that these binding sites respond
in a paracrine fashion to locally produced GnRH-like molecules (Siler-Khodr, 1987).
Similar 'low affinity' extrapituitary GnRH binding sites have been demonstrated recently in
human cancers of the prostrate (Kadar et al, 1988), endometrium (Pahwa et al, 1991), breast
(Eidne, Flanagan and Millar, 1985; Fekete, Wittliff and Schally, 1989) and ovary (Pahwa et
al, 1989; Emons et al, 1989).
Previous studies have highlighted differences between human extrapituitary GnRH
binding sites and pituitary receptors, related to the mid-chain region of the GnRH molecule
(Bramley et al, 1986; Bramley, 1989). Although both placental and pituitary tissues express
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the gene for the precursor for mammalian GnRI 1 (Seeburg et al, 1987), there is evidence for
the existence for differential processing of prepro-GnRH in the two tissues. Furthermore,
hypothalamic forms ofGnRH differ in different species (King &. Millar, 1987; see Table 1).
Moreover, different isoforms ofGnRH may co-exist in some species, and their localization
may differ in hypothalamic and extrahypothalamic tissues (Branton, Phillips and Van, 1986).
We wished to examine whether human extrapituitary receptors recognized m GnRI 1
preferentially, or whether other isoforms of GnRH were also capable of binding. W e have
therefore compared the ligand specificities of human placental and rat pituitary GnRI 1
binding sites.
Sephadex G25 (fine) was obtained from Pharmacia Ltd, Milton Keynes, Bucks, LK and
from Sigma Chemical Co. Ltd, Poole, Dorset, UK. Sephadex G25 QAE-A was from
Pharmacia. All other fine chemicals and reagents were from Sigma or from BDI I, Poole,
Dorset, UK. Radiolabelled sodium iodide (Nal2H) was from Amersham International pic,
Bucks, UK.
Chicken GnRH I and II were purchased from Peninsula Laboratories, Belmont, CA,
USA, and m GnRH from Ayerst Laboratories Ltd, Andover, Hants, UK. Salmon and
lamprey GnRH were generous gifts ofDrJ. King, MRC Regulatory Peptides Research Unit,
University of Cape Town, RSA, and the GnRH agonist, Buserelin ([D-Ser (tBu)6] 1-9
GnRH ethylamide), was the kind gift ofDrJ. Sandow, Hoescht AG, Frankfurt, Germany. All
other GnRH analogues and the GnRH antagonist ([Ac 3,4-dehydro-Pro1, D-p-F-Phe2,
D-Trp3,6] LHRH) were purchased from Sigma. The structures of GnRH isoforms and
analogues are shown in Figure 1. Peptides identical to different regions of the human
gonadotrophin-releasing hormone-associated protein (GAP) (amino acid sequences 14-26,
14-37, 28-36, 38-49, 51-66 and 54-66) were generously supplied by Dr K. Eidne, MRC
Reproductive Biology Unit, Edinburgh.
Tracer preparation and characterization
Peptides were radioiodinated using the glucose oxidase/lactoperoxidase method (Sharpe
and Fraser, 1980), and were purified by chromatography on Sephadex G25 columns (1 x 40
or 1 x 60 cm) in 0.01 M acetic acid-0.1 per cent bovine serum albumin (BSA). Relative
elution volumes were calculated from the formula (Ve-V,/Vt-V0), where Ve is the elution
MATERIALS AND METHODS
Materials
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Figure 1. Purification of 12Tlabelled GnRHA and GnRHA\T tracers by chromatography on Sephadex G25.
Radioiodinated GnRH,\ (Buserelin; a) or GnRHANT (b) were prepared on Sephadex G25 (tine) columns
(1 x 40 cm) equilibrated and eluted with 0.01 M acetic acid-0.1 per cent BSA. Fractions (2 ml) were collected and
counted (o), and aliquots (5—50/(1) incubated with 100//I of rat pituitary membranes (4°C for 4 h) for measurement
of inhibition of binding of 1 '"O-labelled GnRH analogue by uniodinated GnRH analogue (•). Analogue-
concentration was estimated by comparison of inhibition of binding with standard curves constructed with
unlabelled GnRHA or GnRHANT-
volume of the peak, VQ, is the void volume of the column (Dextran Blue), and Y, is the total
column volume (Na12;,I). In some experiments, aliquots of the purified peaks from Sephadex
G25 chromatography were rechromatographed on Sephadex QAE-A25 equilibrated and
eluted with 0.1 M ammonium bicarbonate buffer, pH 7.8. Relative elution volumes from
QAE-A25 were calculated relative to elution of 12T-iodide.
The elution positions of unlabelled GnRH analogues were determined by measuring the
inhibition of specific binding of GnRH analogue tracer to rat pituitary homogenate in the
presence and absence of aliquots of Sephadex G25 fractions (5-50 u\). Comparison of
inhibition of binding by eluate fractions with displacement curv es for unlabelled agonist or
antagonist enabled calculation of the mass of unlabelled analogue in each fraction.
Specific activities of '^I-labelled GnRH tracers
Self-displacement assay of GnRHA tracers by binding to immature female rat pituitary
homogenates gave values for specific activity of binding ranging from 160 to 880 Ci/g.
Specific activities of radioiodinated GnRH isoforms were estimated by self-displacement
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assay (Clayton, 1983), using an anti-GnRH antibody (EL-14), generously provided by
Dr W. E. Ellinwood, Oregon Health Sciences University, Portland, Oregon. This antibody
recognizes both N- and C-terminal regions of the GnRH molecule, and therefore binds all
isoforms of GnRH, but not GnRH analogues (see below). Values for specific activities of
binding to antibody calculated by self-displacement assay for three separate tracer prep¬
arations of all five GnRH isoforms ranged from 60 to 1104 Ci/g.
Thin layer chromatography of radioiodinated GnRH digests
Aliquots of 123I-labelled GnRH tracer fractions from Sephadex G25 chromatography were
dried under a stream ofnitrogen. Ammonium bicarbonate buffer (200 /d of0.1 M) was added,
followed by 5 /rg of Streptococcus griseus protease. Tubes were sealed under nitrogen, then
incubated at 37°C for 48 h. Unlabelled mono- and di-iodotvrosine standards were added
(2 and aliquots (100 000 ct/min) were spotted onto prewashed glass-silica TLC plates
(Sigma) equilibrated and run with 295 ml t-butyl alcohol, 160 ml t-amyl alcohol, 75 ml 7.5 M
ammonium hydroxide, 35 ml methyl ethyl ketone and 85 ml distilled water (Nett and Adams,
1977). TLC plates were air-dried, stained with ninhydrin to localize amino acids and mono-
and di-iodotyrosine standards, and autoradiographed (Kodak XR-4 film; 20 h).
Tissue
Placenta
Human placentae were obtained by elective caesarian section at term from several normal
women. Placentae were washed extensively in ice-cold isotonic phosphate-buffered saline
(PBS: Flow Laboratories, Irvine, Scotland) to remove blood. Placental tissue was gently
spread out, and pieces ofvillous tissue (ca. 1 g) were cut from different central regions of the
placental plate, taking care to avoid blood vessels and fibrous connective tissue. Villous pieces
(10-20 g) were rinsed once more in cold PBS, then homogenized in ice-cold 0.3 M sucrose-
10 mM Tris-1 m.M EDTA, pH 7.4 (SET buffer; 5 ml/g) using a Polytron homogenizer (two
10 sec bursts at full speed, separated by a 1 min cooling period in ice). After filtration through
four layers of cheesecloth, homogenates were fractionated immediately, or stored frozen
(2 ml aliquots) in liquid nitrogen.
Rabbit placentae were obtained from two late-pregnant New Zealand White rabbits.
Animals were sacrificed by Nembutal overdose and placentae cleaned of decidual tissue and
membranes. Tissue from the placental plate was dissected, weighed, minced and homogen¬
ized in SET medium (Polytron) and stored frozen at — 20°C.
Pituitary
Rat pituitaries were obtained from immature (28-35 day) female Sprague-Dawley rats killed
by CO2 asphyxiation. Pituitaries were excised and homogenized (2 glands/ml) in ice-cold
SET medium, using a loose-fitting all-glass Dounce homogenizer. Aliquots (2 ml) were
snap-frozen in solid CO2, and stored at — 20°C until required.
Rabbit pituitaries were recovered from three virgin New Zealand White does following
Nembutal overdose and were homogenized in SET medium (2 ml/pituitary) and stored at
-20°C.
Tissue fractionation
Homogenates were centrifuged at 1000 g for 10 min (4°C), and the resulting pellet
resuspended in SET medium. Supernatants were then centrifuged at 50 000g for 60 min in a
Sorvall OTD-50 refrigerated ultracentrifuge. Pellets were gently rehomogenized (loose
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Dounce) in SET medium (membrane fraction). Supernatants (cytosol fraction) were also
kept. Fractions were stored in aliquots of 2 ml at —20°C until required.
Assays
Protein was measured by the method of Lowrey et al (1951) with crystalline bovine serum
albumin as a standard.
Binding assays
Receptor binding. Triplicate aliquots (20—200//l) of placental tissue fractions were incubated
in a 1 ml system containing 40 mM Tris-HCl, pH 7.4, 0.5 per cent bovine serum albumin
(BSA) and 100 000 ct/min of12r,I-labelled GnRH analogue or GnRH isoform tracer. After
incubation at 20°C for 1 h, bound hormone was recovered by polvethyleneglycol (PEG)
precipitation (Bramley et al, 1985), and 12:,I bound to the pellet counted in a Packard 'Crystal'
gamma-counter at an efficiency of 75 per cent. Non-specific binding was measured in
duplicate in the presence of 10 /<g unlabelled Buserelin, and was normally 3-5 per cent of
total counts added. The difference between binding in the presence and absence of
unlabelled GnRHA represented specific binding (normally 5-25 per cent of total counts
added). Controls without tissue, with and without unlabelled GnRH\, were included to
correct for displacement of tracer from assay tubes by cold analogue (0.5-1 per cent of total
counts added). Binding of GnRH tracers to rat pituitary tissue fractions was performed as
described above for placental tissue (100 000 ct/min added), except that incubation was
performed at 4°C for 4 h.
Antibody binding. Binding of12^I-labelled GnRH tracers (20-30 000 ct/min added) to anti-
GnRH antibody (1:10 000-1:50 000 dilution) w as performed in the presence or absence of
an excess of the appropriate unlabelled hormone. Incubation w as for 6 h at 4°C. Ice-cold
bovine y-globulin (0.5 ml; 0.5 per cent w/v) was added and bound hormone recovered by
PEG precipitation (Bramley, Menzies and Baird, 1985).
Specificity studies
Concentrations of peptides, proteins, GnRH or GnRH analogues required to reduce the
specific binding of radiolabeled GnRH or GnRHA by 50 per cent (IC50) were estimated
from displacement curves with increasing concentrations of the appropriate GnRH analogue
and tracer. Values for experiments where n > 1 w ere expressed as means ± SEM.
Inactivation ofGnRH analogues
Quintuplicate aliquots (100 ,«1) of human placental or rat pituitary tissue fractions were
incubated in Eppendorf tubes at 37°C for 30 min (or as shown) in a 1 ml system containing
40 m.\l Tris-HCl, pH 7.4, 0.5 per cent BSA and 600 000 ct/min 12T-labelled GnRH or
GnRHA. Tubes were immediately placed in ice-water, and centrifuged at 30 000 g for 10 min
(4°C). Supernatants were carefully aspirated, and pellets counted for 12T. Supernatants were
counted, and their volumes adjusted with incubation buffer to give either 90 000 ct/min/ml
for receptor assays (GnRH analogues, m GnRH, s GnRH, ch GnRH II) or
20 000 ct/min/ml for antibody assay (all GnRH isoforms). Triplicate aliquots of super¬
natants (1 ml) and duplicate aliquots containing the appropriate unlabelled GnRH (10/<g)
were then added to: (a), fresh human placental membranes and incubated at 20°C for 1 h
(12T-labelled GnRHA, s GnRH, ch GnRH II, m GnRH); (b), rat pituitary membranes
(125I-GnRHA) and incubated at 4°C for 4 h or (c), EL-14 antibody (1:10 000 dilution; all
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12>I-labelled GnRH isoforms) and incubated at 4°C for 6 h. After incubation, bound
hormone was recovered by PEG precipitation, and l2'l measured in the pellets bv gamma-
counting. Three controls were always included:
(a) tissue fraction incubated with tracer at 0°C for 30 min during the first incubation;
(b) tracer incubated without tissue fraction during the first incubation at either 0°C or
(c) tracer incubated without tissue fraction at 37°C for 30 min.
Values of specific binding for all three controls always agreed to within ±5 per cent.
Inactivation of tracer during the first incubation w as reflected by a reduction in the specific
binding of the unbound tracer (supernatant) fraction, follow ing re-incubation with fresh
receptor or antibody. Inactivation was expressed as a percentage of binding to controls.
Statistics
Statistical significance of differences between means was estimated by Student's /-test.
RESULTS
Characterization of 125I-labelled GnRH tracers
Since it is vital to ensure that all studies of GnRH binding were conducted with tracer
fractions having maximal receptor binding activity, we first characterized the different
radioiodinated forms produced during GnRH tracer preparation. Typical elution profiles for
'^I-labelled GnRHA [Buserelin; Figure 1(a)] or GnRHAVi [Figure 1 (b)] follow ing chroma¬
tography on Sephadex G25 showed four distinct activity peaks. The first peak (I) w as due to
high molecular weight material which eluted in the column void volume (V0); peak II was free
12sI-iodide which eluted in the total volume of the column (Yt). The retarded peak III
appeared to be due to damaged forms of 12,I-labelled GnRH analogue which bound poorly
to rat pituitary and human placental receptors (Table 2). Peak IV w as retarded strongly and
bound well to rat pituitary and human placental receptors (Table 2). Similar data were
obtained for binding of the four peaks with m GnRH, ch GnRH II, GnRHANr (Table 2) and
other GnRH isoforms (not shown). Unlabelled GnRH agonist eluted betw een peaks II and
III [Figure 1(a)] and unlabelled antagonist, between peaks III and IV [Figure 1(b)].
Elution profiles for peaks III and IV following Sephadex G25 chromatography of
Table 2. Binding of different GnRH tracer peaks to receptors and anti-GnRH antibody
Tracer bound specifically (% total)
Rat pituitary Human placenta Antibody
Peak GnRHA GnRHANT GnRHA ch GnRH II m GnRH ch GnRH II
I 0.01 0.02 0.02 0.01 0.05 0
II n.d n.d n.d n.d n.d 0
III 0.3 0.2 0.6 0.05 2 3
IV 6.8 10.6 8.3 4.5 68 73
Radioactive peaks from radioiodination and Sephadex G2S chromatography of GnRHA,
GnRHAvr, m GnRH and ch GnRH II were incubated (100 000 ct/min) with rat pituitary
(100 fil) or human placental membranes (100 /d), or (20 000 ct/min) with anti-GnRH
antibody, EL-14 (1:10 000). Specific binding was measured as described and expressed as a
percentage of total counts bound. Values are means of three different preparations for each
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Figure 3. Antibody binding and self-displacement assay of l2SI-labelled GnRH isoforms. (a). Aliquots of
I-labelled GnRH isoforms and GnRH,\ (peak IV) were incubated with increasing dilutions of anti-GnRH
antibody (EL-14) for 6 h at 4°C, and tracer bound measured by PEG precipitation. Binding was expressed as a
percentage of total counts added. (•), m GnRH; (O), ch GnRH II: (A), ch GnRH I; (A), 1 GnRH; (■), S GnRH;
(□), Buserelin. (b). Binding of GnRH isoform tracers to EL-14 antibody (1:10 000) in the presence of increasing
concentrations ofunlabelled GnRH isoform (•) orwith increasingGnRH tracer concentrations (O). (b), m GnRH;
(c), ch GnRH I; (d), ch GnRH II; (e), s GnRH; (0,1 GnRH.
radioiodinated tracers from a number of tracer preparations are shown in Figure 2. Peak III
always eluted at a similar position (Ve; 2-3) for both GnRH agonists [Figures 2(a,h)] for
GnRHANT [Figure 2(b)] and for all GnRH isoforms [Figures 2(c-g)]. However, the elution
volumes of peak IV tracers for the different isoforms of GnRH differed from one another.
Moreover, Ve values varied between tracer preparations for the same GnRH form (Figure 2).
(This variation was related in part to different adsorption properties of various batches of
Sephadex G25 from the different suppliers; unpublished data). Horizontal arrows in Figures
2(a,b) indicate the separation between the elution volumes of unlabelled (arrow head) and
123I-labelled (Peak IV; arrow base) Buserelin [Figure 2(a)] and GnRHANT [Figure 2(b)].
Unlabelled hormone was always well separated from the tracer peak (IV). Hence, GnRH
tracers (peak IV) should be minimally contaminated with unlabelled hormone.
For each 125I-labelled GnRH isoform preparation, the tracer fraction eluting in peak IV
bound well to EL-14 anti-GnRH antibody [65-75 per cent binding at 1:1000 dilution;
Figure 3(a)], whereas peaks I, II and III bound poorly (Table 2). Moreover, as predicted from
\
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Elution volume (ml)
Figure 4. Purification of Buserelin tracer fractions on Sephadex QAE-A25. Fractions of peak III (O) and peak IV
(•) were prepared as described in the legend to Figure 1, and aliquots applied to columns (1x2 cm) of Sephadex
QAE-A25 packed into the barrel of a 5 ml plastic syringe. 12H-labelled sodium iodide was also chromatographed as
an internal and external standard (A). Columns were eluted with 0.1 \i ammonium bicarbonate (pH 7.8) and 2 ml
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Figure 5. Sephadex QAE-A25 elution profiles for GnRH analogues and isoforms. Fractions from peak III (□) and
peak IV (■) from chromatography of1 H-labelled GnRH tracer preparations were pooled and rechromatographed
on Sephadex QAE-A25 columns. Fractions were counted for I, and frequency of elution volume (relative to
'I-iodide) plotted.
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the requirement of this antibody for both N- and C-terminal regions ofGnRH, 12H-labelled
tracers from peak IV ofGnRH agonist [Figure 3(a)] and GnRHANT preparations (not shown)
did not bind to antibody, although they showed excellent binding to receptors (Table 2).
Typical self-displacement curves for 12SI-labelled m GnRH [Figure 3(b)], ch GnRH 1
[Figure 3(c)], ch GnRH II [Figure 3(d)], s GnRH [Figure 3(e)] and 1 GnRH tracer
preparations [Figure 3(f)] are illustrated. Differences in maximal binding ofdifferent GnRH
isoform tracers to antibody were related to the specific activity of the tracers.
Peaks III and IV of a Buserelin tracer preparation were subjected to ion exchange
chromatography on Sephadex QAE-A25 (Figure 4). Material from peak IV was not retarded
by the gel, suggesting that this peak lacked strong negative charges, and hence, consisted of
radioiodinated (uncharged) Buserelin. In contrast, peak III was bound quite strongly
(Figure 4), suggesting that this material carried a negative charge. This could arise either by
opening of the N-terminal pyro-Glu, or by loss of the terminal amine group. Profiles from a
number ofGnRH tracer fractions chromatographed on QAE-A25 showed a similar pattern
(Figure 5); tracers from peak IV consistently failed to bind to the gel, whereas material from
peak III was always retarded.
Previous studies have suggested that peaks III and IV represent GnRH with di-iodinated
and mono-iodinated Tyr5 residues respectively (Sharpe and Fraser, 1980; Nett and Adams,
1977) Digestion of peaks III and IV by prolonged incubation with Streptococcus griseus
protease (37°C for 48 h) followed by thin layer chromatography and autoradiography
indicated that both peaks III and IV contained largely mono-iodinated tyrosine, with minimal
di-iodoty rosine (Figure 6).
Binding of GnRH analogues
Specificity. Having established for all GnRH tracer preparations that material eluted in peak
IV was bound with high affinity to rat pituitary homogenate (GnRH agonists and antagonist)
or to EL-14 antibody (GnRH isoforms), we studied the specific binding of radioiodinated
GnRH agonist (Buserelin) and GnRHANT to rat pituitary [Figure 7(a)] and to human
placental membranes [Figure 7(b)]. As expected, GnRH agonist and antagonist tracers
bound well to rat pituitary receptors, and binding of both tracers was displaceable by excess
cold agonist or antagonist. GnRH agonist tracers also bound well to human placental
membrane fractions, and there was a good linear correlation (r = 0.93) between the abilities
of different 125I-labelled GnRH agonist preparations to bind to pituitary and placental
membranes (data not shown), suggesting that the same radioiodinated species binds to both
receptors. Specific binding of GnRH agonist tracer to placental membranes increased with
increasing protein concentration [Figure 7(b)]. In contrast, although total binding of
123I-labelled GnRHANX increased with increasing concentrations of human placental
membranes, GnRHANT binding was not displaceable by excess unlabelled agonist or
antagonist [Figure 7(b)], even after prolonged preincubation before addition of antagonist
tracer (data not shown).
Binding and inactivation of 12T-labelled GnRH and GnRH isoform tracers
Specific binding of GnRH tracers to rat pituitary [Figure 8(a)] and human placental
membranes [Figure 8(b)] was measured, and the unbound tracer fraction was assessed for its
ability to rebind to fresh placental or pituitary receptors, or to EL-14 GnRH antibody.
Pituitary. 12H-labelled GnRHA bound well (~8 per cent of total counts added) to both
tissues, and much of the unbound tracer was still capable of rebinding specifically to fresh
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Figure 6. '2H-labelled monoiodo- and diiodo-tyrosine in peaks III and IV. Pooled fractions from peaks III and IV of
Sephadex G25-purified GnRH isoforms and agonist were digested with protease, and mono- and diiodo-tvrosine
separated by thin layer chromatography. Radioactivity was localized by autoradiography. Arrows indicate the
positions ofmonoiodo- and diiodo-tvrosine standards.
Lane 1, m GnRH (IV); lane 2, m GnRH (III); lane 3, ch GnRH I (IV); lane 4, ch GnRH I (III); lane 5, s GnRH (IV);
lane 6, s GnRH (III); lane 7,1 GnRH (IV); lane 8,1 GnRH (III).
receptors in both systems [80-90 per cent ofcontrols incubated without membranes; Figures
8(a,b)]. Much lower levels ofm GnRH tracer were bound to rat pituitary- membranes in the
first incubation (~1 per cent of total counts added), and the proportion of tracer capable of
rebinding (40-50 per cent ofcontrols incubated without membranes) was reduced compared
to GnRHA [80-90 per cent of controls; Figure 8(a)]. However, appreciable quantities of
tracer which were still capable of rebinding to fresh placental receptor or antibody were
detectable in the unbound tracer fraction after the first binding incubation with pituitary
membranes. Other GnRH isoforms bound poorly to rat pituitary membranes [<0.4 per cent
oftotal counts added; Figure 8(a), solid bars], though once again, the unbound tracer fraction
still contained appreciable levels of GnRH tracer capable of rebinding to human placental
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Figure 7. Binding of radiolabeled GnRHA and GnRHA\T by rat pituitary and by human placental membranes.
Triplicate aliquots of rat pituitary (a) and human placental (b) membrane fractions were incubated with 100 000 ct/
min of 125I-labelled GnRHA (•, O) orGiiRHant (A, A) in the absence (A, •) or in the presence (A,0) of 10»g
of unlabelled GnRHA or GnRHAN:T respectively. After incubation (pituitary , 4°C for 4 h; placenta; 20°C for 1 h),
bound and free hormone were separated by PEG precipitation, and bound hormone measured.
receptors [25-35 per cent relative to controls; Figure 8(a); stippled bars] or antibody [25-50
per cent relative to controls; Figure 8(a); open bars]. Moreover, estimation of the proportions
of tracer rebound by pituitary receptors, and to anti-GnRH antibody, correlated well.
Placenta. GnRHA bound well to human placental membranes (~8 per cent of total counts
added), and most of the unbound tracer fraction was capable of rebinding to fresh placental
or pituitary receptors [—70 per cent relative to controls; Figure 8(b)]. Once again, m GnRH
tracers bound to placental membranes at lower levels than GnRHA [—4 per cent of
counts added; Figure 8(b), solid bars], and rebinding in the second incubation was reduced
(—30-50 per cent relative to controls) compared to GnRHA [Figure 8(b)], suggesting greater
inactivation of m GnRH tracer than GnRHA tracer during incubation with placental
membranes. Lamprey GnRH and ch GnRH I also bound poorly to human placental
membranes [solid bars; Figure 8(a)]. However, s GnRH and ch GnRH II bound specifically
to placental tissue at similar levels to GnRHA [solid bars; Figure 8(b)]. Moreover, whether or
not different GnRH isoforms bound to placental membranes in the first incubation bore no
relationship to the degree of inactivation during incubation. Thus, s GnRH bound well to
placental membranes [Figure 8(b); solid bars] whereas ch GnRH I did not, but the
proportion of tracer capable of rebinding was about 20-30 per cent for both tracers [Figure
8(b); open bars]. Similarly, ch GnRH II bound well to placental membranes [Figure 8(b);
solid bars], whereas 1 GnRH did not. However, both tracers were rebound by antibody at
50-60 per cent of controls [Figure 8(b); open bars]. Furthermore, the inability of GnRH
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Figure 8. Inactivation of 12:>I-labelled GnRH tracers following incubation w ith rat pituitary or human placental
membranes. Quintuplicate aliquots of rat pituitary (a) or human placental membranes (b) were incubated with
600 000 ct/min of I-labelled GnRH.\ or GnRH isoforms under the usual incubation conditions, and bound
hormone (■, left-hand scale) recovered by centrifugation at 30 000 g for 10 min. Supernatant fractions were then
adjusted to either 90 000 ct/min/ml with binding incubation buffer, and reincubated with fresh placental
membranes, or adjusted to 20 000 ct/min/ml and incubated with EL-14 antibody (1:10 000). Bound hormone was
recovered by PEG precipitation, and binding was expressed as a percentage of tracer added which was capable of
binding to fresh placental membranes (□) or to antiGnRH antibody (□) relative to the mean of the three binding
controls (right-hand scale). Bars are means ± SEM of GnRH tracer bound (2-8 separate experiments) using four
different 12,l-labelled GnRH tracer preparations to the same pituitary and placental membrane preparations.
isoforms which bound to placenta but not to rat pituitary receptors was not due to greater
degradation of tracer by rat pituitary membranes, since similar proportions of tracers were
capable of rebinding to antibody following incubation with both tissues [compare open bars in
Figures 8(a,b)]. Thus, although GnRH isoforms were inactivated to a greater extent than
GnRHA during incubation with placental or pituitary tissues, appreciable levels of all tracers
1










Figure 9. Binding of 125I-labelled GnRH isoforms and GnRHA to human placental homogenates and membrane
fractions. Radioiodinated GnRH isoforms (100 000 ct/min/ml) were incubated for 1 h at 20°C with aliquots of (a),
human placental homogenate, (b), 1000 g pellet or (c), 50 000 g pellet and specific binding measured in triplicate in
the presence and absence of unlabelled GnRHA. Tracers were: (O), GnRHA [Buserelin]; (•), ch GnRH I; (A),
s GnRH; (▲), ch GnRH II; (□), 1 GnRH; (■), m GnRH.
remained which were still capable of re-binding to receptor [stippled bars; Figure 8(a,b)] or
anti-GnRH antibody [open bars; Figure 8(a,b)] after preincubation with either tissue.
Differential binding ofGnRH tracers was not related to differential saturation ofbinding,
since specific binding of all GnRH tracers increased wdth increasing receptor concentration
(Figure 9). Furthermore, specific GnRFI binding activity (per mg. protein) was greater for
placental 50 000 g membrane fractions [Figure 9(c)] than for 1000 g pellet [Figure 9(b)] or
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Table 3. Specific activity of 12^I-labelled GnRH^ binding and percentage
ligand inactivation during incubation
Homogenate 1000 pellet 50 000 pellet
Specific binding 7.2 ± 0.5 8.8 ± 0.8 24.3 ± 3.8
(pg per mg protein)
Tracer inactivation 46 ± 7 28 + 4 13 ± 6
(% control)
Specific binding of l2H-Iabelled GnRH a, (600 000 ct/min/ml) was measured
following incubation at 20°C for 1 h with triplicate aliquots (100/d) of human
placental homogenates or membrane fractions, in the presence or absence of
10 tig of unlabelled Buserelin. After centrifugation at 30 000 g for 10 min,
supernatant fractions were carefully aspirated, 12'I-GnRHA bound by each
pellet was counted, and the fraction of the unbound tracer in each supernatant
fraction which was capable of rebinding to fresh placental membranes was
measured and expressed as a percentage of controls. Figures shown are
means ± SEM for four separate experiments.
homogenate [Figure 9(a)]. Salmon GnRH (s GnRH) and chicken GnRH II (ch GnRH II)
binding reached a plateau at lower tissue levels than for GnRH A [particularly with placental
homogenate; Figure 9(a)]. However, chicken GnRH I (ch GnRH I) and lamprey GnRH
(1 GnRH) bound poorly at all protein concentrations for all fractions, and mammalian GnRH
(m GnRH) binding levels were intermediate. Purification of placental membranes enhanced
specific activity of GnRH binding (per mg protein) over that of 1000 g membranes and
homogenate, but increasing binding activity was associated with progressively lower levels of
GnRH.\ tracer inactivation (Table 3). Membranes prepared at 50 000 g were therefore used
routinely for most further studies.
Effects of pH
Binding of 12;,I-labelled GnRHA, s GnRH and ch GnRH II to placental membranes varied
markedly with pH (Figure 10). Binding was low at both high and low extremes of pH, but a
broad plateau was observed between pH 6 to 8. Maximal binding levels for all three GnRH
tracers were similar, and all three showed inflection points at similar pH values (pH 5.8 and
8.1).
Effects of time and temperature
The effects of temperature and duration of incubation on the binding of GnRH agonists to
placental membranes have been published previously (Currie, Fraser and Sharpe, 1981;
Belisle etal, 1984; 1986; Iwashita, Evans and Catt, 1986). Specific binding of s GnRH tracer
to placental membranes was dependent on time and temperature of incubation [Figure
11(a)]. Binding at 4°C increased to a plateau at 1 to 2 h, and declined slowly thereafter. At
20°C, binding was greatest at 1 h, and declined more rapidly with time, whereas at 37°C,
maximal binding was observed at the earliest time measured (15 min), and by 4 h had
declined dramatically such that little specific binding was detectable. Specific binding of ch
GnRH II followed a similar pattern [Figure 11(b)], Binding at 4°C was slower than for s
GnRH, maximal levels being reached only after 4 h. However, binding at 20 and 37°C were
very similar to s GnRH.
Inactivation of 125I-labelled GnRH tracers
The rapid decrease in s GnRH and ch GnRH II binding with duration of incubation at 20
and 37°C [Figure 1 l(a,b)] may be due to inactivation of receptor and/or tracer. Inactivation
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Figure 10. Effects ofpH on binding of 12:,I-labelled GnRH analogues to placental membranes. Aliquots (100 ,/<!) of
human placental 50 000 g pellet were incubated with 125l-labelled s GnRH (O), ch GnRH II (□) or GnRHA (•) for
1 h at 20°C at a range of different pH values. Specific binding was measured and plotted on a logarithmic scale
against pH.
of receptor was dependent on both time and temperature of incubation, but was too slow
(T50, 190 min at 30°C) to account for the rates of loss ofbinding observed in Figure 11 (data
not shown). We therefore compared the rate of degradation ofGnRHA and s GnRH tracers
by placental membranes at 4 and 30°C (Figure 12).
Rates ofbinding of s GnRH to placental membranes at 4°C [Figure 12(a)] were similar to
data shown in Figure 11(a). However, following exposure of 12:iI-labelled s GnRH to
placental membranes at 4°C, the binding ability of the unbound tracer fraction decreased
sharply with time at 4°C (Tso, 20 min), and was almost completely abolished within 15 min at
30°C [Figure 12(c)]. At 4°C, binding of GnRHA was much slower, and was still increasing
after 2 h [Figure 12(b)]. Following incubation ofGnRHA tracer with placental membranes at
4°C, the unbound tracer fraction was still capable ofhigh binding when incubated with fresh
placental membranes [Figure 12(d)]. At 30°C, GnRHA binding was high at 15 min, and
remained elevated for up to 60 min, decreasing slowly with time thereafter [Figure 12(b)],
and the receptor binding activity of the unbound fraction decreased more rapidly than at 4°C,
with a T5o of 3.5 h. Rates of tracer inactivation were much lower for GnRHA than for s
GnRH at both temperatures.
Dissociation rates
Radiolabelled GnRHA and s GnRH were incubated to equilibrium at 4°C with placental
membranes, then excess unlabelled GnRHA was added, and the rate of dissociation ofboth
tracers measured at 4, 20 and 37°C (Figure 13). At 4°C, dissociation rates for GnRHA
[Figure 13(a)] and s GnRH [Figure 13(b)] were low. At 20°C, dissociation ofGnRHA was
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Figure 11. Effects of temperature and duration of incubation on binding of l2'I-labelled s GnRH (a) and ch GnRH
II (b) to human placental membranes. Specific binding of12r>I -labelled s GnRH (a) and ch GnRH II (b) to human
placental membranes was measured following incubation at 4 (O), 20 (•) or 37°C (A) for various periods of time.
Points are means ± SEM for three separate experiments in triplicate.
more rapid [T50, 20 min; Figure 13(a)] than for s GnRH [T50, 50 min; Figure 13(b)], while
the dissociation rate of s GnRH at 37°C [T50, 20 min; Figure 13(b)] was similar to that of
GnRHA at 20°C [Figure 13(a)],
Specificity of placental GnRH binding sites
A range of proteins (BSA, bovine IgG, FSH, LH, hCG, PRL), steroids (androgens,
oestrogens, progesterone), di- and tri-peptides, chemotactic peptides and peptide hormones
(angiotensins I, II and III, vasopressin, oxytocin, EGF, Substance P, neurotensin, met- and
leu-enkephalins, TGF-/3, TRF, insulin, bradykinin, somatostatin and eledoisin) failed to
inhibit binding of GnRHA to placental binding sites (data not shown). Furthermore, a
number of peptidase inhibitors specific for the four major classes of tissue peptidases
(Barrett, 1977) failed to inhibit placental GnRHA binding (see Bramley, Menzies and Baird,
1986). The GnRH-related peptide, yeast ai-mating factor, and a series of peptides derived
Bramie)' et al: Placental GnRH Receptors 573
0 60 120 0 60 120
Duration of incubation (min)
Figure 12 Binding and inactivation of 12riI-labelled GnRH ^ and s GnRH by placental membranes. Aliquots of
placental membrane fractions were incubated with 600 000 ct/min of1I-labelled s GnRH (a, c) or GnRH ^ (b, d)
at 4 (•) or 30°C (O) for various times. Hormone bound specifically (a, b) was measured by centrifugation at 30 000 g
for 10 min. Supernatants were recovered and diluted to 100 000 ct/min/ml with incubation buffer, then 1 ml
aliquots were reincubated with fresh placental membranes at 20°C for 1 h. Specific binding was measured and the
decrease in binding relative to controls (inactivation of tracer; c, d) was calculated.
from the gonadotrophin-releasing hormone-associated peptide (GAP) region of the human
GnRH precursor protein (Millar, Wormald and Milton, 1986) also failed to inhibit GnRHA
binding to human placental membranes (data not shown).
The specificity of human placental GnRH binding sites was studied with radiolabelled
GnRHA, s GnRH and ch GnRH II as binding ligands (Table 4). For comparison, the
affinities of these peptides in competing for 12^I-labelled GnRHA binding sites in the rat
pituitary were also measured. Concentrations of GnRH and GnRH agonists required to
compete for GnRI IA binding to rat pituitary receptors (Table 4) were in line with values
published previously (Clayton and Catt, 1981; Loumaye, Naor and Catt, 1982; Bramley,
Menzies and Baird, 1986). The concentrations of GnRH from different species required to
inhibit GnRHA, s GnRH and ch GnRH II binding to human placental membranes were
similar to levels required to displace agonist binding from rat pituitary (with the exception of
m GnRH). Loss of N- or C-terminal amino acids led to loss of potency (as reported
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Figure 13. Dissociation of 12H-labelled GnRHv and s GnRH from human placental membranes. Aliquots of
human placental 50 000 g membrane fractions were incubated to equilibrium (1 h at 20°C) with either 125I-labelled
GnRHv (a) or s GnRH (b). Then 10/rl ofmedium alone (O, A), or medium containing 10(«gofunlabelled GnRH^
was added (•, ▲), and incubation was continued at 4°C (O), 20°C (A) or 37°C (□) as indicated. Specific binding
was measured by PEG precipitation at various times thereafter, and binding plotted against duration of incubation.
previously for rat pituitary and human luteal GnRH binding sites; Bramley, Menzies and
Baird, 1986), whereas substitution of D-amino acids at Gly6 (with or without ethylamide
substitution at position 10) led to increased GnRH agonist activity, and markedly increased
receptor binding potency relative to m GnRH in the rat pituitary. However, these structural
alterations did not enhance agonist potency for human placental GnRH receptors appreci¬
ably (Table 4).
GnRH antagonist analogues with enhanced potency towards rat pituitary receptors had
markedly reduced potencies for placental binding sites. Antagonist concentrations required
to displace GnRH binding to placental membranes were 200- to 50 000-fold higher than for
the rat pituitary receptors.
GnRH binding and inactivation in rabbit placenta
No specific GnRH binding to homogenates of rabbit placenta was observ ed with any GnRH
isoform tracer under the same incubation conditions which allowed measurement of high
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Table 4. Binding potencies of GnRH analogues and isoforms for 1I-labelled GnRH binding sites in human
placenta and rat pituitary
Concentration required to inhibit binding by 50% (ng)
Rat pituitary Human placenta
GnRH analogue
Tracer !25I GnRHA l25I-CnRHA 125I-sGnRH 125I-ch GnRH II
GnRH forms
m GnRH 180 ± 30 (8) 1456 ± 530(8) 2500 (2) 400 (2)
ch GnRH I 1550 ± 160 (6) 2300 ± 670 (5) 4000 (2) 1800
ch GnRH II 220 -± 130 (3) 740 ±512 (5) 900 250 (2)
s GnRH 600 300 (2) 300 500
1 GnRH 12 000 >10 000 (2) >10 000 (2) >10 000(2)
[3-10] GnRH 4000 ± 600 (3) >10 000 (2) >10 000 (2) >10 000(2)
[Glv(OH)ln]GnRH >10 000 (4) >10 000 (3) >10 000 (2) 1900(2)
[des pGlu']GnRH 4000 30 000 (2) 6000 20 000
Agonist analogues
[D-Ser(tBu)6]EtA 0.3 ± 0.03 (23) 243 ± 166(17) 387 ±155 (4) 200 (2)
[D-Ala6]EtA 0.5 ± 0.1 (5) 867 ± 234 (6) 750 ± 200 (3) 400 (2)
[D-Ala6N-MeLeu7]EtA 0.8 ± 0.2 (3) 367 ±115 (3) - 795 (2)
[D-Trp6] GnRH 0.3 (2) 268 ± 40 (6) - 700 (2)
[D-Trp6] EtA 0.6 ± 0.3 (5) 336 ± 153 (5) 400 200 (2)
[D-Phe6] EtA 0.2 (2) 533 ± 258 (6) - 710(2)
1-9 GnRH EtA 3.0 (2) 1000 (2) 900 680
Antagonist analogues
A 13 ± 5 (3) >10 000 (3) >10 000 >10 000
B 0.85 (2) >10 000 (3) 10 000 (2) 15 000 (2)
C 1.0 ±0.4 (3) >10 000 (2) - >10 000 (2)
D 0.23 ± 0.1 (5) >10 000 (4) >10 000 (2) >10 000(2)
E 60 (2) >10 000 (3) - -
F 0.6 ± 0.3 (5) >10 000(2) >10 000 (2) >10 000 (2)
Specific binding of '' !-labelled GnRH analogues was measured to rat pituitary homogenate or human placental
membranes in the absence and in the presence of increasing concentrations of unlabelled GnRH antagonist
analogues, and the concentrations required to reduce specific binding by 50 per cent was calculated. Figures are
means ± SEM for (n) separate experiments (except where « = 1).
A, [D-Phe2,6 Pro3] GnRH;
B, [AcD-pCl-Phe '2 D-Trp3 D-Arg6 D-Ala10] GnRH;
C, [D-pGlu1 D-Phe2 D-Trp3'6] GnRH;
D, [Ac-dehvdro 3,4-Pro1 D-p-F-Phe2 D-Trp3,6] GnRH;
E, [D-Phe2 D-Ala6] GnRH;
F, [Ac D-Trp1 D-p-Cl-Phe2 D-Trp3 D-Arg6 D-Ala10] GnRH.
A range of proteins (BSA, bovine IgG, FSH, LH, hCG, PRL), steroids (androgens, oestrogens, progesterone),
di- and tri-peptides, chemotactic peptides and peptide hormones (angiotensins I, II and III, vasopressin, oxytocin,
EGF, Substance P, neurotensin, met- and leu-enkephalins, TGF-/?, TRF, insulin, bradvkinin, somatostatin and
eledoisin) failed to inhibit binding of GnRHA to placental binding sites (data not shown).
levels of binding to human placental receptors (Table 5). However, preincubation of tracer
with rabbit placenta induced almost complete inactivation of all forms of GnRH, and
unbound tracers were incapable of rebinding to either fresh human placental or rat pituitary
receptors, or to GnRH antibody (Table 5).
DISCUSSION
Binding studies of placental GnRH receptors have used radiolabeled GnRH agonists
(Currie, Fraser and Sharpe, 1981; Belisle et al, 1984, 1986; Iwashita et al, 1986) and
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Table 5. Tracer binding and inactivation by pituitary and placental tissue
Hormone tracer
Buser mGnRH sGnRH chGnRH I chGnRH 11 IGnRH
Human placenta
% Specific binding 7.8 4.8 6.5 0.4 6.8 0.2
% Rebinding:
Antibody - 48 23 27 45 46
Placental Receptor 68 - 22 - 25 -
Pituitary Receptor 74 - - - - -
Rat pituitary
% Specific binding 6.7 0.9 0.1 0 0.2 0
% Rebinding:
Antibody - 48 18 42 52 61
Placental Receptor 70 - 21 - 58 -
Pituitary Receptor 91 - - - - -
Rabbit pituitary
% Specific binding 5.6 0.5 0 0.1 0 0
% Rebinding:
Antibody - 10 12 16 25 29
Placental Receptor 60 - 10 - 19 -
Pituitary Receptor 40 - - - - -
Rabbit placenta
% Specific binding 0 0.2 0 0.1 0 0.1
% Rebinding:
Antibody - 1 8 0 12 2
Placental Receptor 0 2 9 - 8 -
Pituitary Receptor 0 2 5 2 6 3
Rat and rabbit pituitary, and human and rabbit placenta were homogenized in SET and triplicate aliquots (100 td)
were incubated in Eppendorf tubes (2 ml) with 600 000 ct/min of l2'4-labelled GnRHA (Buserelin) or with GnRH
isoforms in Tris-BSA buffer for 1 h at 20°C, with and without excess hormone (10 /<g/tube). Tubes were
centrifuged at 30 000 g for 10 min (4°C) and supernatants carefully removed. Pellets were counted for 125I-GnRHA
or GnRH isoform bound specifically. Supernatants were adjusted to 90 000 ct/min/ml, and incubated with fresh rat
pituitary (4 h at 4°C), or adjusted to 20 000 ct/min/ml and incubated with anti-GnRH antibody (1:50 000 final
concentration). Tracer bound specifically was measured by PEG precipitation, and expressed as a percentage of
controls incubated: (a) at 4°C and (b) at 20°C without addition ofovarian or placental tissue, and (c) with tissue, but
incubated on ice for lh. All controls agreed to within ±5 per cent. Specific binding of GnRHA and GnRH isoform
tracers in the second incubation were expressed as a percentage of control binding.
antagonists (Mackiewicz et al, 1987; Escher et al, 1988) as binding ligands. Agonist
analogues bound to placental membranes with high specificity, but with low apparent affinity
(Kd, 10~6 to 10~7 m) compared to pituitary GnRH receptors (Kd, 10~10 m). However,
human placental binding sites did not discriminate between GnRH and a range of GnRH
superagonists with d-aminoacid substitutions at Glv6, with or without replacement of
glycinamide with ethylamide at position 10 (Currie, Fraser and Sharpe, 1981; Belisle et al,
1984; Iwashita, Evans and Catt, 1986). Furthermore, the differences observed between
binding ofGnRH and its analogues to rat pituitary and human placental GnRH binding sites
were not species-dependent, since the properties, affinities and specificities of human
pituitary receptors (Clayton and Huhtaneimi, 1982; Wormald, Eidne and Millar, 1985) were
similar to those of rat pituitary (Hazum, 1985; Clayton and Catt, 1981; Loumaye, Naor and
Catt, 1982), but quite distinct from those of human placental GnRH receptors (Currie,
Fraser and Sharpe, 1981; Iwashita, Evans and Catt, 1986; Belisle et al, 1984). Thus, the
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differences observed herein must reflect the distinct hormonal specificities of pituitary and
extra-pituitary GnRH receptors.
In this study, we have shown marked differences between human placental and rat
pituitary receptors. Firstly, human placental membranes bound s GnRH and ch GnRH II to
the same extent as GnRHA [Figures 8(b), 9], and binding of these two isoforms (and
GnRHA) increased with purification ofplacental membranes (Figure 9; Table 3). In contrast,
these two isoforms were not bound appreciably by rat pituitary receptors (Table 5), and they
competed poorly for pituitary GnRHA binding sites (Table 4). Differences in the abilities of
12SI-labelled GnRH isoforms to bind to rat pituitary and human placental receptors may
reflect differential inactivation of tracer during the binding incubation. Thus, if 1 GnRH and
ch GnRH I were degraded more rapidly during incubation with placental membranes than s
GnRH or ch GnRH II, the former tracers would appear to be incapable ofbinding. Similarly,
all GnRH isoforms may be inactivated rapidly by rat pituitary tissue, and therefore appear to
be unable to bind, whereas agonist (being resistant to proteolytic inactivation) may bind well.
Indeed, differential inactivation of GnRHA and m GnRH has been shown to occur in rat
pituitary membranes (Clayton et al, 1979) and inactivation ofGnRHA tracer was always less
than inactivation of m GnRH and other GnRH isoforms in both rat pituitary and human
placenta (Figure 8). However, measurements ofbinding and degradation for each tracer by
both human placental and rat pituitarymembranes in these same incubations [Figures 8(a,b)]
showed clearly that, although differences in inactivation of GnRH isoforms by rat pituitary
and human placental membranes did occur, differential binding of GnRH isoforms was
unrelated to the degree of tracer inactivation which occurred during preincubation with
membranes. Thus, levels of rebinding of ch GnRH II and 1 GnRH tracers to antibody after
exposure to human placental membranes was similar [open bars; Figure 8(b)], even though
initial binding of these tracers to placenta was markedly different [solid bars; Figure 8(b)],
Hence, differential binding of GnRH isoforms must reflect differences in placental ligand
specificity rather than differences in tracer inactivation rates.
Human placental GnRH receptors bound s GnRH and ch GnRH II well compared to m
GnRH, 1 GnRH and ch GnRH I, suggesting a preference for the Trp' group. The low
potency ofl GnRH (which also has a Trp' residue) may be due to the additional replacement
ofTrp3 with a Tyr residue (Table 4). Alternatively, differences in binding may be related to
the overall hydrophobicity of the peptides (although differences in potency did not appear to
correlate with hydrophobicity and hydropathy plots of the different forms ofGnRH: data not
shown). It will be of interest to compare the binding potencies of synthetic GnRH peptides
with specific amino acid substitutions in these and other positions to human placental and rat
pituitary membranes.
Secondly, a 12H-labelled GnRH antagonist tracer, which had a high potency for rat
pituitary receptors and which was displaceable by either cold agonist or antagonist [Figure
7(a)], bound to human placental membranes, but in a non-displaceable manner [Figure 7(b)].
Moreover, GnRHANT binding was not displaceable by eitherGnRH agonists or antagonists,
with or without preincubation, in the presence or absence of various GTP analogues (data
not shown). This observation suggests that apparent size differences reported for complexes
of solubilized placental GnRH-receptors radiolabelled with either GnRH agonist and
antagonist may be due to binding of antagonist tracer to non-displaceable binding sites,
rather than to differences in receptor-G-protein involvement (Escher et al, 1988). Further¬
more, although there are reports of the partial reversal of GnRH effects in human
extrapituitary tissues by GnRH antagonists (Siler-Khodr, Kuehl and Vickery, 1984; Siler-
Khodr et al, 1986d), the molar ratio ofantagonist to GnRH required was high, and a different
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GnRH antagonist ([D-Phe2'6,Pro3] GnRH) failed to affect hCG secretion by placental tissue
in vitro (Belisle et al, 1984). Thus, GnRH antagonists, which have played such an important
role in establishing whether extrapituitary GnRH effects in rat gonadal tissues were exerted
through GnRH receptors, may be of only limited use in defining GnRH effects in human
extrapituitary tissues.
A paracrine role for GnRH-like peptides has been proposed in the human placenta (Siler-
Khodr, 1987). It is suggested that GnRH-like peptides produced by the cytotrophoblast act
on receptors on the syncytiotrophoblast membrane and regulate placental hCG, steroid and
prostaglandin secretion. Both GnRH (Osathanondh and Elkind-Hirsch, 1981; Tan and
Rousseau, 1982; Zhuang et al, 1991) and GnRH-like peptides have been extracted from
placenta (Siler-Khodr, 1987; Mathialagan and Rao, 1986a; Zhuang et al, 1991). However,
although the gene for human GnRH precursor is expressed in human placenta (Seeburg and
Adelman, 1984), in contrast to the hypothalamus, the first intron is not spliced out.
Furthermore, there appear to be differences in promoter regions (Seeburg et al, 1987).
Differences in prepro-GnRH precursor processing may give rise to prepro-GnRH-derived
peptides which are extended at either the N-terminal (signal peptide) or at the C-terminal
(GnRH-GAP) region. It will be of interest to examine the placental receptor binding activity
of extended forms of GnRH.
In the frog central nervous system, m GnRH was localized exclusively in the hypothalamic
region, whereas teleost GnRH was localized exclusively in the spinal cord (Branton, Phillips
and Yan, 1986). Thus, within the same species, the form of GnRH expressed in different
tissues varied. Since we have shown that human placenta binds s GnRH and ch GnRH II to
much higher levels than other GnRH forms, it is possible that the genes for s GnRH and/or
ch GnRH II are expressed in addition to m GnRH in the human placenta. These forms may
not be detected under stringent binding conditions with probes raised to the m GnRH
sequence (see Seeburg et al, 1987). Thus, the placental GnRH receptors may recognize
preferentially s GnRH- or ch GnRH-like molecules.
GnRH-like peptides have been described in placental tissues of the rat (Gautron, Pattou
and Kordon, 1981) and rabbit (Nowak, Wiseman and Bahr, 1984), suggesting a possible
paracrine role in these species also. We were unable to demonstrate binding of any form of
GnRH to rat (not shown) or rabbit placental tissues under conditions where binding was
readilymeasured in human placental homogenates (Table 5). However, attempts to measure
GnRH binding to these tissues were confounded by the very high rate of degradation of all
forms of GnRH by these tissues (Table 5). Thus, the demonstration ofGnRH binding sites
in these tissues must await binding assays which eliminate the effects of tracer degradation.
The properties ofhuman placental and luteal GnRI I binding sites appear to be very similar
to one another (Bramley, 1987; 1989), but distinct from these of the pituitary gland (Clayton
and Huhtaneimi, 1982; Wormald, Eidne and Millar, 1985). Since the corpus luteum and
placenta are required for the establishment and continuation of human pregnancy, a better
understanding of the physiological role of GnRH-like peptides in human extrapituitary
tissues may offer exciting prospects for the regulation of human fertility, from ovulation
throughout a large part of early pregnancy.
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SUMMARY
We have measured the levels ofgonadotrophin-releasing hormone (GnRH) binding
sites in human placental villous membrane fractions obtained at different stages of
gestation. There mas a marked decrease in the specific activity of '2*I-labelled
GnRH binding to membranefractions obtained between 10-20 weeks gestation, but
there was no change in either affinity or ligand specificity ofthese binding sites. The
observed decrease in binding was not due to contamination of placental villous
membranes by membranes from other tissues, since there was no gestation-dependent
decrease in the specific activity of epidermal growth factor receptor or alkaline
phosphatase activity in villous membrane fractions between 10—20 weeks ofges¬
tation. Furthermore, incubation of GnRH tracer with membranes from different
stages ofgestation, followed by re-incubation of the unbound tracer fraction with
fresh membranes, demonstrated unequivocally that decreased GnRH binding to 10—
20 week membranes was not due to increased degradation of GnRH tracer. We
conclude that the observed changes in GnRH receptor levels between 10-20 weeks
gestation must reflect either decreased expression/synthesis (or increased catabolism)
ofplacental GnRH receptors, or increased occupancy (or down-regulation) ofpla¬
cental GnRH receptors by an endogenous GnRH-like ligand.
INTRODUCTION
Human placental membranes bind radiolabelled gonadotrophin-releasing hormone
(GnRH) with high specificity (Currie, Fraser and Sharpe, 1981; Belisle et al, 1984, 1986;
0143-4004/94/070733 + 13 $08.00/0 © 1994 W. H. Saunders Company Ltd
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Iwashita, Evans and Catt, 1986; Mackiewicz ct al, 1987; Escher ct al, 1988; Bramley,
McPhie and Mcnzies, 1992), though the affinity of these binding sites for GnRI 1 agonists
is low (Aj, 10~6 to 10~7m) relative to that of the pituitary GnRIl receptor [Ad, 10"'m
(Hazum, 1985)]. Since the circulating level of hypothalamic GnRH is thought to be too low
(around 10"m) to activate these 'low affinity' receptors, it has been suggested that
placental GnRll receptors must respond to locally-produced GnRIl. Indeed, GnRI I can
stimulate the release and synthesis of human chorionic gonadotrophin (hCG) and other
placental steroids and prostaglandins in a dose- and gestation-dependent fashion (see
Siler-Khodr, 1987 for review).
Our previous studies have highlighted a number of differences between human extra-
pituitary GnRH binding sites and rat and human pituitary GnRH receptors (Bramley,
1987, 1989; Bramley, Menzies and Baird, 1986; Bramley, McPhie and Menzies, 1992).
Thus, although both placental and hypothalamic tissues express the gene for the precursor
for mammaliam GnRH (Seeburg et al, 1987), different promoters are probably used, and
differential processing of prcpro-GnRH may give rise to different forms of'GnRH' in the
two tissues. Thus, differential processing of the mammalian prepro-GnRH gene in the
human placenta may give rise to other (possible larger) forms of GnRH which have a
preferential affinity for the placental and luteal GnRH receptor. Furthermore, there is
increasing evidence in several species that different isoforms of GnRI 1 may coexist in
different tissues (Sherwood, Lovejoy and Coe, 1993).
We have therefore extended our previous studies to examine the concentrations of
GnRH binding sites in placental villous membranes in human placental tissues from
different stages of gestation.
MATERIALS AND METHODS
Sephadex G25 (fine) was obtained from Pharmacia Ltd, Milton Kcvnes, Bucks, UK and
from Sigma Chemical Co. Ltd, Poole, Dorset, UK. Sephadex G25 QAE-A was from
Pharmacia. All other fine chemicals and reagents were from Sigma or from BDH, Poole,
Dorset, UK. Radiolabellcd sodium iodide [123I]Na, was from Amersham International pic,
Bucks, UK.
Chicken GnRH I and II were purchased from Peninsula Laboratories, Belmont, CA,
USA, and m GnRH from Ayerst Laboratories Ltd, Andover, Hants, UK. Salmon and
lamprey GnRH were generous gifts of Dr J. King, Department of Chemical Pathology,
University of Cape Town, RSA, and the GnRH agonist, Buserelin {[D-Ser(tBu)6] 1-9
GnRH ethylamide}, was the kind gift of Dr J. Sandow, Hoescht AG, Frankfurt, Germany.
All other GnRH analogues were purchased from Sigma.
Tracer preparation and characterization
Peptides were radioiodinated using the glucose oxidase/lactoperoxidasc method (Sharpe
and Eraser, 1980), and were purified by chromatography on Sephadex G25 columns (1 x
40 or 1 x 60 cm) in 0.01 m acetic acid-0.1 per cent bovine scrum albumin (BSA) (Bramley,
McPhie and Menzies, 1992).
Specific activities of ,25I-labelled GnRH tracers
Self-displacement assay of GnRHA tracers by binding to immature female rat pituitary
homogenates gave values for specific activity of binding ranging from 350-1105 Ci/g.
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Specific activities of radioiodinated GnRH isoforms were estimated by self-displacement
assay (Clayton, 1983), using an anti-GnRH antibody (EL-14), generously provided by Dr
W. E. Ellinwood, Oregon Health Sciences University, Portland, OR. This antibody recog¬
nizes both N- and C-terminal regions of the GnRH molecule, and therefore binds all
isoforms of GnRH, but not GnRH analogues (Bramley, McPhie and Menzies, 1992).
Values for specific activities ofbinding to antibody calculated by self-displacement assay for
three separate tracer preparations of ch GnRH II ranged from 85-1100 Ci/g.
Tissue placenta
Human placentae were obtained by elective cacsarean section at term from several normal
women, and from several women with lOmin of spontaneous vaginal delivery, with or
without induction of labour. Placental tissue was also obtained from women undergoing
elective termination ofpregnancy between 6 and 22 weeks gestation. Early terminations (6-
9 weeks) were generally by vacuum aspiration or by treatment with Mifepristone (RU486)
followed by induction of labour using Gemeprost pessaries (Norman et al, 1992). From 9-
22 weeks gestation, pregnancies were generally terminated using prostaglandin alone. All
terminations were performed with full informed consent of the patient, following counsel¬
ling for termination of pregnancy.
Placental villous tissue was carefully recovered and dissected free of other tissues, then
washed extensively in ice-cold isotonic phosphate-buffered saline (PBS: Flow Labora¬
tories, Irvine, Scotland) to remove blood. Pieces ofvillous tissue were either frozen in liquid
nitrogen or homogenized immediately in ice-cold 0.3 m sucrose-10m m Tris-lmM
EDTA, pH 7.4 (SET buffer; 5 ml/g) using a Polvtron homogenizer (two 10 sec bursts at
full speed, separated by a 1 min cooling period in ice). After filtration through four layers of
cheesecloth, homogenates were fractionated immediately. There was no difference in
GnRH binding concentrations between membranes prepared immediately, or membranes
isolated from tissue which had been frozen in liquid nitrogen for several months (unpub¬
lished data).
Tissue fractionation
Homogenates were centrifuged at 1000 g for 10 min (4°C), and the resulting pellet resus-
pended in SET medium. Supernatants were then centrifuged at 50 000 g for 60 min in a
Sorvall OTD-50 refrigerated ultracentrifuge. Pellets were gently rehomogenized (loose
Dounce) in SET medium (membrane fraction). Supcrnatants (cvtosol fraction) were also
kept. Fractions were stored in aliquots of 2 ml at —70°C until required.
Assays
Protein was measured by the method of Lowrv et al (1951) with crystalline BSA as a
standard.
Binding assays
Receptor binding. Triplicate aliquots (5-200 pi) of placental tissue fractions (approximately
1 mg membrane protein per tube) were incubated in a 0.5 ml system containing 40 mM
Tris-HCl, pH 7.4, 0.5 per cent BSA and lOOOOOct/min of 125I-labelled GnRH analogue
or GnRH isoform tracer. After incubation at 20°C for 1 h, bound hormone was recovered
by polyethyleneglycol (PEG) precipitation (Bramley, Menzies and Baird, 1985), and 12;,I
bound to the pellet, counted in a Packard 'Crystal' gamma-counter at an efficiency of 75
I
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per cent. Non-specific binding was measured in duplicate in the presence of 10p.g un¬
labeled Buserelin and was normally 3-5 per cent of total counts added for Buserelin and
chicken GnRH II, and 8-12 per cent for Tryptorclin tracers. The difference between
binding in the presence and absence of unlabelled GnRHA represented specific binding
(normally 5-35 per cent of total counts added). Controls without tissue, with and without
unlabelled GnRHA, were included to correct for displacement of tracer from assay tubes by
cold analogue (0.5-1 per cent of total counts added).
Antibody binding. Binding of125I-labellcd GnRI I tracers (20-30 000 ct/min added) to anti-
GnRH antibody (1:10 000-1:50 000 dilution) was performed in the presence or absence of
an excess of the appropriate unlabelled hormone. Incubation was for 6 h at 4°C. Ice-cold
bovine y-globulin (0.5 ml; 0.5 per cent w/v) was added and bound hormone recovered by
PEG precipitation (Bramlcv, McPhie and Menzies, 1992).
Inactivation ofGnRH analogues
Quintuplicate aliquots (100 p.1) of human placental tissue fractions were incubated in
Eppendorf tubes at 20°C for 60-120min (or as shown) in a 0.5 ml system containing
40 mM Tris-HCl, pH 7.4, 0.5 per cent BSA and 600 000 ct/min 12lI-labelled GnRH
analogue or GnRHA. Tubes were immediately placed in ice-water, and centrifuged at
30000gfor lOmin (4°C). Supernatants were carefully aspirated, and pellets counted for
125I. Supernatants were counted, and their volumes adjusted with incubation buffer to give
90000 ct/min/ml. Triplicate aliquots of supernatants (1 ml) and duplicate aliquots contain¬
ing the appropriate unlabelled GnRH (10 pg) were then added to fresh human placental
membranes and incubated at 20°C for 1 h. After incubation, bound hormone was recovered
by PEG precipitation, and I2SI measured in the pellets by gamma-counting. Three controls
were always included:
(a) tissue fraction incubated with tracer at 0°C for 1 h during the first incubation;
(b) tracer incubated without tissue fraction during the first incubation at either 0°C or
(c) tracer incubated without tissue fraction at 20°C for 1 h.
Values of specific binding for all three controls always agreed to within ± 7 per cent.
Inactivation of tracer during the first incubation was reflected by a reduction in the specific
binding of the unbound tracer (supernatant) fraction, following re-incubation with fresh
receptor or antibody. Inactivation was expressed as a percentage of binding to controls.
Statistics
Statistical significance of differences between means was estimated by Student's /-test.
RESULTS
Comparison of the specific binding of 125I-labclled ch GnRH II and the GnRH agonists,
Tryptorelin and Buserelin indicated that all three tracers were bound to placental mem¬
branes equivalently (Figure 1) with several different tracer preparations to a number of
placental membrane preparations over a wide range of specific binding activities. Indeed,
the binding of Buserclin tracer to term placental membranes could be displaced by similar
levels of unlabelled ch GnRH II, Buserelin or Tryptorelin [300-1000 nM analogue; Figure
2(a)], and the levels of the unlabellcd Buserclin required to inhibit binding of l2T-labclled
Buserelin to placental membranes from early, mid-gestation and term placentae were also
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Figure 1. Comparison of specific binding of 1?M-labelled Buserclin with binding of radiolabellcd Trvptorelin (•)
and ch GnRI I II (O) tracers to human placental membrane fractions. Specific binding of several tracer prep¬
arations for each different GnRH agonist tracer was measured to human placental membrane fractions prepared
from a number of placentae at different stages of gestation, as described in Materials and Methods section.
very similar [Figure 2(b)]. Furthermore, inhibition of the binding of1 ""I-labelled eh GnRH
II (Bramley, McPhie and Menzies, 1992) and Tryptorelin traeers (data not shown)
occurred with similar levels of unlabelled ch GnRIl II, Tryptorelin and Buserelin, suggest¬
ing that all three tracers bound to the same placental binding site.
As shown in Figure 2(b), l2T-labelled GnRH agonist binding varied markedly from
different membrane fractions. It is possible that low GnRH binding was associated with
villous membranes from pathological placental tissues, or to a gestation-dependent change
in GnRH binding. We therefore measured radiolabeled Buserelin binding to villous
membranes prepared from 105 normal or pathological placentae (Table 1). Whilst there
was wide variation in GnRH binding by villous membranes from different stages of ges¬
tation, changes in GnRH binding were observed which appeared to be related to the stage
of gestation at which the placenta was recovered (Figure 3). A number of possible causes
were examined for the marked reduction in GnRH binding to placental membranes ob¬
served at 10-20 weeks gestation.
Changes in receptor affinity or specificity
Differences in binding were not related to the use of Buserelin as a tracer, since the binding
of radiolabeled Buserelin and Tryptorelin was similar for villous membranes from 7 week,
16 week and term placentae, despite marked differences in membrane binding activity
(Figure 4). Furthermore, radiolabeled tracers prepared from GnRH isoforms which bind
to human term placental membranes (ch GnRH II, s GnRH, m GnRH) and GnRH
isoforms which do not (ch GnRH I, 1 GnRH; Bramley, McPhic and Menzies, 1992)
showed no change in GnRH analogue binding specificity to placental membrane fractions
from different stages of gestation (Figure 5). This indicated that there had been no change
in GnRH analogue specificity, despite marked changes in specific binding activity at
different stages of pregnancy [note the scale changes between Figures 5(a), (b) and (c)].
This was further confirmed using several different GnRH tracers and placental membrane
preparations from different stages throughout pregnancy (Figure 6). At all stages of ges-













tation, GnRII agonist, ch GnRH II and s GnRH bound similarly, whilst m GnRII bound
less well, and ch GnRH I and 1 GnRH bound poorly.
GnRH agonist concentration (nM)
Figure 2. Competition curves for 'M-labelled Buserelin tracer binding to human placental membranes: (a) Term
membranes in the absence, or in the presence of increasing concentrations, of unlabelled Buserelin (O), Tryptore-
lin (•) or ch GnRII II (A); (b) Term (•), 7 weeks gestation (O) or 16 weeks gestation (A) membranes in the
absence or presence of increasing concentrations of unlabelled Buserelin. Points are means ± s.d. for one
representative experiment in triplicate.
Villous membrane contamination
The decrease in GnRH binding to placental membranes recovered at 10-20 weeks ges¬
tation could be due to contamination of villous tissue by membranes of other tissues,
leading to an artefactual reduction of specific binding per mg (membrane protein). This is
due to suction termination leading to the extensive fragmentation of fetal and placental
tissues. However, membranes prepared from villous tissue from early pregnancies termi¬
nated by RU486/Gemeprost treatment, by suction termination or by PG treatment alone
gave similar levels of GnRH binding at 6-16 weeks (Figure 3). This also indicates that the
decline in GnRH binding activity was not due to the use of prostaglandin to induce
abortion, though this requires confirmation by others, as the number of suction termin¬
ations between 10 and 20 weeks was low.
Moreover, if contamination by non-villous tissue was responsible for low GnRH binding
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Table I. Levels of placental villous plasma-membrane markers in
membrane fractions isolated at different stages of gestation
Stage of gestation
(weeks)
GnRHA Binding" mEGF Binding'"
6-8 5.1 ± 0.5 (27) 14.9 ± 5.9 (6)
10-20 1.0 ± 0.2 (23)** 22.4 ± 2.1 (7)
21-38' 7.7 ± 0.9 (12)** n.d.
Term 9.2 ± 0.7 (43) 48.4 ± 9.7 (7)*
" Human placental villous membrane fractions were assayed for
specific binding of GnRl IA (Buserelin; % tracer bound/p.g protein)
or h mEGF (ct/min/p,g protein).
' Abnormal placentae. All placental tissue was from women with preg¬
nancy complicated by either severe hypertension or intrauterine
growth retardation.
Figures are means ± sem for (n) measurements at each stage.





Figure 3. Specific binding of radiolabeled Buserelin to human placental villous membranes from different stages
of gestation. '^I-labelled Buserelin binding to microsomal fractions from human placentae was measured as
described in materials and methods, and specific binding adjusted for membrane protein content. Stage of
gestation was estimated from LMP and CRI. measurements by ultrasound. (O), Suction termination of normal
pregnancy; (•), RU486/Gemeprost induced termination; (A), prostaglandin only; (□), normal spontaneous
vaginal delivery.
at 10-20 weeks, other markers of villous surface membranes should also be reduced by a
similar amount. In contrast to the marked fall in GnRH binding observed at 10-20 weeks
gestation, there was no marked reduction in the levels of epidermal growth factor (EGF)
receptor (a marker of placental villous membranes; Menzies and Bramley, 1992) in mem¬
brane fractions prepared from placentae at 10-20 weeks of gestation (Table 1). Similar
results were obtained for alkaline phosphatase activity (data not shown). Hence, the re¬
duction of GnRH binding levels at 10-20 weeks could not be accounted for in terms of
contamination of villous membranes of other tissues at this stage of gestation.
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Figure 4. Comparison of specific binding of Buserelin (OB A) and Tryptorelin (COA) to membranes from term
(OO), 7 weeks gestation (■□) or 16 weeks gestation (A A) human placentae. Specific binding was measured as
described in Materials and Methods section. Points are means of triplicate determinations.
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Figure 5. Specificity of human placental GnRl I binding sites from different stages of gestation. Specific binding of
a range of radiolabeiled GnRH analogues was measured to aliquots of placental villous membrane fractions
prepared from: (a) term; (b) 7 weeks gestation; (c) 16 weeks gestation, as described in Materials and Methods
section. (•), Buscrelin; (O), Salmon GnRH; (A), 1 GnRI I; (A), ch GnRI 1 II; (■), ch GnRH I; (□), m GnRl 1.
Note the marked scale changes between term, 7 and 16 week placental membranes.
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Figure 6. Specificity of human placental GnRl 1 binding sites from different stages of gestation. Specific binding of
a range of radiolabelled GnRH analogues was measured to aliquots ot placental villous membrane fractions
prepared from: 7-8 weeks; 10-11 weeks; 14-16 weeks; 38-40 weeks gestation, as described in Materials and
Methods section. (■), Buserelin; (0), Salmon GnRI 1; (0), 1 GnRI I; (□), ch GnRl I II; (□), ch GnRH I; (S), m
GnRII.
Degradation of GnRH tracers
Placental levels of GnRH-degrading enzymes may be greatly increased between 10-20
weeks of gestation, leading to increased degradation of 12;,I-labelled GnRH tracers during
the binding assay incubation at these stages of gestation. We therefore incubated radio-
labelled Buserelin tracer with placental membranes prepared from villous tissue obtained at
different stages of gestation, and separated the bound and unbound tracer fractions by
high-speed centrifugation. The unbound tracer fraction was then re-incubated under
standard conditions with either; (a) placental membranes from the same stage ofpregnancy,
or (b) with a term placental membrane fraction as a receptor source, and specific GnRH
agonist binding measured. Once again, GnRH agonist binding to placental villous mem¬
branes during the first incubation was low in microsomes prepared from between 10 and 20
weeks gestation [Figure 7(a) and (b); though two preparations of 16 week placenta showed
quite high binding levels]. On re-incubation of the unbound tracer fraction with the same
membranes, similar levels of GnRH binding were observed in the second incubation (■).
However, re-incubation of unbound tracer with term membranes gave similar levels of
binding whatever the stage of gestation of the placental membrane fraction used in the first
incubation [Figure 7(a) and (b)j.
Furthermore, measurement of 12;,I-labelled GnRH binding to 16 week and term pla¬
cental membranes in the presence or absence of inhibitors of serine-, metallo-, thiol- or
carboxypeptidases had little or no effect on GnRH binding to term membranes, and failed
to 'rescue' low binding to 16 week membranes (Table 2). Thus, low levels of GnRH
binding at 10-20 weeks gestation cannot be accounted for by increased degradation of
GnRH tracer during the assay. Binding was abolished by phenvlmethylsulphonyl fluoride:
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Figure 7. Re-binding of radiolabeled Buserelin tracer following pre-incubation with placental membranes from
different stages of gestation, as shown. (0), binding to membranes during first incubation; (□), re-binding of
unbound tracer fraction from first incubation to a preparation of term placental membranes; (■), re-binding of
unbound tracer from first incubation to same membranes as first incubation.
this was shown to be due to inhibition of placental GnRH binding by the ethanol solvent
used (Table 2). However, the serine protease inhibitor, soybean trypsin inhibitor, did not
inhibit GnRH binding.
DISCUSSION
In previous studies, we (Bramley, McPhie and Menzies, 1992) and others (Currie, Fraser
and Sharpe, 1981; Belisle et al, 1984; Iwashita, Evans and Catt, 1986; Mackiewicz et al,
1987; Escher et al, 1988) have demonstrated highly specific, moderate-affinity GnRH
binding sites in human placental membrane fractions. The properties of these binding sites
differ from those of pituitary GnRH receptors in several important respects:
(a) Placental GnRH binding sites do not discriminate between GnRH and agonist
analogues with super-activity in the pituitary gland (Currie, Fraser and Sharpe, 1981;
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Table 2. I .ack of effect of protease inhibitors on GnRI 1 binding to 16 week
and term human placental membrane preparations
'"^-labelled GnRI 1 binding (ct/min/50 pi membranes)
Inhibitor 16 Week gestation Term
Bo NSB Bo NSB
Control 8118 6804 24074 8882
EDTA" 7206 6976 23710 8910
N-EM" 7868 7668 19553 7438
Pepstatin A* 8613 7668 23848 8766
SBTI'' 8221 6786 25016 8902
PMSF" 7782 7271 8333 7629
Ethanol 7868 7668 8561 8385
Aliqnnts (50 pi) of placental membranes from either a 16 week (RU486
termination) or a spontaneous vaginal delivery term placenta were incubated
as described in the Materials and Methods section in the presence of ,2:d-
labelled Buserelin under standard incubation conditions (20°C for 1 h) in the
absence or presence of different protease inhibitors. Phenylmethvlsulphonyl
fluoride (PMSF) was dissolved in ethanol, and 10 pi added to the 1 ml assay
system. Values are means of triplicate determinations; similar values were
obtained in two (16 week) and three (term) separate experiments. Bo, binding
in the absence of unlabelled GnRII agonist (10 pg); NSB, binding in the
presence of excess unlabelled GnRH agonist; EDTA, ethylenediamine-
N,N'-tetraacetic acid; N-EM, N-ethylmaleimide; SBTI, soybean trypsin in¬
hibitor.
" Final concentration, lOm.M; Final concentration, 1 pg/ml.
Iwashita, Evans and Catt, 1986; Bramlcy, 1987). Hence, rat pituitary and human pla¬
cental binding sites have similar potencies for GnRI I, but different potencies for GnRH
agonists (Bramley, 1989);
(b) Pituitary GnRH receptors do not bind non-mammalian isoforms of GnRH, whereas
human placental GnRH binding sites bind ch GnRH II, s GnRH (but not ch GnRH I
and 1 GnRH; Bramley, McPhie and Menzies, 1992);
(c) A number of GnRH antagonist analogues with high affinity for pituitary GnRH
receptors bind poorly (Bramley, McPhie and Menzies, 1992) to human placental binding
sites [though Barnea ct al (1991) reported abolition of GnRH- and GnRH agonist-
dependent release of hCG by superfused placental explants using a GnRH antagonist
analogue].
This report now documents changes in the levels of these GnRH binding sites in
embrane fractions isolated from placentae from different stages of gestation. Specific
nRH binding activity was significantly reduced in membranes from placentae recovered
:twcen 10-20 weeks gestation, compared to 6-9 weeks and term placental membranes
igure 3). These differences could not be accounted for by:
(a) The use of radiolabelled Buserelin as a GnRH agonist tracer (since Buserelin,
Tryptorelin and ch GnRH II tracers bound equivalently to human placental membranes;
Figures 1 and 4);
(b) Changes in GnRH binding site affinity with gestational age [since binding of three
GnRH analogue tracers was competed by similar concentrations of unlabelled analogue
(300-1000 nM; Figures 2 and 3)]. Furthermore, the binding specificity for GnRI 1 agon-
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ists and GnRH isoforms did not change throughout gestation, despite marked differ¬
ences in specific binding activity (figure 6);
(c) Increased degradation of GnRH by membrane fractions from 10-20 week placentae
(since re-binding experiments demonstrated that unbound GnRH tracer exposed to
membranes from placentae of differing gestational age bound equally well to term
placental membranes; Figure 7). Furthermore, GnRH binding levels to 16 week and
term placental membranes were unaltered when assays were conducted in the presence
of broad-spectrum inhibitors of serine-, metallo-, thiol- and carboxypeptidasc proteases
(Table 2). Note that inclusion of peptidase inhibitors did not increase GnRH binding to
16 week placental membranes, suggesting that protease degradation of tracer and/or
receptor was not responsible for low binding at this stage of pregnancy. However, we
cannot rule out that the use ofEDTA in the homogenization buffer may have inactivated
some placental metallopeptidases during membrane preparation;
(d) Contamination of placental villous membranes by membranes from other tissues,
since the levels of EGF receptor (and alkaline phosphatase, data not shown) did not show
a similar marked decrease at this stage of gestation (Table 1);
(e) The use of prostaglandin or RU486 to induce termination of pregnancy, since no
significant differences were observed in GnRH binding activity for placental membranes
prepared from suction terminations or from RU486 or prostaglandin terminated preg¬
nancies between 6-16 weeks in this study (Figure 3; though numbers were low in some
groups at some stages of gestation). Furthermore, similar GnRH binding levels were
observed in term placental membranes obtained after spontaneous vaginal delivery
(SVD) (with or without induction of labour, with or without oxytocin treatment) and after
elective caesarean section (data not shown), suggesting that labour per se has little effect
on GnRH binding.
Decreased GnRH binding levels at 10-20 weeks gestation may reflect either sup¬
pression of GnRH receptor expression or synthesis, increased receptor catabolism and/or
down-regulation, or increased occupancy of GnRH binding sites by an endogenous
GnRH-like ligand. The former explanation must await the isolation, sequencing, cloning
and analysis of the human placental GnRH-binding site gene and the raising of specific
immunochemical reagents for detection of the placental GnRH-binding site. Mixing
experiments involving pre-incubation of membranes from 10-20 week and term placenta
suggest that there was no marked increase in receptor catabolism at this stage of gestation
(Bramley and Menzies, unpublished data). However, human placental cytosol fractions
(assayed under conditions which would be expected to eliminate placental protease activi¬
ties) can inhibit GnRH binding to placental membranes in a time-, temperature- and dose-
dependent manner (Bramley and Menzies; submitted). Experiments are now in progress to
isolate this factor.
ACKNOWLEDGEMENTS
C.A.M. was supported by a grant from the Medical Research Council. We are most grateful for the generous gifts
of lamprey and salmon GnRH from Dr J. King, Department of Chemical Pathology, University of Cape Town,
RSA, the gift of Buserelin from DrJ. Sandow, Hoescht AG, Frankfurt, Germany, and ofGnRH antibody from Dr
R. Ellinwood, Portland, OR, USA. We should also like to thank our many colleagues in the Department of
Obstetrics and Gynaecology and the Labour Ward of the Simpson Memorial Maternity Pavilion for their
assistance in obtaining human placental tissue, particularly Ms Linda Harkness and Drs J. Norman and S.
Tovanabutra.
•nley el al: Placenta! GnRH Receptors 745
REFERENCES
'nea, E. R. & Kaplan, M. (1989) Spontaneous, gonadotropin-releasing hormone-induced, and progesterone-
lhibited secretion of human chorionic gonadotropin in the first trimester placenta in vitro. Journal ofClinical
ndocrinology and Metabolism, 69, 215-217.
isle, S., Guevin, J.-F., Bellabarba, D. & Lehoux, J.-G. (1984) Luteinizing hormone-releasing hormone
inds to enriched human placental membranes and stimulates in vitro the synthesis of bioactive human
horionic gonadotropin. Journal ofClinical Endocrinology and Metabolism, 59, 119-126.
isle, S., Lehoux, J.-G., Bellabarba, D., Gallo-Payet, N. & Guevin, J.-F. (1986) On the role of luteinizing
ormone-releasing hormone in the in vitro synthesis of bioactive human chorionic gonadotropin in human
regnancies. Canadian Journal ofPhysiology and Pharmacology,, 64, 1229-1235.
imley, T. A. (1987) LHRH binding sites in human tissues. In LHRH and its Analogs: Contraceptive and
Eerapeutic Applications, Part 2 (F.ds) Vickery, B. H. & Nestor Jr., J. J. pp. 123-139. Lancaster: MTP Press,
imley T. A. (1989) GnRH peptides and the regulation of the corpus luteum. Journal of Reproduction and
'ertility Supplement, 37, 205-213.
tmley, T. A., Menzies, G. S. & Baird, D. T. (1985) Specific binding of gonadotrophin-releasing hormone
nd an agonist to human corpus luteum homogenates: characterization, properties, and luteal phase levels.
oumal ofClinical Endocrinology and Metabolism, 61, 834—841.
unley, T. A., Menzies, G. S. & Baird, D. T. (1986) Specificity of gonadotrophin-releasing hormone binding
ites of the human corpus luteum: comparison with receptors of rat pituitarv gland. Journal ofEndocrinology, 108,
23-328.
tmley, T. A., McPhie, C. A. & Menzies, G. S. (1992) Human placental gonadotrophin-releasing hormone
GnRH) binding sites: 1. Characterization, properties and ligand specificity. Placenta, 13, 555-581.
ivton, R. N. (1983) Preparation of radiolabeled neuroendocrine peptides. Methods in Enzymology, 103, 32-48.
rrie, A. J., Fraser, H. M. & Sharpe, R. M. (1981) Human placental receptors for luteinizing hormone-
eleasing hormone. Biochemical and Biophysical Research Communications, 99, 332-338.
:her, E., Mackiewicz, Z., Lagace, G., Lehoux, J.-G., Gallo-Payet, N., Bellabarba, D. & Belisle, S. (1988)
luman placental LI IRI1 receptor: agonist and antagonist labelling produces differences in the size of the non-
lenatured, solubilized receptor. Journal ofReceptor Research, 8, 391-406.
zum, E. (1985) GnRH receptors: Identification, localization and implications for biological function. In
lormonal Control of the Hypothalamo-Pituitary-Gonadal Axis (Eds) McKerns, K. W. & Naor, Z. pp. 127-139.
^ondon: Plenum Press.
tshita, M., Evans, M. I. & Catt, K.J. (1986) Characterization of a gonadotrophin-releasing hormone receptor
ite in the term placenta and chorionic villi .Journal ofClinical Endocrinology and Metabolism, 62, 127-133.
wry, O. H., Rosebrough, N.J., Farr, A. L. & Randall, R.J. (1951) Protein measurement with the Folin
ihenol reagent. Journal ofBiological Chemistry, 193, 265-275.
ickiewicz, Z., Belisle, S., Bellabarba, D., Gallo-Payet, N., Lehoux, J.-G., Lagace, G. & Escher, E. (1987)
Synthesis and placental binding potencies of photosensitive analogues of luteinizing hormone-releasing hor-
none (LHRH) with agonistic and antagonistic structures. Helvetica Chimica Acta, 70, 423-429.
:nzies, G. S. & Bramlev, T. A. (1992) 1 lurnan placental gonadotrophin-releasing hormone (GnRl 1) binding
ites: II. Comparison of binding and inactivation of 12"'I-labelled GnRH agonist to subcellular fractions
ollowing density gradient centrifugation. Placenta, 13, 583-595.
rman, J. E., Thong, K. J., Rodger, M. W. & Baird, D. T. (1992) Medical abortion in women of < 56 days
imcnorrhoea: a comparison between gemeprost (a PGE| analogue) alone and mifepristone and gemeprost.
british Journal ofObstetrics and Gynaecology 99, 601-606.
■burg, P. H., Mason, A. J., Stewart, T. A. & Nikolics, K. (1987) The mammalian GnRH gene and its pivotal
ole in reproduction. Recent Progress in Hormone Research, 43, 69—98.
arp, R. M. & Fraser, H. M. (1980) Levdig cell receptors for luteinizing hormone releasing hormone and its
igonist and their modulation by administration or deprivation of the releasing hormone. Biochemical and
biophysical Research Communications, 95, 256-262.
erwood, N. M., Lovejoy, D. A. & Coe, I. R. (1993) Origin of mammalian gonadotrophin-releasing hormones.
Endocrine Reviews, 14, 241—254.
er-Khodr, T. M. (1987) Placental LI IRI 1-like activity. In LHRH and its analogs: Contraceptive and Therapeutic
applications, Part 2 (Eds) Vickery, B. H. & Nestor Jr., j. J. pp. 161-178. Lancaster: MTP Press.
